Heightened resistance to type 1 interferons characterizes HIV-1 at transmission and following analytical treatment interruption

Marcos V. P. Gondim^{1†}, Scott Sherrill-Mix^{1,2†}, Frederic Bibollet-Ruche^{1,2}, Ronnie M. Russell^{1,2},
Stephanie Trimboli¹, Andrew G. Smith¹, Yingying Li¹, Weimin Liu¹, Alexa N. Avitto¹,
Julia DeVoto¹, Jesse Connell^{1,2}, Angharad E. Fenton-May³, Pierre Pellegrino⁴, Ian Williams⁴,
Emmanouil Papasavvas⁵, Julio C. C. Lorenzi⁶, D. Brenda Salantes¹, Felicity Mampe¹,
M. Alexandra Monroy¹, Yehuda Z. Cohen⁶, Sonya Heath⁷, Michael S. Saag⁷, Luis J. Montaner⁵,
Ronald G. Collman^{1,2}, Janet M. Siliciano⁸, Robert F. Siliciano^{8,9}, Lindsey Plenderleith^{10,11},
Paul M. Sharp^{10,11}, Marina Caskey⁶, Michel C. Nussenzweig^{6,12}, George M. Shaw^{1,2},
Persephone Borrow³, Katharine J. Bar^{1,2}, Beatrice H. Hahn^{1,2*}

¹Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

²Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104, USA.

³Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7FZ, UK.

⁴Centre for Sexual Health and HIV Research, University College London, London WC1E 6JB, United Kingdom.

⁵Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.

⁶Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.

⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

⁸Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.

⁹Howard Hughes Medical Institute, Johns Hopkins University, Baltimore, MD 21205, USA.

¹⁰Institute of Evolutionary Biology, University of Edinburgh, Edinburgh EH9 3FL, United Kingdom.

¹¹Centre for Immunity, Infection and Evolution, University of Edinburgh, Edinburgh EH9 3FL, United Kingdom.

¹²Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.

*To whom correspondence should be addressed: bhahn@pennmedicine.upenn.edu.

†These authors contributed equally to this work.

One Sentence Summary

HIV-1 resistance to IFN-I is highest during acute infection and following analytic treatment interruption, indicating a dynamic interplay between host innate immunity and virus biology.

Abstract

Type 1 interferons (IFN-I) are potent innate antiviral effectors that constrain HIV-1 transmission. However, harnessing these cytokines for HIV-1 cure strategies has been hampered by an incomplete understanding of their anti-viral activities at later stages of infection. Here, we characterized the IFN-I sensitivity of 500 clonally-derived HIV-1 isolates from plasma and CD4+ T cells of 26 individuals sampled longitudinally following transmission and/or after antiretroviral therapy (ART) and analytical treatment interruption (ATI). Determining the concentration of IFN α 2 and IFN β that reduced HIV-1 replication by 50% (IC₅₀), we found remarkably consistent changes in the sensitivity of viruses to IFN-I inhibition, both across individuals and over time. IFN-I resistance was uniformly high during acute infection, decreased in all subjects in the first year post-infection, was reacquired concomitant with CD4+ T cell loss, and remained elevated in subjects with accelerated disease. Isolates obtained by viral outgrowth during suppressive ART were relatively IFN-I sensitive, resembling viruses circulating just prior to ART initiation. However, viruses that rebounded following treatment interruption displayed the highest levels of IFN α 2 and IFN β resistance observed at any time during the infection course. These findings indicate a dynamic interplay between host innate immune responses and the evolving HIV-1 quasispecies, with the relative contribution of IFN-I to HIV-1 control impacted by both ART and ATI. Although elevated at transmission, IFN-mediated pressures are the highest during viral rebound, limiting the viruses that successfully reactivate from latency.

Introduction

Type 1 interferon (IFN-I) comprises a family of pro-inflammatory and immunomodulatory cytokines with potent antiviral activity (1, 2). In humans, this family includes 13 IFN α subtypes as well as IFN β , IFN ϵ , IFN κ , and IFN ω , of which IFN α and IFN β are the best characterized (3). IFN-I is rapidly up-regulated in response to pathogen exposure and infection (4, 5), and mediates its activity by binding to the heterodimeric IFNAR receptor expressed on all nucleated cells (6). This binding results in the activation of signal transduction cascades that trigger the expression of hundreds of interferon-stimulated genes (ISGs), which have direct and indirect antiviral activity, and regulate the activation state, function, proliferation and survival of host immune cells (7, 8). Although all IFN-I subtypes bind to the same receptor, they differ in their affinity for the two IFNAR subunits and elicit different patterns of ISG expression, suggesting that they vary in their *in vivo* activity and potency (9-12).

Up-regulation of IFN-I expression is one of the earliest innate responses to infection with both human (HIV-1) and simian (SIV) immunodeficiency viruses (13-17). In acute HIV-1 infection, maximal IFN-I levels are detected in the plasma prior to peak viremia (18). In acute SIVmac infection of macaques, plasmacytoid dendritic cells (pDCs) are actively recruited to mucosal sites, where they produce high levels of both IFN α and IFN β (19, 20). IFN-I is known to control HIV/SIV replication in CD4 $^{+}$ T cells and macrophages by targeting multiple steps in the viral lifecycle (8). Consistent with this, pre-treatment of rhesus macaques with exogenous IFN α 2 increased the number of intrarectal challenges required to achieve systemic SIVmac infection (21) and vaginal administration of IFN β protected rhesus macaques from recombinant simian/human immunodeficiency virus (SHIV) infection (22). Likewise, blocking IFN-I during acute SIVmac infection led to higher viral titers, more rapid decline of CD4 $^{+}$ T cells, and faster

disease progression (23). Thus, numerous studies in both humans and primates have shown that IFN-I play a key role in controlling HIV/SIV replication during the earliest stages of infection.

In contrast to the beneficial effects of IFN-I upregulation during acute HIV-1 infection, sustained IFN-I signaling during chronic infection appears to have an overall negative effect (17, 24-28). In untreated subjects, plasma IFN α levels are positively correlated with HIV-1 viral load and inversely correlated with CD4 $^{+}$ T cell counts, and individuals with higher viral loads and faster disease progression frequently exhibit higher ISG expression (24, 27) and heightened IFN β production in the gut (29). Continuous IFN-I signaling increases the number of susceptible CD4 $^{+}$ target cells, induces CD4 T cell apoptosis, limits antigen specific CD4 $^{+}$ and CD8 $^{+}$ T cell responses, and contribute to immune exhaustion (15, 30, 31). In SIVmac infected macaques, prolonged IFN α 2 treatment resulted in decreased antiviral ISG expression, an increased SIVmac reservoir size, and the loss of CD4 $^{+}$ T cells (21). Indeed, sustained IFN-I signaling and ISG up-regulation differentiates pathogenic from non-pathogenic SIV infections (32-34) and drives systemic immune activation in HIV-1 infection, which is associated with poor CD4 $^{+}$ T-cell recovery and a predictor of disease progression (35).

Given the highly pleiotropic and context-dependent effects of IFN-I, it is not surprising that clinical studies evaluating its therapeutic benefits have yielded mixed results (14, 16, 36). IFN α 2 administration can suppress HIV-1 replication, blunt rebound viremia, and extend viral control following analytic treatment interruptions (ATI) (37-40). However, various combinations of anti-retroviral and IFN-I treatments have not led to long-term improvements of CD4 T cell reconstitution or clinical outcome (14). Moreover, blocking rather than stimulating IFN-I signaling, or selectively counteracting only certain ISGs, had beneficial effects in HIV-1 infected humanized mice (41, 42). Thus, it seems clear that effective manipulation of the IFN-I system to prevent, treat or cure HIV-1 infection will require a much more detailed understanding of the kinetics, potency and quality of the endogenous IFN-I response.

One approach to gain insight into the *in vivo* IFN-I response is to test the IFN sensitivity of plasma viruses, which are reliable indicators of selection pressures that act on virions and virus-infected cells (43-48). Such studies have shown that transmitted founder (TF) viruses are highly IFN-I resistant (49) and that this resistance constitutes a major determinant of HIV-1 transmission fitness (50). In contrast, viruses isolated during chronic infection are generally IFN-I sensitive (45, 46, 47), although this sensitivity seems to revert as subjects progress toward AIDS (51, 52). Here, we performed a systematic analysis of the IFN-I sensitivity of plasma and CD4+ T cell derived viral isolates from prospectively sampled subjects before and after antiretroviral therapy (ART), and following analytical treatment interruption (ATI). We found that the *in vivo* IFN-I response is much more dynamic than previously assumed and places varying pressures on the viral population at different stages of the infection. In particular, the high IFN-I resistance of rebound viruses indicates intensified IFN-I activity during viral recrudescence.

Results

Generation of plasma isolates from longitudinally sampled individuals

To characterize the kinetics of IFN-I resistance over the course of HIV-1 infection, we generated plasma isolates from 10 prospectively sampled individuals, who were followed from shortly after transmission until 4.1 - 12.4 years post-infection (table S1). All participants were men-who-have-sex-with-men (MSM) who presented with symptomatic primary subtype B infection. Peripheral blood was collected at regular intervals immediately following onset of symptoms and continued for 74 to 318 weeks (1.6 to 6.2 years) in the absence of antiretroviral treatment. At each time point, patients underwent clinical evaluation, including viral load and CD4+ T cell count determinations (table S1). Six individuals experienced a gradual loss of their CD4+ T cells over the study period (typical progressors; Fig. 1A), two individuals maintained high CD4+ T cell

counts and low viral loads throughout their 3.6- and 5.6-year clinical follow-up (non-progressors; Fig. 1B), and two individuals developed AIDS (CD4 T cells < 300 cell/ μ l) within 0.7 and 1.5 years of infection (rapid progressors; Fig. 1C). ART was initiated in eight participants between 85 and 323 weeks post onset of symptoms based on the standard-of-care at the time (shaded in Fig. 1).

We also characterized the evolving HIV-1 quasiespecies in these subjects. This was done by amplifying viral RNA directly from the plasma using single genome amplification (SGA), which retains genetic linkage across viral genes and generates sequences devoid of PCR-induced artifacts (53, 54). For each individual, 3' half genomes or *env* gene sequences were amplified from sequential plasma samples, with sequences from the earliest time point used for TF enumeration (fig. S1). This analysis showed that seven participants acquired a single TF virus, while the remaining three became infected with two or more TF viruses (table S1). Sequences from subsequent time points exhibited the expected patterns of viral diversification (55-57), except for MM14, MM23 and MM33, who became superinfected with additional subtype B strains 5 to 29 weeks following the initial infection (Fig. 1 and fig. S2).

To determine the IFN sensitivity of individual quasiespecies members at different stages of HIV-1 infection, we generated 277 limiting dilution plasma isolates from five of the 10 subjects (table S1). Plasma samples were end-point diluted, co-cultured with healthy donor CD4+ T-cells, and the resulting isolates sequenced to ensure that they were indeed single virion-derived (50). In phylogenetic trees of *env* gene sequences, the limiting dilution isolates were completely interspersed with sequences amplified directly from the plasma, thus confirming their authenticity (fig. S2). To characterize their sensitivity to IFN-I inhibition, we determined the IFN α 2 and IFN β concentrations that reduced virus replication *in vitro* by 50% (50). Briefly, donor CD4+ T cells were treated with increasing quantities of IFN α 2 and IFN β , and then infected with equal amounts of virus (50). Cells were cultured for 7 days, with the IFN-containing media replenished every second day. Virus replication was measured for each IFN-I concentration by

quantifying p24 antigen in supernatants and used to calculate the half-maximal inhibitory concentrations (IC_{50}) (fig. S3).

Since the IFN α 2 and IFN β IC_{50} values for limiting dilution isolates from the same plasma sample were very similar (Fig. 2), we reasoned that conventional (bulk) virus isolation was likely sufficient to capture the IFN-I sensitivity of the circulating virus pool. To test this, we generated 18 bulk isolates from 11 of these plasma samples (table S1) and determined their IFN-I resistance (table S2). All bulk isolates yielded IC_{50} values that fell within 5-fold of the mean of the corresponding limiting dilution isolates (Fig. 2; note that the IC_{50} range spanned over 1,000-fold for IFN α 2 and over 40,000-fold for IFN β). Moreover, the mean interferon resistance of the bulk isolates was highly correlated with that of the corresponding limiting dilution isolates (IFN α 2 $r=0.95$ and IFN β $r=0.96$). We thus used the less labor-intensive conventional approach to generate 79 plasma isolates for the remaining five subjects.

Kinetics of IFN-I resistance in untreated HIV-1 infection

Analysis of 374 plasma isolates from 10 prospectively sampled subjects revealed marked differences in their sensitivity to IFN α 2 and IFN β inhibition over the course of the infection (Fig. 2). To quantify these dynamic changes, we developed a Bayesian hierarchical change point model (50, 58), which allowed us to infer the temporal patterns of IFN α 2 and IFN β IC_{50} values and their associations with CD4 $^{+}$ T cell counts across different individuals while accounting for differences in sampling times and frequencies (Supplementary Methods, fig. S4).

Consistent with previous results (49, 50, 59), isolates obtained during acute HIV-1 infection were uniformly IFN-I resistant, yielding mean IC_{50} values for IFN α 2 of 0.90 pg/ml and for IFN β of 19 pg/ml (Fig. 2). This resistance decreased in all subjects, with IFN α 2 and IFN β IC_{50} values falling in typical progressors on average 180-fold (95% Credible Interval [CrI]: 100 - 340-fold) and 3,500-fold (95% CrI: 1500 - 8900-fold) within 340 days (95% CrI: 250 - 490 days)

and 460 days (95% CrI: 310 - 700 days), respectively. Isolates from non-progressing individuals fell to similar levels, but reached a nadir earlier at an estimated 100 days (95% CrI: 50 - 200 days) for IFN α 2 and 110 days (95% CrI: 50 - 240 days) for IFN β . The time to nadir for fast progressing individuals was difficult to determine because IFN α 2 and IFN β IC₅₀ values decreased only 2.8-fold (95% CrI: 0.78 - 10.5-fold) and 2.7-fold (95% CrI: 0.52 - 16-fold), respectively, resulting in 39-fold and 1,000-fold higher levels than in subjects with more typical disease progression (Fig. 2C and fig. S4, A and B).

Plasma virus from typical progressors exhibited a consistent rise in IFN α 2 and IFN β resistance during the later stages of infection (Fig. 2). This rise and other fluctuations in resistance during chronic infection (e.g., MM34 in Fig. 2), appeared to associate with changes in CD4⁺ T cell counts. Each decrease of 100 CD4⁺ T cells/ μ l was associated with a 2.3-fold (95% CrI: 1.3 - 4.4-fold) increase in mean IFN α 2 IC₅₀ and a 4.0-fold (95% CrI: 1.9 - 8.7-fold) increase in mean IFN β IC₅₀ values (Fig. 2A and fig. S4, C and D). The two non-progressing individuals maintained their CD4⁺ T cell counts at relatively high levels and the two fast progressing individuals were largely depleted of CD4⁺ T cells early in infection. Thus, the model predicted little association between IFN-I resistance and CD4⁺ T cell counts in these participants (Fig. 2, B and C and Fig. S4, C and D).

Overall, the temporal changes in IFN-I resistance were remarkably similar among the different individuals. Without exception, viral IFN-I resistance was high during acute infection, decreased during early chronic infection, and increased again during later stages concomitant with CD4⁺ T cell loss and disease progression. Remarkably, neither the number of transmitted founder viruses at transmission nor subsequent superinfection events appeared to influence these kinetics (Fig. 2). In all analyses, IFN α 2 and IFN β IC₅₀ values were highly correlated (fig. S5), although IFN β IC₅₀ values spanned nearly four orders of magnitude compared to two orders of magnitude for IFN α 2 (Fig. 2). These findings thus indicate a highly dynamic interplay between host innate immune responses and the evolving HIV-1 quasispecies, with the relative

contribution of IFN-I to HIV-1 control varying markedly, but predictably, over the course of HIV-1 infection.

IFN-I sensitivity of ex vivo reactivated latent viruses

Having characterized the IFN-I response of plasma virus during untreated infection, we next used a quantitative viral outgrowth assay (QVOA) to generate reactivated latent viruses from some of the same individuals after they were placed on therapy. For five of the 10 longitudinally followed subjects, cryopreserved peripheral blood mononuclear cells (PBMCs) collected 1 to 4 years after ART initiation were available (Fig. 1). These were stimulated, co-cultured with primary CD4⁺ T cells from healthy donors, and tested for viral replication by monitoring p24 levels in culture supernatants (60). Due to limited numbers of cryopreserved cells, only eight QVOA isolates were recovered (Fig. 2 and table S1). All isolates were sequenced (fig. S2) and their IFN-I resistance determined (table S2). Although participant WEAU received zidovudine (AZT) beginning 1.6 years post infection (Figs. 1 and 2), this monotherapy was not sufficient to maintain suppression of plasma viral loads (table S1). Thus, post-treatment samples from this individual were not suitable for QVOA analyses.

As shown in Fig. 2, seven of the eight QVOA isolates were moderately IFN-I resistant, exhibiting IC₅₀ values very similar to plasma isolates obtained from the same individuals immediately prior to ART initiation. This was true for individuals with single as well as multiple QVOA isolates, including viruses collected several months apart (MM34). A single QVOA isolate from a rapidly progressing subject (MM15) was more IFN-I resistant, but again plasma virus obtained just prior to treatment initiation displayed the same elevated IFN-I resistance. Phylogenetic analyses confirmed these findings, showing that the eight outgrowth isolates did not cluster with viruses recovered during acute or early infection, but were most closely related to plasma viruses replicating during late infection (Fig. 3 and fig. S2). Thus, both IFN-I and

phylogenetic analyses indicated that the QVOA derived viruses had entered the latent reservoir near the time of therapy initiation.

To increase the number of outgrowth viruses for IFN-I phenotypic analyses, we obtained cryopreserved PBMCs or previously generated QVOA isolates from 9 additional ART suppressed individuals who participated in different HIV-1 treatment interruption and/or latency studies (table S3). Two individuals were leukapheresed after prolonged ART suppression for a qualitative and quantitative analysis of their replication competent HIV-1 reservoir (61); four individuals were leukapheresed before (-2 weeks) and during (12 weeks) ATI, but prior to viral rebound while receiving the two human broadly neutralizing antibodies 3BNC117 and 10-1074 (62); and three individuals were leukapheresed before and six months after ATI and infusion of the broadly neutralizing antibody VRC01 (63, 64). From the available material, we were able to generate or expand 52 QVOA isolates and test their IFN-I sensitivity (table S4). The results showed a range of IFN α 2 and IFN β IC₅₀ values that was very similar to that of the eight QVOA isolates from the longitudinally sampled cohort, with most isolates exhibiting low or moderate IFN-I resistance (Fig. 4, A and C). There were only two outgrowth viruses that displayed an unusually high IFN-I resistance, especially for IFN α 2, both of which were isolated from the post-ATI leukapheresis sample of a single individual (A08).

IFN-I sensitivity of rebound viruses following treatment interruption

Some of the individuals for whom QVOA isolates were available also underwent treatment interruptions, which allowed the comparison of the IFN-I sensitivity of *in vitro* and *in vivo* reactivated viruses. Using plasma samples collected shortly after detection of recrudescence viremia, we generated 37 limiting dilution isolates from six such individuals (table S3). In addition, we obtained plasma samples from seven individuals who participated in other treatment interruption trials (table S3). Three of these underwent successive ATI cycles of increasing duration, but without further intervention (65); one individual was infused with the

broadly neutralizing human monoclonal antibody 3BNC117 prior to and during ATI (66); and three individuals received a 20 week course of pegylated IFN α 2 (1 μ g/kg) prior to and during ART interruption (67). Again, using samples collected shortly after detectable viremia, we were able to generate 29 additional limiting dilution isolates (table S3). All rebound isolates formed individual-specific clusters in a phylogenetic tree (fig. S6) and grew efficiently in CD4+ T cells (table S4). However, analysis of their IFN α 2 and IFN β IC₅₀ values yielded unexpected results: All 66 rebound isolates were highly IFN-I resistant, exceeding even highly resistant isolates from acute infection (Fig. 4).

To quantify differences in IFN-I sensitivity between viral groups, we developed a hierarchical Bayesian model (Supplementary Methods), which combined the data from the QVOA and rebound isolates with results from the longitudinal cohort and previously published transmission pairs (50). Specifically, we compared IFN-I IC₅₀ values of acute infection isolates (<30 days after onset of symptoms) with those from rebound, chronic (>300 days after onset of symptoms) and outgrowth viruses, dividing the latter into pre- and post-ATI isolates (Fig. 4, B and D). Two apparent outliers isolated from the CD4+ T cells of participant A08 six months after re-initiation of therapy suggested that viruses phenotypically resembling rebound viruses might be present in post-ATI samples (Fig. 4, A and C). To account for this possibility, we included a mixture term into the model that allowed for some proportion of post-ATI viruses to derive from the rebound population. This mixture term was also included for pre-ATI samples to allow comparison between pre- and post-ATI viruses.

Comparing all available IFN-I IC₅₀ data, we determined the fold-change in IFN α 2 and IFN β IC₅₀ values of acute, rebound, chronic as well as pre-ATI and post-ATI isolates (Fig. 4, B and D). Acute infection isolates from untreated individuals were on average 18-fold (95% CrI: 9.3 – 31-fold) more IFN α 2 and 99-fold (33 – 230-fold) more IFN β resistant than chronic isolates. This was also the case for pre-ATI QVOA isolates, which exhibited 13-fold (7.5 – 21-fold) lower IFN α 2 and 50-fold (19 – 107-fold) lower IFN β IC₅₀ values than acute infection

isolates. Remarkably, rebound viruses were the most IFN-I resistant, exhibiting on average 3.0-fold (2.3 - 3.8-fold) and 6.4-fold (3.8 - 10-fold) higher IFN α 2 and IFN β IC₅₀ values than acute infection isolates, respectively. These differences were highly significant and observed regardless of whether ART interruption was combined with additional interventions, such as the administration of broad neutralizing antibodies. Interestingly, the IFN α 2 IC₅₀ values of rebound isolates from individuals who were treated with pegylated IFN α 2 (1 μ g/kg) before and during ART interruption (subjects 004, 030, 044) were on average 1.8-fold (1.2 - 2.6-fold) higher than those of rebound viruses from IFN α 2 untreated individuals, while no significant differences were observed for the corresponding IFN β IC₅₀ values. The fact that IFN α 2 administration had a measurable effect suggests that the *in vivo* concentrations of IFN α 2 were not saturating. However, the increase in viral IFN α 2 resistance resulting from exogenous administration was modest compared to that driven by endogenous IFN α 2 and lacked a concomitant IFN β response. Taken together, it seems clear that treatment interruption and viral recrudescence trigger a vigorous IFN-I response that places near-maximal pressures on the rebounding virus.

IFN-I sensitivity of post-ATI outgrowth viruses

Given the heightened IFN-I resistance of rebound viruses, we examined post-ATI isolates for an enrichment of such viruses. Post-ATI outgrowth viruses had mean IFN-I resistance values that were very similar to those of pre-ATI viruses, but appeared to comprise two populations (Fig. 4, B and D), primarily because of two post-ATI outgrowth viruses from one individual (A08) that displayed an unusually high IFN-I resistance. The model estimated the proportion of "rebound-like" viruses in post-ATI isolates to be 13% (2.9 - 29%) for IFN α 2 and 4% (0.1% - 15%) for IFN β . While no "rebound-like" highly resistant viruses were detected in pre-ATI samples, this group had large credible intervals that overlapped those estimated for post-ATI samples. Thus,

existing data are insufficient to determine whether “rebound-like” isolates are exclusively observed in post-ATI samples.

To further characterize the two post-ATI QVOA isolates with elevated IC_{50} values (Fig. 4), we compared their sequences to those of other QVOA and rebound viruses from the same individual (Fig. 5). As previously reported (63, 64), participant A08 initiated ART during chronic infection, underwent treatment interruption and VRC01 monoclonal antibody treatment, and was restarted on ART after detection of rebound viremia. Phylogenetic analysis of viral sequences obtained before, during and after treatment interruption identified multiple rebound lineages, some of which were closely related to both pre-ATI and post-ATI QVOA isolates (Fig. 5). When 20 of these QVOA isolates were phenotypically tested, 18 exhibited very low IFN α 2 and IFN β IC_{50} values, indicating that they were highly IFN-I sensitive (Fig. 4). The exception were the two post-ATI QVOA isolates (3D8 and 6F6), which were not only more IFN-I resistant, but also shared identical *env* sequences with three rebound viruses (highlighted in Fig. 5). Further sequencing of the entire genome showed that the two QVOA isolates differed from the closest rebound virus (2F4) by only three nucleotides, which conferred single amino acid changes in Pol and Vpr, and a nucleotide substitution in the LTR (table S5). These genetic and phenotypic relationships suggest that treatment interruption in participant A08 may have re-seeded the reservoir with IFN-I resistant viruses.

Discussion

In untreated HIV-1 infected individuals, plasma virus has a half-life of less than one hour and the cells that are producing most of this virus have a half-life of less than one day (43, 47, 48, 68). Thus, virus circulating in the plasma of infected individuals is a sensitive real time indicator of the *in vivo* selection pressures that act on virus and virally infected cells, such as neutralizing antibodies (Nab), cytotoxic T lymphocytes (CTL), and antiviral drugs (43-46). Here, we

characterized the resistance of plasma viruses to IFN α 2 and IFN β in prospectively sampled individuals and show that the relative contribution of these cytokines to HIV-1 control varies markedly throughout the infection course (Fig. 2). IFN α 2 and IFN β IC₅₀ values were uniformly high during acute infection, consistent with the rapid induction of a potent innate antiviral state that selects for founder viruses that are highly IFN-I resistant (18, 50). IFN α 2 and IFN β IC₅₀ values declined in all individuals in the first year post infection (Fig. 2), at least in part because of viral escape from adaptive immune responses (45, 46, 69, 70). Recent studies showed that HIV-1 resistance to interferon-induced transmembrane proteins (IFITMs), and IFN-I itself, decreased over the first 6 months of infection as a direct result of acquiring neutralizing antibody (Nab) escape mutations (69). Although a similar causal relationship has not yet been shown for escape from cellular immune pressures, CTL responses are known to place strong pressure on the viral quasispecies during early HIV-1 infection and rapidly select for escape variants (45, 46). Thus, some of the same mutations that allow HIV-1 to successfully evade potent Nab, CTL and other adaptive immune pressures likely result in a loss of IFN-I resistance, even if IFN-I signaling is maintained at a higher than normal level (26, 32, 71, 72). IFN-I resistance is re-acquired during later stages of infection due to a decline in cellular immunity and increasing IFN-I production, fueled in part by microbial translocation in the gut (29, 73). Thus, there is a dynamic interplay between innate and adaptive immune pressures, with the circulating virus reflecting the predominant selective forces at any given time.

Although IFN-I IC₅₀ values varied by orders of magnitude, the observed temporal changes were surprisingly similar across all individuals (Fig. 2). Plasma viruses from all typical progressors displayed the same initial decline of IFN α 2 and IFN β IC₅₀ values irrespective of the multiplicity of infection (number of TF viruses), followed by the gradual reacquisition of IFN-I resistance during later stages of infection (Fig. 2A). In most individuals, a nadir was reached for both IFN α 2 and IFN β within two years of symptom onset, with a large overlap in credible intervals suggesting that the respective times were not significantly different. Surprisingly,

superinfection did not change this trajectory, although minor differences in IC_{50} values could have been missed due to infrequent sampling. A similar course was also observed in the two rapid progressors, although the fall and rise of IFN-I IC_{50} values was much less pronounced (Fig. 2C). Plasma viruses from the two non-progressors displayed the same initial IC_{50} decline, but then maintained low resistance values (Fig. 2B). These varying kinetics are most likely explained by differences in the quality, magnitude and duration of the adaptive immune response. In the two rapid progressors, the initial reduction in IFN-I resistance was likely curtailed by rapidly declining adaptive responses (43, 45). In the non-progressors, IFN-I resistance remained low after the initial decline because adaptive responses maintained effective anti-viral control (74). Thus, despite differences in disease progression, similar dynamics in IFN-I resistance suggest common patterns of virus-host interactions.

The balance between innate and adaptive immune pressures is also reflected in the IFN-I phenotype of outgrowth and rebound viruses. The latent reservoir is largely comprised of proviruses that are transcriptionally and translationally silent and are therefore not subject to ongoing innate or adaptive immune pressures. Moreover, adaptive immune responses are reduced under suppressive ART due to reduced viremia and may require time for reactivation after treatment interruption (75, 76). This likely explains the importance of rapidly induced innate responses at the time of viral recrudescence (77) and the resulting striking IFN-I resistance of rebound viruses (Fig. 4). The fact that rebound viruses were uniformly IFN-I resistant, irrespective of the clinical trial or type of treatment interruption, supports this hypothesis (38, 62, 64-66). Whether the superior IFN-I resistance of rebound viruses confers enhanced transmissibility is not known, but the occurrence of unintended transmissions during treatment interruption suggests that this possibility needs to be investigated (78, 79).

Recent studies by Abrahams and colleagues showed that 71% of outgrowth viruses are genetically most similar to viruses replicating in the plasma just prior to ART initiation (80). Since this proportion is far greater than would be expected if the reservoir formed continuously,

treatment appears to alter the host environment to facilitate the formation of latently infected cells (80). By characterizing the pathways of viral evolution in the longitudinally studied participants, we also found that outgrowth viruses isolated years after ART suppression were genetically most similar to viruses replicating late in untreated infection (Fig. 3 and fig. S2). Moreover, these outgrowth viruses exhibited IFN-I IC₅₀ values that were near identical to those of viruses circulating in the plasma just prior to ART (fig. S2). Our data thus confirm and extend these earlier findings, showing that outgrowth viruses are not only genetically, but also phenotypically, most similar to viruses replicating late in infection and provide additional evidence for the preferential entry of HIV-1 into the latent reservoir near the time of ART initiation.

The viral determinants that confer IFN-I resistance during HIV-1 infection are not known. Studying infectious molecular clones of transmitted founder and six-month consensus viruses from the same individual, a previous study failed to identify resistance or sensitivity signatures that were common among the different virus pairs (59). Sequence changes occurred at many sites throughout the viral genome, suggesting differential responses to numerous ISGs. Given the myriad of IFN-I effector pathways and the plasticity of the HIV-1 quasispecies, these results are not surprising. Moreover, IFN-I resistance levels can be altered by a small number of sequence changes (Fig. 5). Thus, it is unlikely that a set of universal IFN-I resistance determinants will be identified. Instead, the path to resistance for any one HIV-1 strain is likely context-dependent and driven by the particular viral and immunological circumstances.

A critical question in cure research is whether treatment interruption and the associated transient viremia have an impact on the composition and size of the latent reservoir. Comparing pre-ATI and post-ATI QVOA isolates, a previous study found only minimal changes in the abundance of replication-competent viruses, with little genetic evidence of rebound viruses significantly enriching the post-ATI reservoir (64). The exception was one individual (A08), who harbored a subset of post-ATI viruses that were genetically closely related to rebound viruses

(64). Examining existing and newly derived QVOA isolates from this same individual, we found that pre-ATI and post-ATI viruses had largely similar IFN-I resistance values (Fig. 4). However, the post-ATI QVOAs included two isolates with elevated IFN-I resistance, which were genetically very similar to a subset of rebound viruses (highlighted in Fig. 5). Thus, the post-ATI outgrowth viruses in this individual comprised two viral populations, one of which represented “rebound-like” viruses based on genetic and phenotypic analyses (Fig. 4, B and D and Fig. 5).

Treatment interruptions are the gold standard to evaluate promising cure strategies (81) and are employed with increasing frequency. Thus, it is essential that they are safe and well designed. Consistent with results from previous studies (64, 66), we found that pre-ATI QVOA isolates were neither predictive nor representative of the viruses that subsequently rebounded *in vivo*. This disconnect reinforces the clinical importance of ATIs since merely testing cure strategies *in vitro* on reactivated latent viruses may generate misleading results. A comprehensive analysis of post-ATI isolates in participant A08 suggested that treatment interruption may have re-seeded the reservoir with IFN-I resistant viruses, although the existence of these variants prior to ART could not be formally excluded. Although rebound-like (IFN-resistant) viruses comprised only a minor subset of the sampled post-ATI reservoir, this possibility requires further exploration in additional participants and cohorts to assure the safety of ATIs.

The finding that rebound viruses are uniformly IFN-I resistant is also relevant to the design of cure strategies that directly or indirectly engage IFN-I pathways. These approaches attempt to harness the antiviral activity of IFN-I either by administering these cytokines directly (38) or by eliciting IFN-I responses via immunomodulators, such as TLR 7 and 9 agonists (82, 83), and other latency reversal agents (84). The fact that ART cessation likely induces near-maximal IFN-I responses at the sites of virus recrudescence will need to be factored into the design of these strategies. Consistent with this, a recent study found that activation of NK cell cytotoxicity,

and not the induction of interferon stimulated genes, correlated with exogenous IFN α 2-mediated HIV-1 control (85).

A limitation of the present study is the lack of diversity among the study participants, all but one of them were men-who-have-sex-with-men from the US and western Europe. This is a longstanding issue in translational HIV-1 research that will have to be addressed by enrolling trial participants who are more representative of the gender, ethnicity, co-morbidity, disease progression and viral subtype composition of the HIV-1 pandemic. Our study also focused on IFN α 2 and IFN β , because the potency of these cytokines has previously been demonstrated both *in vitro* (50) and *in vivo* (29). However, additional IFN-I subtypes will need to be analyzed to elucidate the full spectrum of relevant innate immune pressures on HIV-1. It will also be important to perform viral outgrowth assays in the presence and absence of IFN-I to see whether pre-treatment of latently infected CD4⁺ T cells activates viruses that genetically or phenotypically resemble rebound viruses. Similarly, integration site analysis will be important to determine whether IFN-I resistant proviruses preferentially integrate in chromatin regions that restrict viral gene expression in the absence of high levels of IFN-I. The striking IFN-I resistance of rebound viruses also reinforces the need for nonhuman primate models that faithfully recapitulate this key feature of HIV-1 persistence. Studies are underway to determine whether SIVmac or SHIV infected rhesus macaques recapitulate the IFN-I kinetics observed in humans, and if so, whether these models can be used to trace the provenance and activation requirements of rebound viruses.

In summary, we show here that IFN-I play an important role in the control of HIV-1, not only during acute, but also later stages of infection. The IFN-I resistance of plasma viruses reflects the contribution of IFN-I mediated activity relative to other antiviral forces at the site of virus production. The kinetics of the IFN-I response vary over the course of infection, from very high levels in acute infection to low levels in early infection to elevated levels prior to ART initiation and near maximal levels during viral rebound following ART cessation. Although the

tissue and cell origins of rebound viruses remain to be determined, our data indicate that they arise either from a cryptic reservoir of highly IFN-I resistant viruses or rapidly evolve at the sites of viral recrudescence by acquiring IFN-I resistance.

Materials and Methods

Study design

The role of IFN-Is in the control of HIV-1 during infection was determined by generating 500 plasma and PBMCs derived viral isolates from 26 individuals sampled prospectively before and after antiretroviral therapy (ART) and/or during treatment interruption. Viruses were genetically characterized and their susceptibility to IFN α 2 and IFN β inhibition (IC₅₀) was determined. Sample sizes were dependent on availability and not predetermined by power calculations.

Study participants

Participants MM14, MM15, MM23, MM33, MM34, MM39, MM40, MM55, and MM62 were recruited to an acute HIV-1 infection cohort at the Mortimer Market Centre for Sexual Health and HIV Research in London, United Kingdom, while participant WEAU was followed at the 1917 Clinic of the University of Alabama at Birmingham. Six individuals who experienced a gradual loss of their CD4⁺ T cells, were classified as typical progressors; two individuals who maintained high CD4⁺ T cell counts and low viral loads, were classified as non-progressors; and two individuals, who developed AIDS within 8 and 18 months post-infection, respectively, were classified as rapid progressors (Fig. 1). Peripheral blood was collected in EDTA-containing tubes following onset of symptoms and at regular intervals thereafter (table S1). Plasma was separated by centrifugation, while PBMCs were isolated using a Histopaque 1.077 density gradient and cryopreserved. Subjects provided informed consent and were offered antiretroviral

therapy based on the standard-of-care at the time. Ethical approval for the London cohort study was provided by the National Health Service Camden/Islington Community Local Research Ethics Committee. The use of stored (de-identified) samples from participant WEAU was approved by the University of Alabama at Birmingham Institutional Review Board. Plasma and viably frozen PBMC samples were also obtained from 16 individuals who participated in six different treatment interruption and latency trials (MNU-0628, NCT02825797, NCT0246322, NCT00051818, NCT02227277, NCT02588586). These materials were obtained from existing repositories and their use was approved by the respective Institutional Review Boards as previously described (61-67).

Virus isolation from plasma

For limiting dilution isolation, plasma samples were end-point diluted and used to infect 1×10^6 activated CD4⁺ T cells from multiple healthy donors in 24-well plates (50). To generate bulk isolates, plasma aliquots containing 1,500 - 20,000 viral RNA copies were used to infect 4×10^6 healthy donor CD4⁺ T cells in 6-well plates. Cultures were maintained for 21 days and tested weekly for the presence of p24 antigen in the supernatant. Virus positive cultures were expanded in pooled healthy donor CD4⁺ T cells (1×10^7) and the resulting viral stocks were used for all genetic and biological analyses.

Quantitative viral outgrowth assay

Virus isolations were performed essentially as described (60) with minor modifications. CD4⁺ T cells were isolated from viably frozen PBMC, incubated in RPMI media containing 15% FBS without IL-2 for 24 hours, and stimulated for 24 hours using a combination of anti-CD2, CD3 and CD28 antibody-coated beads (Miltenyi Biotec T Cell Activation/Expansion Kit). Cells were then cocultured with healthy donor CD4⁺ T cells (1:10 patient:donor cells) and cultured for 3 weeks with weekly monitoring of p24 production. Positive cultures were expanded and viral stocks

generated as described above. In cases where QVOA isolates were already available (61-64), supernatants were obtained and used to generate viral stocks in healthy donor CD4+ T cells (table S3).

Single genome amplification

Single genome amplification of 3' half genomes or viral *env* genes from plasma RNA and proviral DNA was performed as previously described (54, 86). Briefly, ~20,000 copies of viral RNA were extracted from plasma using QIAamp Viral RNA kit (Qiagen) and reverse transcribed using SuperScript III Reverse Transcriptase (Invitrogen). PBMC DNA was extracted using a DNeasy Blood and Tissue kit (Qiagen). Viral cDNA and PBMC DNA were then endpoint diluted and amplified using nested PCR using primers and conditions as previously reported (54, 86).

Isolate sequencing

Viral RNA was extracted from isolate stocks, reverse-transcribed, and the resulting cDNA used to amplify overlapping 5' and 3' genome halves in separate PCR reactions (50). Amplicons were sequenced using Illumina MiSeq and paired-end reads assembled to generate a sample-specific reference sequence. Viral reads were mapped to this reference, and the extent of genetic diversity was examined for each position along the alignment. Isolates that exhibited more than 15% diversity at any one position were judged to contain more than one variant.

Phylogeny

Plasma viral, proviral and isolate derived sequences for each subject were aligned with Clustal Omega (87) and inspected for misassemblies, overly truncated sequences and sequences with abundant G to A mutations (considered to be the result of APOBEC hypermutation). Alignments were trimmed to the shortest sequence and positions with gaps in any sequence were masked in all sequences. Trees were generated using RAxML v8.2.12 (88) with model GTRGAMMA and

bootstrap values calculated from 1,000 replicates. Potential recombinants from superinfected subjects were identified in alignments using Recco (89) using default parameters; recombinants were reported if they had an alignment p-value <0.05 and contained at least 10 recombination induced mutations.

Interferon IC₅₀ determinations

To determine the IFN α 2 and IFN β concentrations required to inhibit virus replication by 50% (IC₅₀), pooled activated CD4⁺ T cells were left untreated or cultured in the presence of increasing amounts of IFN α 2 or IFN β for 24 hours, essentially as described (50). Cultures (2.5x10⁵ cells) were then infected overnight with equal amounts of virus (0.25 ng of RT) and maintained for 7 days in IL-2 (30 U/ml) media, while replenishing IFN-I every 48 hours. Virus replication was measured as the amount of p24 produced at day 7 and IC₅₀ was calculated as the amount of IFN necessary to reduce viral growth by 50% from levels measured in the absence of IFN-I (Fig. S3).

Statistical analyses

We developed hierarchical Bayesian models to analyze the longitudinal changes of interferon resistance while avoiding bias from differential sampling (50, 58). These models assumed that the data were log normally distributed with the resistance observed in each individual deriving from a common population-level distribution (Supplementary Methods). For the longitudinal analysis, IFN-I resistance was assumed to start at an acute infection level, fall (or rise) to some nadir change point, and then rise (or fall) based on changes in CD4⁺ T cell counts (fig. S4). For comparisons of outgrowth and rebound viruses, each isolate was assumed to be a random sample from the viruses circulating within an individual, and each individual was assumed to be representative of a larger population. Outgrowth isolates were assumed to represent mixed populations that could include rebound-like viruses (Supplementary Methods). Data was

processed and analyzed using R v3.4.4 (90). Posterior probability distributions were estimated using Markov chain Monte Carlo sampling as implemented in Stan v2.23 (91). Statistical significance was assessed by determining if the 95% credible interval overlapped the null hypothesis.

References and Notes

1. D. B. Stetson, R. Medzhitov, Type I interferons in host defense. *Immunity* **25**, 373-381 (2006). <https://doi.org/10.1016/j.immuni.2006.08.007>.
2. S. Pestka, C. D. Krause, M. R. Walter, Interferons, interferon-like cytokines, and their receptors. *Immunol Rev* **202**, 8-32 (2004). <https://doi.org/10.1111/j.0105-2896.2004.00204.x>.
3. H. M. Lazear, J. W. Schoggins, M. S. Diamond, Shared and distinct functions of type I and type III interferons. *Immunity* **50**, 907-923 (2019). <https://doi.org/10.1016/j.immuni.2019.03.025>.
4. E. V. Mesev, R. A. LeDesma, A. Ploss, Decoding type I and III interferon signalling during viral infection. *Nat Microbiol* **4**, 914-924 (2019). <https://doi.org/10.1038/s41564-019-0421-x>.
5. G. Schreiber, The molecular basis for differential type I interferon signaling. *J Biol Chem* **292**, 7285-7294 (2017). <https://doi.org/10.1074/jbc.R116.774562>.
6. C. Thomas, I. Moraga, D. Levin, P. O. Krutzik, Y. Podoplelova, A. Trejo, C. Lee, G. Yarden, S. E. Vleck, J. S. Glenn, G. P. Nolan, J. Piehler, G. Schreiber, K. C. Garcia, Structural linkage between ligand discrimination and receptor activation by type I interferons. *Cell* **146**, 621-632 (2011). <https://doi.org/10.1016/j.cell.2011.06.048>.
7. T. Doyle, C. Goujon, M. H. Malim, HIV-1 and interferons: who's interfering with whom? *Nat Rev Microbiol* **13**, 403-413 (2015). <https://doi.org/10.1038/nrmicro3449>.

8. J. W. Schoggins, S. J. Wilson, M. Panis, M. Y. Murphy, C. T. Jones, P. Bieniasz, C. M. Rice, A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature* **472**, 481-485 (2011). <https://doi.org/10.1038/nature09907>.
9. C. M. Berry, Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the power of the innate immune system. *Cytokine Growth Factor Rev* **31**, 83-90 (2016). <https://doi.org/10.1016/j.cytogfr.2016.08.001>.
10. T. B. Lavoie, E. Kalie, S. Crisafulli-Cabatu, R. Abramovich, G. DiGioia, K. Moolchan, S. Pestka, G. Schreiber, Binding and activity of all human alpha interferon subtypes. *Cytokine* **56**, 282-289 (2011). <https://doi.org/10.1016/j.cyto.2011.07.019>.
11. H. P. Moll, T. Maier, A. Zommer, T. Lavoie, C. Brostjan, The differential activity of interferon-alpha subtypes is consistent among distinct target genes and cell types. *Cytokine* **53**, 52-59 (2011). <https://doi.org/10.1016/j.cyto.2010.09.006>.
12. R. Szubin, W. L. Chang, T. Greasby, L. Beckett, N. Baumgarth, Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells. *J Interferon Cytokine Res* **28**, 749-763 (2008). <https://doi.org/10.1089/jir.2008.0037>.
13. P. Borrow, Innate immunity in acute HIV-1 infection. *Curr Opin HIV AIDS* **6**, 353-363 (2011). <https://doi.org/10.1097/COH.0b013e3283495996>.
14. S. E. Bosinger, N. S. Utay, Type I interferon: understanding its role in HIV pathogenesis and therapy. *Curr HIV/AIDS Rep* **12**, 41-53 (2015). <https://doi.org/10.1007/s11904-014-0244-6>.
15. K. Nganou-Makamdop, D. C. Douek, Manipulating the interferon signaling pathway: Implications for HIV infection. *Virol Sin* **34**, 192-196 (2019). <https://doi.org/10.1007/s12250-019-00085-5>.
16. N. S. Utay, D. C. Douek, Interferons and HIV infection: The Good, the Bad, and the Ugly. *Pathog Immun* **1**, 107-116 (2016). <https://doi.org/10.20411/pai.v1i1.125>.

17. S. E. Bosinger, D. L. Sodora, G. Silvestri, Generalized immune activation and innate immune responses in simian immunodeficiency virus infection. *Curr Opin HIV AIDS* **6**, 411-418 (2011). <https://doi.org/10.1097/COH.0b013e3283499cf6>.
18. A. R. Stacey, P. J. Norris, L. Qin, E. A. Haygreen, E. Taylor, J. Heitman, M. Lebedeva, A. DeCamp, D. Li, D. Grove, S. G. Self, P. Borrow, Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. *J Virol* **83**, 3719-3733 (2009). <https://doi.org/10.1128/JVI.01844-08>.
19. K. Abel, D. M. Rocke, B. Chohan, L. Fritts, C. J. Miller, Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. *J Virol* **79**, 12164-12172 (2005). <https://doi.org/10.1128/JVI.79.19.12164-12172.2005>.
20. Q. Li, J. D. Estes, P. M. Schlievert, L. Duan, A. J. Brosnahan, P. J. Southern, C. S. Reilly, M. L. Peterson, N. Schultz-Darken, K. G. Brunner, K. R. Nephew, S. Pambuccian, J. D. Lifson, J. V. Carlis, A. T. Haase, Glycerol monolaurate prevents mucosal SIV transmission. *Nature* **458**, 1034-1038 (2009). <https://doi.org/10.1038/nature07831>.
21. N. G. Sandler, S. E. Bosinger, J. D. Estes, R. T. Zhu, G. K. Tharp, E. Boritz, D. Levin, S. Wijeyesinghe, K. N. Makamdop, G. Q. del Prete, B. J. Hill, J. K. Timmer, E. Reiss, G. Yarden, S. Darko, E. Contijoch, J. P. Todd, G. Silvestri, M. Nason, R. B. Norgren, Jr., B. F. Keele, S. Rao, J. A. Langer, J. D. Lifson, G. Schreiber, D. C. Douek, Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. *Nature* **511**, 601-605 (2014). <https://doi.org/10.1038/nature13554>.
22. R. S. Veazey, H. A. Pilch-Cooper, T. J. Hope, G. Alter, A. M. Carias, M. Sips, X. Wang, B. Rodriguez, S. F. Sieg, A. Reich, P. Wilkinson, M. J. Cameron, M. M. Lederman, Prevention of SHIV transmission by topical IFN-beta treatment. *Mucosal Immunol* **9**, 1528-1536 (2016). <https://doi.org/10.1038/mi.2015.146>.

23. D. Carnathan, B. Lawson, J. Yu, K. Patel, J. M. Billingsley, G. K. Tharp, O. M. Delmas, R. Dawoud, P. Wilkinson, C. Nicolette, M. J. Cameron, R. P. Sekaly, S. E. Bosinger, G. Silvestri, T. H. Vanderford, Reduced chronic lymphocyte activation following interferon alpha blockade during the acute phase of simian immunodeficiency virus infection in rhesus macaques. *J Virol* **92**, (2018). <https://doi.org/10.1128/JVI.01760-17>.
24. G. A. Hardy, S. Sieg, B. Rodriguez, D. Anthony, R. Asaad, W. Jiang, J. Mudd, T. Schacker, N. T. Funderburg, H. A. Pilch-Cooper, R. Debernardo, R. L. Rabin, M. M. Lederman, C. V. Harding, Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. *PLoS One* **8**, e56527 (2013). <https://doi.org/10.1371/journal.pone.0056527>.
25. A. R. Sedaghat, J. German, T. M. Teslovich, J. Cofrancesco, Jr., C. C. Jie, C. C. Talbot, Jr., R. F. Siliciano, Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. *J Virol* **82**, 1870-1883 (2008). <https://doi.org/10.1128/JVI.02228-07>.
26. H. Rempel, B. Sun, C. Calosing, S. K. Pillai, L. Pulliam, Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. *AIDS* **24**, 1415-1423 (2010). <https://doi.org/10.1097/QAD.0b013e32833ac623>.
27. S. Fernandez, S. Tanaskovic, K. Helbig, R. Rajasuriar, M. Kramski, J. M. Murray, M. Beard, D. Purcell, S. R. Lewin, P. Price, M. A. French, CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells. *J Infect Dis* **204**, 1927-1935 (2011). <https://doi.org/10.1093/infdis/jir659>.
28. G. Silvestri, D. L. Sodora, R. A. Koup, H. M. McClure, S. I. Staprans, M. B. Feinberg, Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. *Immunity* **18**, 441-452 (2003). [https://doi.org/https://doi.org/10.1016/S1074-7613\(03\)00060-8](https://doi.org/https://doi.org/10.1016/S1074-7613(03)00060-8).

29. S. M. Dillon, K. Guo, G. L. Austin, S. Gianella, P. A. Engen, E. A. Mutlu, J. Losurdo, G. Swanson, P. Chakradeo, A. Keshavarzian, A. L. Landay, M. L. Santiago, C. C. Wilson, A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis. *AIDS* **32**, 1599-1611 (2018). <https://doi.org/10.1097/QAD.0000000000001863>.
30. J. P. Herbeuval, A. Boasso, J. C. Grivel, A. W. Hardy, S. A. Anderson, M. J. Dolan, C. Chougnet, J. D. Lifson, G. M. Shearer, TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. *Blood* **105**, 2458-2464 (2005). <https://doi.org/10.1182/blood-2004-08-3058>.
31. D. Sauce, C. Elbim, V. Appay, Monitoring cellular immune markers in HIV infection: from activation to exhaustion. *Curr Opin HIV AIDS* **8**, 125-131 (2013). <https://doi.org/10.1097/COH.0b013e32835d08a9>.
32. S. Lederer, D. Favre, K. A. Walters, S. Proll, B. Kanwar, Z. Kasakow, C. R. Baskin, R. Palermo, J. M. McCune, M. G. Katze, Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. *PLoS Pathog* **5**, e1000296 (2009). <https://doi.org/10.1371/journal.ppat.1000296>.
33. S. E. Bosinger, Q. Li, S. N. Gordon, N. R. Klatt, L. Duan, L. Xu, N. Francella, A. Sidahmed, A. J. Smith, E. M. Cramer, M. Zeng, D. Masopust, J. V. Carlis, L. Ran, T. H. Vanderford, M. Paiardini, R. B. Isett, D. A. Baldwin, J. G. Else, S. I. Staprans, G. Silvestri, A. T. Haase, D. J. Kelvin, Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. *J Clin Invest* **119**, 3556-3572 (2009). <https://doi.org/10.1172/JCI40115>.
34. B. Jacquelin, V. Mayau, B. Targat, A. S. Liovat, D. Kunkel, G. Petitjean, M. A. Dillies, P. Roques, C. Butor, G. Silvestri, L. D. Giavedoni, P. Lebon, F. Barre-Sinoussi, A. Benecke, M. C. Muller-Trutwin, Nonpathogenic SIV infection of African green monkeys

- induces a strong but rapidly controlled type I IFN response. *J Clin Invest* **119**, 3544-3555 (2009). <https://doi.org/10.1172/JCI40093>.
35. P. W. Hunt, HIV and inflammation: mechanisms and consequences. *Curr HIV/AIDS Rep* **9**, 139-147 (2012). <https://doi.org/10.1007/s11904-012-0118-8>.
36. A. Soper, I. Kimura, S. Nagaoka, Y. Konno, K. Yamamoto, Y. Koyanagi, K. Sato, Type I interferon responses by HIV-1 infection: Association with disease progression and control. *Front Immunol* **8**, 1823 (2017). <https://doi.org/10.3389/fimmu.2017.01823>.
37. D. M. Asmuth, R. L. Murphy, S. L. Rosenkranz, J. J. Lertora, S. Kottlilil, Y. Cramer, E. S. Chan, R. T. Schooley, C. R. Rinaldo, N. Thielman, X. D. Li, S. M. Wahl, J. Shore, J. Janik, R. A. Lempicki, Y. Simpson, R. B. Pollard, A. C. T. G. A. Team, Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. *J Infect Dis* **201**, 1686-1696 (2010). <https://doi.org/10.1086/652420>.
38. L. Azzoni, A. S. Foulkes, E. Papasavvas, A. M. Mexas, K. M. Lynn, K. Mounzer, P. Tebas, J. M. Jacobson, I. Frank, M. P. Busch, S. G. Deeks, M. Carrington, U. O'Doherty, J. Kostman, L. J. Montaner, Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. *J Infect Dis* **207**, 213-222 (2013). <https://doi.org/10.1093/infdis/jis663>.
39. F. Boue, J. Reynes, C. Rouzioux, D. Emilie, F. Souala, R. Tubiana, C. Goujard, R. Lancar, D. Costagliola, Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. *AIDS* **25**, 115-118 (2011). <https://doi.org/10.1097/QAD.0b013e328340a1e7>.
40. C. Goujard, D. Emilie, C. Roussillon, V. Godot, C. Rouzioux, A. Venet, C. Colin, G. Pialoux, P. M. Girard, V. Boilet, M. L. Chaix, P. Galanaud, G. Chene, A.-I. S. Group, Continuous versus intermittent treatment strategies during primary HIV-1 infection: the

- randomized ANRS INTERPRIM Trial. *AIDS* **26**, 1895-1905 (2012).
<https://doi.org/10.1097/QAD.0b013e32835844d9>.
41. A. Zhen, V. Rezek, C. Youn, B. Lam, N. Chang, J. Rick, M. Carrillo, H. Martin, S. Kasparian, P. Syed, N. Rice, D. G. Brooks, S. G. Kitchen, Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. *J Clin Invest* **127**, 260-268 (2017). <https://doi.org/10.1172/JCI89488>.
42. L. Cheng, J. Ma, J. Li, D. Li, G. Li, F. Li, Q. Zhang, H. Yu, F. Yasui, C. Ye, L. C. Tsao, Z. Hu, L. Su, L. Zhang, Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. *J Clin Invest* **127**, 269-279 (2017).
<https://doi.org/10.1172/JCI90745>.
43. X. Wei, J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, N. L. Komarova, M. A. Nowak, B. H. Hahn, P. D. Kwong, G. M. Shaw, Antibody neutralization and escape by HIV-1. *Nature* **422**, 307-312 (2003). <https://doi.org/10.1038/nature01470>.
44. K. J. Bar, C. Y. Tsao, S. S. Iyer, J. M. Decker, Y. Yang, M. Bonsignori, X. Chen, K. K. Hwang, D. C. Montefiori, H. X. Liao, P. Hraber, W. Fischer, H. Li, S. Wang, S. Sterrett, B. F. Keele, V. V. Ganusov, A. S. Perelson, B. T. Korber, I. Georgiev, J. S. McLellan, J. W. Pavlicek, F. Gao, B. F. Haynes, B. H. Hahn, P. D. Kwong, G. M. Shaw, Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. *PLoS Pathog* **8**, e1002721 (2012). <https://doi.org/10.1371/journal.ppat.1002721>.
45. P. Borrow, H. Lewicki, X. Wei, M. S. Horwitz, N. Pfeffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, G. M. Shaw, Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. *Nat Med* **3**, 205-211 (1997).
<https://doi.org/10.1038/nm0297-205>.

46. N. Goonetilleke, M. K. Liu, J. F. Salazar-Gonzalez, G. Ferrari, E. Giorgi, V. V. Ganusov, B. F. Keele, G. H. Learn, E. L. Turnbull, M. G. Salazar, K. J. Weinhold, S. Moore, C. C. C. B, N. Letvin, B. F. Haynes, M. S. Cohen, P. Hraber, T. Bhattacharya, P. Borrow, A. S. Perelson, B. H. Hahn, G. M. Shaw, B. T. Korber, A. J. McMichael, The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. *J Exp Med* **206**, 1253-1272 (2009). <https://doi.org/10.1084/jem.20090365>.
47. A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho, HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science* **271**, 1582-1586 (1996). <https://doi.org/10.1126/science.271.5255.1582>.
48. B. Ramratnam, S. Bonhoeffer, J. Binley, A. Hurley, L. Zhang, J. E. Mittler, M. Markowitz, J. P. Moore, A. S. Perelson, D. D. Ho, Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. *Lancet* **354**, 1782-1785 (1999). [https://doi.org/10.1016/S0140-6736\(99\)02035-8](https://doi.org/10.1016/S0140-6736(99)02035-8).
49. N. F. Parrish, F. Gao, H. Li, E. E. Giorgi, H. J. Barbian, E. H. Parrish, L. Zajic, S. S. Iyer, J. M. Decker, A. Kumar, B. Hora, A. Berg, F. Cai, J. Hopper, T. N. Denny, H. Ding, C. Ochsenbauer, J. C. Kappes, R. P. Galimidi, A. P. West, Jr., P. J. Bjorkman, C. B. Wilen, R. W. Doms, M. O'Brien, N. Bhardwaj, P. Borrow, B. F. Haynes, M. Muldoon, J. P. Theiler, B. Korber, G. M. Shaw, B. H. Hahn, Phenotypic properties of transmitted founder HIV-1. *Proc Natl Acad Sci U S A* **110**, 6626-6633 (2013). <https://doi.org/10.1073/pnas.1304288110>.
50. S. S. Iyer, F. Bibollet-Ruche, S. Sherrill-Mix, G. H. Learn, L. Plenderleith, A. G. Smith, H. J. Barbian, R. M. Russell, M. V. Gondim, C. Y. Bahari, C. M. Shaw, Y. Li, T. Decker, B. F. Haynes, G. M. Shaw, P. M. Sharp, P. Borrow, B. H. Hahn, Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. *Proc Natl Acad Sci U S A* **114**, E590-E599 (2017). <https://doi.org/10.1073/pnas.1620144114>.

51. M. S. Kunzi, H. Farzadegan, J. B. Margolick, D. Vlahov, P. M. Pitha, Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression. *J Infect Dis* **171**, 822-828 (1995). <https://doi.org/10.1093/infdis/171.4.822>.
52. B. R. Edlin, M. H. St Clair, P. M. Pitha, S. M. Whaling, D. M. King, J. D. Bitran, R. A. Weinstein, In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response. *Ann Intern Med* **117**, 457-460 (1992). <https://doi.org/10.7326/0003-4819-117-6-457>.
53. J. F. Salazar-Gonzalez, E. Bailes, K. T. Pham, M. G. Salazar, M. B. Guffey, B. F. Keele, C. A. Derdeyn, P. Farmer, E. Hunter, S. Allen, O. Manigart, J. Mulenga, J. A. Anderson, R. Swanstrom, B. F. Haynes, G. S. Athreya, B. T. Korber, P. M. Sharp, G. M. Shaw, B. H. Hahn, Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. *J Virol* **82**, 3952-3970 (2008). <https://doi.org/10.1128/JVI.02660-07>.
54. B. F. Keele, E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J. L. Kirchherr, F. Gao, J. A. Anderson, L. H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A. Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C. Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C. Seoighe, A. S. Perelson, T. Bhattacharya, B. T. Korber, B. H. Hahn, G. M. Shaw, Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A* **105**, 7552-7557 (2008). <https://doi.org/10.1073/pnas.0802203105>.
55. F. Gao, M. Bonsignori, H. X. Liao, A. Kumar, S. M. Xia, X. Lu, F. Cai, K. K. Hwang, H. Song, T. Zhou, R. M. Lynch, S. M. Alam, M. A. Moody, G. Ferrari, M. Berrong, G. Kelsoe, G. M. Shaw, B. H. Hahn, D. C. Montefiori, G. Kamanga, M. S. Cohen, P. Hraber, P. D. Kwong, B. T. Korber, J. R. Mascola, T. B. Kepler, B. F. Haynes, Cooperation of B

- cell lineages in induction of HIV-1-broadly neutralizing antibodies. *Cell* **158**, 481-491 (2014). <https://doi.org/10.1016/j.cell.2014.06.022>.
56. M. Bonsignori, E. F. Kreider, D. Fera, R. R. Meyerhoff, T. Bradley, K. Wiehe, S. M. Alam, B. Aussedat, W. E. Walkowicz, K. K. Hwang, K. O. Saunders, R. Zhang, M. A. Gladden, A. Monroe, A. Kumar, S. M. Xia, M. Cooper, M. K. Louder, K. McKee, R. T. Bailer, B. W. Pier, C. A. Jette, G. Kelsoe, W. B. Williams, L. Morris, J. Kappes, K. Wagh, G. Kamanga, M. S. Cohen, P. T. Hraber, D. C. Montefiori, A. Trama, H. X. Liao, T. B. Kepler, M. A. Moody, F. Gao, S. J. Danishefsky, J. R. Mascola, G. M. Shaw, B. H. Hahn, S. C. Harrison, B. T. Korber, B. F. Haynes, Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. *Sci Transl Med* **9**, (2017). <https://doi.org/10.1126/scitranslmed.aai7514>.
 57. K. Wagh, E. F. Kreider, Y. Li, H. J. Barbican, G. H. Learn, E. Giorgi, P. T. Hraber, T. G. Decker, A. G. Smith, M. V. Gondim, L. Gillis, J. Wandzilak, G. Y. Chuang, R. Rawi, F. Cai, P. Pellegrino, I. Williams, J. Overbaugh, F. Gao, P. D. Kwong, B. F. Haynes, G. M. Shaw, P. Borrow, M. S. Seaman, B. H. Hahn, B. Korber, Completeness of HIV-1 envelope glycan shield at transmission determines neutralization breadth. *Cell Rep* **25**, 893-908 e897 (2018). <https://doi.org/10.1016/j.celrep.2018.09.087>.
 58. A. Gelman, J. B. Carlin, H. S. Stern, D. B. Rubin, *Bayesian Data Analysis, Second Edition (Texts in Statistical Science)*. (Chapman & Hall/CRC 2003).
 59. A. E. Fenton-May, O. Dibben, T. Emmerich, H. Ding, K. Pfafferoth, M. M. Aasa-Chapman, P. Pellegrino, I. Williams, M. S. Cohen, F. Gao, G. M. Shaw, B. H. Hahn, C. Ochsenbauer, J. C. Kappes, P. Borrow, Relative resistance of HIV-1 founder viruses to control by interferon-alpha. *Retrovirology* **10**, 146 (2013). <https://doi.org/10.1186/1742-4690-10-146>.

60. G. M. Laird, E. E. Eisele, S. A. Rabi, J. Lai, S. Chioma, J. N. Blankson, J. D. Siliciano, R. F. Siliciano, Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. *PLoS Pathog* **9**, e1003398 (2013). <https://doi.org/10.1371/journal.ppat.1003398>.
61. J. C. Lorenzi, Y. Z. Cohen, L. B. Cohn, E. F. Kreider, J. P. Barton, G. H. Learn, T. Oliveira, C. L. Lavine, J. A. Horwitz, A. Settler, M. Jankovic, M. S. Seaman, A. K. Chakraborty, B. H. Hahn, M. Caskey, M. C. Nussenzweig, Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. *Proc Natl Acad Sci U S A* **113**, E7908-E7916 (2016). <https://doi.org/10.1073/pnas.1617789113>.
62. P. Mendoza, H. Gruell, L. Nogueira, J. A. Pai, A. L. Butler, K. Millard, C. Lehmann, I. Suarez, T. Y. Oliveira, J. C. C. Lorenzi, Y. Z. Cohen, C. Wyen, T. Kummerle, T. Karagounis, C. L. Lu, L. Handl, C. Unson-O'Brien, R. Patel, C. Ruping, M. Schlotz, M. Witmer-Pack, I. Shimeliovich, G. Kremer, E. Thomas, K. E. Seaton, J. Horowitz, A. P. West, Jr., P. J. Bjorkman, G. D. Tomaras, R. M. Gulick, N. Pfeifer, G. Fatkenheuer, M. S. Seaman, F. Klein, M. Caskey, M. C. Nussenzweig, Combination therapy with anti-HIV-1 antibodies maintains viral suppression. *Nature* **561**, 479-484 (2018). <https://doi.org/10.1038/s41586-018-0531-2>.
63. K. J. Bar, M. C. Sneller, L. J. Harrison, J. S. Justement, E. T. Overton, M. E. Petrone, D. B. Salantes, C. A. Seamon, B. Scheinfeld, R. W. Kwan, G. H. Learn, M. A. Proschan, E. F. Kreider, J. Blazkova, M. Bardsley, E. W. Refsland, M. Messer, K. E. Clarridge, N. B. Tustin, P. J. Madden, K. Oden, S. J. O'Dell, B. Jarocki, A. R. Shiakolas, R. L. Tressler, N. A. Doria-Rose, R. T. Bailer, J. E. Ledgerwood, E. V. Capparelli, R. M. Lynch, B. S. Graham, S. Moir, R. A. Koup, J. R. Mascola, J. A. Hoxie, A. S. Fauci, P. Tebas, T. W. Chun, Effect of HIV antibody VRC01 on viral rebound after treatment interruption. *N Engl J Med* **375**, 2037-2050 (2016). <https://doi.org/10.1056/NEJMoa1608243>.

64. D. B. Salantes, Y. Zheng, F. Mampe, T. Srivastava, S. Beg, J. Lai, J. Z. Li, R. L. Tressler, R. A. Koup, J. Hoxie, M. Abdel-Mohsen, S. Sherrill-Mix, K. McCormick, E. T. Overton, F. D. Bushman, G. H. Learn, R. F. Siliciano, J. M. Siliciano, P. Tebas, K. J. Bar, HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. *J Clin Invest* **128**, 3102-3115 (2018). <https://doi.org/10.1172/JCI120194>.
65. E. Papasavvas, J. R. Kostman, K. Mounzer, R. M. Grant, R. Gross, C. Gallo, L. Azzoni, A. Foulkes, B. Thiel, M. Pistilli, A. Mackiewicz, J. Shull, L. J. Montaner, Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. *PLoS Med* **1**, e64 (2004). <https://doi.org/10.1371/journal.pmed.0010064>.
66. Y. Z. Cohen, J. C. C. Lorenzi, L. Krassnig, J. P. Barton, L. Burke, J. Pai, C. L. Lu, P. Mendoza, T. Y. Oliveira, C. Sleckman, K. Millard, A. L. Butler, J. P. Dizon, S. A. Belblidia, M. Witmer-Pack, I. Shimeliovich, R. M. Gulick, M. S. Seaman, M. Jankovic, M. Caskey, M. C. Nussenzweig, Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. *J Exp Med* **215**, 2311-2324 (2018). <https://doi.org/10.1084/jem.20180936>.
67. L. Azzoni, E. Papasavvas, J. Kostman, P. Tebas, K. Mounzer, I. Frank, K. M. Lynn, L. Lalley-Chareczko, R. Feng, S. Appel, B. Howell, D. Holder, S. L. Goh, G. Wu, L. M. Montaner, paper presented at the Conference on Retroviruses and Opportunistic Infections, Seattle Washington, 2019. Interferon α 2b reduces inducible CD4-associated HIV in ART-suppressed individuals
68. M. Markowitz, M. Louie, A. Hurley, E. Sun, M. Di Mascio, A. S. Perelson, D. D. Ho, A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. *J Virol* **77**, 5037-5038 (2003). <https://doi.org/10.1128/jvi.77.8.5037-5038.2003>.
69. T. L. Foster, H. Wilson, S. S. Iyer, K. Coss, K. Doores, S. Smith, P. Kellam, A. Finzi, P. Borrow, B. H. Hahn, S. J. D. Neil, Resistance of transmitted founder HIV-1 to IFITM-

- mediated restriction. *Cell Host Microbe* **20**, 429-442 (2016).
<https://doi.org/10.1016/j.chom.2016.08.006>.
70. D. R. Collins, G. D. Gaiha, B. D. Walker, CD8(+) T cells in HIV control, cure and prevention. *Nat Rev Immunol*, (2020). <https://doi.org/10.1038/s41577-020-0274-9>.
71. L. D. Harris, B. Tabb, D. L. Sodora, M. Paiardini, N. R. Klatt, D. C. Douek, G. Silvestri, M. Muller-Trutwin, I. Vasile-Pandrea, C. Apetrei, V. Hirsch, J. Lifson, J. M. Brenchley, J. D. Estes, Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. *J Virol* **84**, 7886-7891 (2010).
<https://doi.org/10.1128/JVI.02612-09>.
72. Q. Li, A. J. Smith, T. W. Schacker, J. V. Carlis, L. Duan, C. S. Reilly, A. T. Haase, Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. *J Immunol* **183**, 1975-1982 (2009).
<https://doi.org/10.4049/jimmunol.0803222>.
73. M. von Sydow, A. Sonnerborg, H. Gaines, O. Strannegard, Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. *AIDS Res Hum Retroviruses* **7**, 375-380 (1991). <https://doi.org/10.1089/aid.1991.7.375>.
74. M. R. Betts, J. F. Krowka, T. B. Kepler, M. Davidian, C. Christopherson, S. Kwok, L. Louie, J. J. Eron, H. Sheppard, J. A. Frelinger, Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. *AIDS Res Hum Retroviruses* **15**, 1219-1228 (2004). <https://doi.org/10.1089/088922299310313>.
75. J. A. Warren, G. Clutton, N. Goonetilleke, Harnessing CD8(+) T cells under HIV antiretroviral therapy. *Front Immunol* **10**, 291 (2019).
<https://doi.org/10.3389/fimmu.2019.00291>.

76. M. Bonsignori, M. A. Moody, R. J. Parks, T. M. Holl, G. Kelsoe, C. B. Hicks, N. Vandergrift, G. D. Tomaras, B. F. Haynes, HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. *J Immunol* **183**, 2708-2717 (2009). <https://doi.org/10.4049/jimmunol.0901068>.
77. J. L. Mitchell, H. Takata, R. Muir, D. J. Colby, E. Kroon, T. A. Crowell, C. Sacdalan, S. Pinyakorn, S. Puttamaswin, K. Benjapornpong, R. Trichavaroj, R. L. Tressler, L. Fox, V. R. Polonis, D. L. Bolton, F. Maldarelli, S. R. Lewin, E. K. Haddad, P. Phanuphak, M. L. Robb, N. L. Michael, M. de Souza, N. Phanuphak, J. Ananworanich, L. Trautmann, R. V. Rv, R. V. S. Groups, Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. *J Clin Invest* **130**, 2845-2858 (2020). <https://doi.org/10.1172/JCI130597>.
78. A. Ugarte, Y. Romero, A. Tricas, C. Casado, C. Lopez-Galindez, F. Garcia, L. Leal, Unintended HIV-1 infection during analytical therapy interruption. *J Infect Dis* **221**, 1740-1742 (2020). <https://doi.org/10.1093/infdis/jiz611>.
79. J. D. Lelievre, L. Hocqueloux, Unintended HIV-1 transmission to a sex partner in a study of a therapeutic vaccine candidate. *J Infect Dis* **220**, S5-S6 (2019). <https://doi.org/10.1093/infdis/jiz012>.
80. M. R. Abrahams, S. B. Joseph, N. Garrett, L. Tyers, M. Moeser, N. Archin, O. D. Council, D. Matten, S. Zhou, D. Doolabh, C. Anthony, N. Goonetilleke, S. A. Karim, D. M. Margolis, S. K. Pond, C. Williamson, R. Swanstrom, The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. *Sci Transl Med* **11**, (2019). <https://doi.org/10.1126/scitranslmed.aaw5589>.
81. B. Julg, L. Dee, J. Ananworanich, D. H. Barouch, K. Bar, M. Caskey, D. J. Colby, L. Dawson, K. L. Dong, K. Dube, J. Eron, J. Frater, R. T. Gandhi, R. Geleziunas, P. Goulder, G. J. Hanna, R. Jefferys, R. Johnston, D. Kuritzkes, J. Z. Li, U. Likhitwonnawut,

- J. van Lunzen, J. Martinez-Picado, V. Miller, L. J. Montaner, D. F. Nixon, D. Palm, G. Pantaleo, H. Peay, D. Persaud, J. Salzwedel, K. Salzwedel, T. Schacker, V. Sheikh, O. S. Sogaard, S. Spudich, K. Stephenson, J. Sugarman, J. Taylor, P. Tebas, C. T. Tiemessen, R. Tressler, C. D. Weiss, L. Zheng, M. L. Robb, N. L. Michael, J. W. Mellors, S. G. Deeks, B. D. Walker, Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. *Lancet HIV* **6**, e259-e268 (2019). [https://doi.org/10.1016/S2352-3018\(19\)30052-9](https://doi.org/10.1016/S2352-3018(19)30052-9).
82. E. N. Borducchi, J. Liu, J. P. Nkolola, A. M. Cadena, W. H. Yu, S. Fischinger, T. Broge, P. Abbink, N. B. Mercado, A. Chandrashekar, D. Jetton, L. Peter, K. McMahan, E. T. Moseley, E. Bekerman, J. Hesselgesser, W. Li, M. G. Lewis, G. Alter, R. Geleziunas, D. H. Barouch, Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. *Nature* **563**, 360-364 (2018). <https://doi.org/10.1038/s41586-018-0600-6>.
83. L. K. Vibholm, C. V. Konrad, M. H. Schleimann, G. Frattari, A. Winckelmann, V. Klastrop, N. M. Jensen, S. S. Jensen, M. Schmidt, B. Wittig, K. Zuwala, K. Mack, R. Olesen, S. Hua, M. Lichterfeld, L. Ostergaard, P. W. Denton, M. Tolstrup, O. S. Sogaard, Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. *AIDS* **33**, 1315-1325 (2019). <https://doi.org/10.1097/QAD.0000000000002213>.
84. D. M. Margolis, J. V. Garcia, D. J. Hazuda, B. F. Haynes, Latency reversal and viral clearance to cure HIV-1. *Science* **353**, aaf6517 (2016). <https://doi.org/10.1126/science.aaf6517>.
85. E. Papasavvas, L. Azzoni, A. V. Kossenkova, N. Dawany, K. H. Morales, M. Fair, B. N. Ross, K. Lynn, A. Mackiewicz, K. Mounzer, P. Tebas, J. M. Jacobson, J. R. Kostman, L. Showe, L. J. Montaner, NK response correlates with HIV decrease in pegylated IFN-alpha2a-treated antiretroviral therapy-suppressed subjects. *J Immunol* **203**, 705-717 (2019). <https://doi.org/10.4049/jimmunol.1801511>.

86. J. F. Salazar-Gonzalez, M. G. Salazar, B. F. Keele, G. H. Learn, E. E. Giorgi, H. Li, J. M. Decker, S. Wang, J. Baalwa, M. H. Kraus, N. F. Parrish, K. S. Shaw, M. B. Guffey, K. J. Bar, K. L. Davis, C. Ochsenbauer-Jambor, J. C. Kappes, M. S. Saag, M. S. Cohen, J. Mulenga, C. A. Derdeyn, S. Allen, E. Hunter, M. Markowitz, P. Hraber, A. S. Perelson, T. Bhattacharya, B. F. Haynes, B. T. Korber, B. H. Hahn, G. M. Shaw, Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. *J Exp Med* **206**, 1273-1289 (2009). <https://doi.org/10.1084/jem.20090378>.
87. F. Sievers, A. Wilm, D. Dineen, T. J. Gibson, K. Karplus, W. Li, R. Lopez, H. McWilliam, M. Remmert, J. Soding, J. D. Thompson, D. G. Higgins, Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol* **7**, 539 (2011). <https://doi.org/10.1038/msb.2011.75>.
88. A. Stamatakis, RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics* **30**, 1312-1313 (2014). <https://doi.org/10.1093/bioinformatics/btu033>.
89. J. Maydt, T. Lengauer, Recco: recombination analysis using cost optimization. *Bioinformatics* **22**, 1064-1071 (2006). <https://doi.org/10.1093/bioinformatics/btl057>.
90. The R Project for Statistical Computing, <https://www.r-project.org/>.
91. B. Carpenter, A. Gelman, M. D. Hoffman, D. Lee, B. Goodrich, M. Betancourt, M. Brubaker, J. Guo, P. Li, A. Riddell, Stan: A Probabilistic Programming Language. *Journal of Statistical Software* **76**, (2017). <https://doi.org/10.18637/jss.v076.i01>.

Acknowledgments

We thank G. H. Learn for sequence analysis, S.S. Iyer for expertise in IFN-I resistance testing, K. Ruffin for preparation of the manuscript and the participants who generously volunteered for these studies.

Funding

This work was supported in part by grants from the National Institutes of Health (U01 AI 129825 to M.C., U01 AI 065279 to L.J.M., UM1 AI 126620 to L.J.M., K.J.B., and B.H.H., P30 AI 045008 to R.G.C., L.J.M., K.J.B., and B.H.H., UM1 AI 126619 to P.B., UM1 AI100663 to M.C.N., R01 AI 111789 to B.H.H., R01 AI 114266 to B.H.H.), the Medical Research Council (MR/K012037 to P.B.) and the Bill and Melinda Gates Foundation (Collaboration for AIDS Vaccine Discovery grant OPP1092074 to M.C. N.). S.S.-M. and R.M.R. were supported by a training grant (T32 AI 007632). P.B. is a Jenner Institute Investigator.

Author contributions

M.V.P.G., S.S.-M., F.B.-R., R.M.R., G.M.S., P.B., K.J.B. and B.H.H. conceived and planned the study; M.V.P.G., F.B.-R., S.T., A.G.S., Y.L., W.L., A.N.A., J.D., and J.C. performed sequence analyses; M.V.P.G., S.S.-M., F.B.-R., R.M.R. and S.T. isolated virus and determined IFN-I IC₅₀ values; L.J.P. and P.M.S. performed evolutionary analyses; S.S.-M. performed statistical analyses; A.E.F.-M., P.P., I.W., E.P., J.C.C.L., D.B.S., F. M., M.A.M., Y.Z.C., S.H., M.S.G., L.J.M., R.G.C., J.M.S., R.F.S., M.C., M.C.N., P.B., K.J.B. conducted clinical trials, provided patient material, performed serological analyses, and performed outgrowth assays; M.V.P.G., S.S.-M. P.B., K.J.B. and B.H.H. coordinated the contributions of all authors and wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Data and materials availability

HIV-1 sequences have been deposited in GenBank as listed in table S5. Analysis code is available at <https://github.com/sherrillmix/ifnDynamicsModels> and will be archived on Zenodo prior to publication.

Figure captions

Fig. 1. HIV-1 viral loads and CD4+ T cell counts in prospectively studied individuals. Viral loads (RNA copies/ml; red) and CD4+ T cell counts (cells/ μ l; blue) are shown for 10 acutely infected individuals (y-axis), who were followed from the onset of symptoms until 213 - 645 weeks (4.1 - 12.4 years) post-infection (x-axis). Participants are grouped based on disease progression, with (A) including typical progressors, (B) non-progressors, and (C) rapid progressors. Gray shading indicates suppressive antiretroviral therapy (alternating shading in WEAU indicates non-suppressive zidovudine monotherapy). Purple arrows denote the time points of PBMC samples that yielded QVOA isolates, open triangles denote superinfection, and dashed vertical lines indicate termination of the study or loss to follow up.

Fig. 2. Kinetics of IFN-I resistance over the course of HIV-1 infection. IFN α 2 (A-C) and IFN β (D-F) IC₅₀ values (pg/ml) are shown for limiting dilution (circles) and bulk culture-derived (squares) plasma isolates from the onset of symptoms until 140 - 466 weeks (2.7 - 8.9 years) post-infection (yellow squares indicate bulk isolates from plasma samples that also yielded limiting dilution isolates). Colored lines denote the average IC₅₀ values as estimated by a Bayesian model, with darker shading indicating the 95% credible and lighter shading the 95% prediction intervals, respectively. Gray shading indicates suppressive antiretroviral therapy

(alternating shading in WEAU indicates non-suppressive zidovudine monotherapy). Blue circles indicate isolates obtained by viral outgrowth from CD4⁺ T cells after years of suppressive ART. Open triangles denote superinfection (fig. S2). Participants are grouped as in Fig. 1, with panels A, B and C showing typical progressors (orange), non-progressors (green), and rapid progressors (pink), respectively.

Fig. 3. Position of QVOA isolates within the evolving HIV-1 quasispecies. The evolutionary relationships of *env* nucleotide sequences generated by SGA either directly from plasma viral RNA or plasma viral isolates of participant MM34 are shown for a 6-year time period. Samples are colored by time point, with blue sequences derived early and red sequences derived late in infection. Purple leaves indicate the position of QVOA isolates obtained 2 and 3 years following ART initiation, while grey leaves indicate proviral sequences amplified from the corresponding PBMC sample (more detailed versions of this and phylogenetic trees from other participants are shown in fig. S2). One hypermutated PBMC-derived sequence is shown with a gap in the branch. The scale bar indicates 0.05 substitutions per site.

Fig. 4. IFN-I resistance of QVOA versus rebound viruses. (A, C) IFN α 2 (A) and IFN β (C) IC₅₀ values are shown for plasma isolates of individuals experiencing rebound viremia after ART cessation (red) and QVOA isolates generated from the PBMCs of ART suppressed individuals before (blue) or after (turquoise) ATI. Isolates are grouped by individuals (shaded boxes), with pre-ATI, rebound, and post-ATI isolates depicted in temporal order when available (see table S4 for details). Also shown are the IFN α 2 (A) and IFN β (C) IC₅₀ values for outgrowth isolates (blue) and plasma viruses (grey) from the longitudinal cohort (Fig. 2) as well as previously reported donor-recipient transmission pairs (50). For the latter, IC₅₀ values were adjusted to account for potency differences among commercial IFN-I batches. Squares indicate isolates from fast progressing individuals. (B,D) The fold-change in IFN α 2 and IFN β IC₅₀ values from acute

infection isolates is shown for rebound (red), chronic (grey), and pre-ATI (blue) and post-ATI (turquoise) QVOA isolates (see Supplementary Methods for a description of the Bayesian model). Violin plots indicate the estimated posterior probability of the mean fold change between isolate types, with the darker shading indicating the 95% credible interval and the lighter the 95% prediction interval. Dashed horizontal line indicates a fold change of 1 (which indicates no change).

Fig. 5. Genotype and IFN-I phenotype of rebound and outgrowth viruses before and after treatment interruption in a single individual. The phylogenetic relationships of *env* gene sequences from pre-ATI QVOA (blue), plasma rebound (red) and post-ATI QVOA (turquoise) isolates are shown for participant A08, along with available IFN α 2 and IFN β IC₅₀ values (pg/ml). Asterisks indicate bootstrap values >90%; the scale bar indicates 0.01 substitution per site. A clade of near identical rebound and QVOA isolates is highlighted by a bracket, with the two post-ATI QVOA isolates with elevated IFN-I resistance denoted by arrows.

Supplementary Materials

Supplementary Methods

Fig. S1. Transmitted founder virus inference and enumeration. Highlighter (v2.1.1) plots and associated phylogenetic trees of SGA and limiting dilution isolate derived *env* gene sequences are shown for the first available plasma sample of eight study participants. Tick marks indicate differences from the inferred TF sequence depicted in bold on top (red, T; green, A; blue, C; orange, G; gray, indel). Participants MM14, MM34 and MM40 were infected with more than one transmitted founder virus (highlighted in bold). Trees were constructed using the neighbor-joining method implemented in the Highlighter v2.1.1 software (hiv.lanl.gov).

Sequences obtained from plasma isolates are indicated by an asterisk. The scale bar indicated 1 base pair. Participants MM39 and WEAU were each infected with a single transmitted founder virus as reported previously (54, 57).

Fig. S2. HIV-1 quasispecies diversification over time. A maximum likelihood tree depicting the phylogenetic relationships of *env* nucleotide sequences amplified either directly from uncultured plasma (PLAS.SGS) or PBMCs (PBMC.SGS), or generated from limiting dilution-derived plasma (PLAS.ISO) and PBMC (PBMC.QVOA) viral isolates, is shown for each of 10 prospectively sampled individuals. Sequences are colored by time point (indicated in the sequence name), with blue (earliest samples) transitioning to red (latest samples) as in Fig. 3. Purple leaves indicates PBMC derived outgrowth viruses obtained after years of suppressive ART, while grey leaves indicate SGA sequences amplified directly from the corresponding PBMCs. Each leaf is labeled to indicate the individual, source, days post onset of symptoms, and a sequence or isolate identifier (see tables S1 and S2 for details). Asterisks indicate recombinants. A gap in a branch accommodates hypermutated sequences. The scale bar indicates 0.05 substitutions per site.

Fig. S3. Determination of IFN-I IC_{50} values. Dose response curves showing the effect of increasing amounts of IFN α 2 (A) and IFN β (B) on the replication potential of limiting dilution plasma viral isolates from participant MM33 are shown for individual timepoints with days following onset of symptoms (DFOs) indicated or combined (last panel). Curves are colored by timepoint. Dashed horizontal lines indicate the half-maximal inhibitory concentration (IC_{50}).

Fig. S4. Dynamic changes in IFN-I resistance over the course of HIV-1 infection. A hierarchical Bayesian change point model was used to estimate the IFN-I resistance of plasma viral isolates in 10 longitudinally sampled HIV-1 infected study participants. The model allowed

the inference of longitudinal patterns of IFN α 2 and IFN β IC₅₀ values across individuals by first predicting resistance as a fall from acute levels to a nadir point and then as variation from nadir levels based on changes in CD4+ T cell counts. (A-B) Predicted mean IFN α 2 (A) or IFN β (B) IC₅₀ values (lines) are shown for plasma virus isolates modelled for typical progressor (orange), non-progressor (green) and rapid progressor (pink) participants from the time of transmission over the early course of infection (the x-axis shows weeks from onset of symptoms), along with corresponding 95% credible (darker shading) and prediction (lighter shading) intervals. (C-D) Predicted mean IFN α 2 (C) or IFN β (B) IC₅₀ values (lines) are shown for plasma virus isolates modeled for individual typical progressor (orange), non-progressor (green) and rapid progressor (pink) participants based on changes in CD4+ T cell counts following the nadir (the x-axis shows decreases and increases from the nadir which is set to 0), along with corresponding 95% credible (darker shading) and prediction (lighter shading) intervals. Individual data points indicate virus isolates from the respective individuals, with shading indicating the estimated posterior probability that the time of nadir preceded the plasma collection time point (from white, probability of 0, to black, probability of 1). Isolates estimated to have less than 5% probability of following the time of nadir are not shown. For display, the nadir CD4+ T cell count was estimated as the posterior mean for that individual.

Fig. S5. Correlation of IFN α 2 and IFN β IC₅₀ values. The IFN α 2 and IFN β IC₅₀ of all longitudinal, outgrowth and rebound isolates are compared. Isolates from longitudinally studied individuals as well as participants in latency and/or treatment interruption trials are represented by points colored as indicated in the legend.

Fig. S6. Phylogenetic relationships of rebound isolates. A maximum likelihood tree depicting the phylogenetic relationships of 3' half-genome sequences of rebound isolates from

different study participants is shown. Isolates are colored according to the respective study (red, NCT02825797; green, NCT02463227; orange, NCT00051818; turquoise, NCT02227277; black, NCT02588586) as indicated in tables S3 and S4. Asterisks indicate bootstrap values of >90%; the scale bar indicates 0.01 substitution per site. Isolate 004.REB.4E3 was not sequenced.

Table S1. Generation of HIV-1 isolates from plasma and peripheral blood mononuclear cells of 10 individuals sampled from acute infection throughout their clinical course.

Table S2. IFN-I resistance of plasma and QVOA isolates from longitudinally sampled study participants.

Table S3. Generation of viral isolates from ART suppressed individuals with and without treatment interruption.

Table S4. IFN-I resistance of viral outgrowth and rebound isolates.

Table S5. Genbank accession numbers.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Supplementary Methods

Bayesian models of IFN-I resistance of HIV-1 plasma isolates from longitudinally sampled participants

To create a simple model of the temporal dynamics of type I interferon (IFN-I) resistance, IFN α 2 and IFN β IC₅₀ values were each modeled using a Bayesian change point hierarchical model. The model is based on a segmented regression of the log IC₅₀ making the following simplifying assumptions:

- Each participant has a level of resistance at the acute infection stage drawn from separate population-level distributions for typical, non- or fast progressors.
- Each participant has a drop (or rise) in IFN-I resistance from acute levels drawn from separate population-level distributions for typical, non- or fast progressors.
- Each participant has a time to nadir drawn from separate population-level distributions for typical, non- or fast progressors.
- Resistance changes linearly from onset of symptoms to time of nadir.
- The nadir of IFN-I resistance represents a changepoint in the data. Following this point, changes in IFN-I resistance are modeled as a linear function of CD4+ T cell count changes away from the count found at nadir.
- Where data is not present, CD4+ T cell counts are assumed to be linearly interpolated between adjacent observations.

The log IC₅₀ observation from each viral isolate i was modeled as a normal distribution $IC50_i \sim \text{Normal}(\mu_i, \sigma)$ with mean μ_i where:

$$\mu_i = \begin{cases} \alpha_{\text{person}_i} + \delta_{\text{person}_i} \frac{\text{time}_i}{s_{\text{person}_i}} & \text{if } \text{time}_i < s_{\text{person}_i} \\ \alpha_{\text{person}_i} + \delta_{\text{person}_i} + \beta_{\text{person}_i} (\text{CD4}_{\text{person}_i, \text{time}_i} - \text{CD4}_{\text{person}_i, s_{\text{person}_i}}) & \text{if } \text{time}_i \geq s_{\text{person}_i} \end{cases}$$

where the parameters α_j represent the level of IFN-I resistance at symptom onset, δ_j represents the change from symptom onset to nadir and s_j represents the time of nadir in person j . Study participant data is represented by time_i corresponding to the time since onset of symptoms and person_i recording the participant from which isolate i was collected, $\text{CD4}_{j,k}$ containing the estimated CD4+ T cell count for person j at time k and progression_j is the disease progression type (fast/non/typical) for participant j . The hierarchical probabilities

for these parameters were:

$$\begin{aligned}\sigma &\sim \text{Gamma}(1, 0.1) \\ \alpha_j &\sim \begin{cases} \text{Normal}(\theta_{\alpha, \text{typical}}, \tau_{\alpha}) & \text{if progression}_j = \text{typical} \\ \text{Normal}(\theta_{\alpha, \text{typical}} + \theta_{\alpha, \text{fast}}, \tau_{\alpha}) & \text{if progression}_j = \text{fast} \\ \text{Normal}(\theta_{\alpha, \text{typical}} + \theta_{\alpha, \text{non}}, \tau_{\alpha}) & \text{if progression}_j = \text{non} \end{cases} \\ \delta_j &\sim \begin{cases} \text{Normal}(\theta_{\delta, \text{typical}}, \tau_{\delta}) & \text{if progression}_j = \text{typical} \\ \text{Normal}(\theta_{\delta, \text{typical}} + \theta_{\delta, \text{fast}}, \tau_{\delta}) & \text{if progression}_j = \text{fast} \\ \text{Normal}(\theta_{\delta, \text{typical}} + \theta_{\delta, \text{non}}, \tau_{\delta}) & \text{if progression}_j = \text{non} \end{cases} \\ s_j &\sim \begin{cases} \text{NegativeBinomial}(\theta_{s, \text{typical}}, \tau_s) & \text{if progression}_j = \text{typical} \\ \text{NegativeBinomial}(\theta_{s, \text{typical}} \exp(\theta_{s, \text{fast}}), \tau_s) & \text{if progression}_j = \text{fast} \\ \text{NegativeBinomial}(\theta_{s, \text{typical}} \exp(\theta_{s, \text{non}}), \tau_s) & \text{if progression}_j = \text{non} \end{cases} \\ \beta_j &\sim \begin{cases} \text{Normal}(\theta_{\beta, \text{typical}}, \tau_{\beta}) & \text{if progression}_j = \text{typical} \\ \text{Normal}(\theta_{\beta, \text{fast}}, \tau_{\beta}) & \text{if progression}_j = \text{fast} \\ \text{Normal}(\theta_{\beta, \text{non}}, \tau_{\beta}) & \text{if progression}_j = \text{non} \end{cases}\end{aligned}$$

where j indicates each participant and $\text{NegativeBinomial}(x, y)$ represents a negative binomial distribution parameterized such that the expected value is x and the variance is $x + \frac{x^2}{y}$. All hyperparameters were given prior probabilities of $\theta_x \sim \text{Normal}(0, 10)$ for parameters representing the means of a distribution and $\tau_x \sim \text{Gamma}(1, 0.1)$ for parameters representing standard deviations other than $\theta_{\alpha, \text{typical}}$ and $\theta_{s, \text{typical}}$ which were given a flat prior and $\tau_s \sim \text{Cauchy}(0, 10)$.

For computational efficiency, the nadir time parameter s was discretized to weekly intervals, assumed to fall within 1 to 150 weeks after symptom onset and marginalized out of the joint probability:

$$p(\text{IC50}, \dots) = p(\dots) \prod_{i=1}^n \sum_{s=1}^{150} \text{Normal}(\text{IC50}_i | \mu_{i,s}, \sigma) \text{NegativeBinomial}(s | \theta_s, \tau_s)$$

where $\dots$ represents all parameters other than s and $\mu_{i,s}$ is defined the same as μ_i :

$$\mu_{i,s} = \begin{cases} \alpha_{\text{person}_i} + \frac{\text{time}_i}{s} \delta_{\text{person}_i} & \text{if time}_i < s \\ \alpha_{\text{person}_i} + \delta_{\text{person}_i} + \beta_{\text{person}_i} (\text{CD4}_{\text{person}_i, \text{time}_i} - \text{CD4}_{\text{person}_i, s}) & \text{if time}_i \geq s \end{cases}$$

Posterior probabilities were estimated with 50 Markov chain Monte Carlo chains of 5000 iterations each using Stan (91).

Bayesian models of IFN-I resistance of outgrowth and rebound HIV-1 isolates

To compare the IFN-I resistance of viral isolates derived from plasma samples collected during acute, chronic and rebound infections, as well as from viably frozen PBMCs collected during ART suppression (QVOA), IFN α 2 and IFN β IC₅₀ values were modeled using a Bayesian hierarchical model. The model is based on the assumptions that:

- Isolates found at acute infection form a base level of IFN-I resistance for a given person. Resistances in virus isolated from chronic, ART suppressed and rebound infection for this person are modelled as changes from this initial level.
- The mean IC₅₀ level within each person for acute isolates and the change from acute levels for chronic, QVOA and rebound isolates are drawn from a population-level distribution for that type.
- QVOA isolates are separated into two populations; a “pre” group composed of QVOA viruses isolated from study participants prior to or in the absence of treatment interruption (ATI) and a “post” group of QVOA viruses isolated from participants following ATI and reinitiation of ART.
- In both QVOA populations, the viruses can include some proportion of rebound-like isolates. This mixture is modeled in both pre- and post-treatment so that differences in mixture proportion between the two populations can be assessed.
- Variation in the potency of INF-I used to experimentally determine IC₅₀ values may shift the inferred resistance for isolates tested in other studies. This effect is modeled as a multiplicative shift in IC₅₀ for all isolates measured outside this study (acute recipient and chronic donor isolates from ref. 50).
- Isolates from participants who received exogenous IFN α 2 during treatment interruption may display altered interferon resistance. This effect is modeled as a multiplicative shift in IC₅₀ for all rebound isolates from such participants (participants 004, 030, and 044 from ref. 38).

The log IC₅₀ observation from each viral isolate i from acute, chronic and rebound isolates was modeled as a normal distribution:

$$\text{IC50}_i \sim \text{Normal}(\mu_{\text{type}_i, \text{person}_i}, \sigma_{\text{type}_j})$$

with the mean resistance for isolate type j from person k :

$$\mu_{j,k} \sim \begin{cases} \text{Normal}(\alpha_k + \beta_{\text{batch}} \text{batch}_k, \psi_j) & \text{if } j = \text{acute} \\ \text{Normal}(\alpha_k + \beta_{j,k} + \beta_{\text{batch}} \text{batch}_k + \beta_{\text{ifn}} \text{IFN}_k, \psi_j) & \text{if } j = \text{rebound} \\ \text{Normal}(\alpha_k + \beta_{j,k} + \beta_{\text{batch}} \text{batch}_k, \psi_j) & \text{otherwise} \end{cases}$$

where type_i indicates whether isolate i was isolated during acute, chronic, QVOA or rebound infection from participant person_i , batch_k indicates when isolates from person k were tested in another study and IFN_k indicates when person k was treated with exogenous IFN α 2 prior to and during treatment interruption. Parameters are included for the mean resistance level during acute infection for each person α_k , standard deviation of isolates of type j within a person σ_j , standard deviation of mean resistance for type j isolates among people ψ_j , change from acute levels in isolates of type j in a given participant $\beta_{j,k}$, the effects of exogenous IFN treatment β_{ifn} and batch to batch variation in IFN in isolates assayed in previous studies β_{batch} .

For QVOA isolates, the IC_{50} was modeled as a mixture of two populations such that:

$$p(\text{IC}_{50}_i | \mu_{\text{qvoa}, \text{person}_i}, \sigma_{\text{qvoa}}, \mu_{\text{rebound}, \text{person}_i}, \sigma_{\text{rebound}}, \phi_{\text{prePost}_i}) = \phi_{\text{prePost}_i} \text{Normal}(\text{IC}_{50}_i | \mu_{\text{rebound}, \text{person}_i}, \sigma_{\text{rebound}}) + (1 - \phi_{\text{prePost}_i}) \text{Normal}(\text{IC}_{50}_i | \mu_{\text{qvoa}, \text{person}_i}, \sigma_{\text{qvoa}})$$

where prePost_i indicates whether isolate i was isolated pre- or post-ATI and ϕ_{pre} and ϕ_{post} represent the proportion of rebound-like virus present in pre- and post-ATI QVOA isolates.

The hierarchical parameter priors were modeled as:

$$\begin{aligned} \sigma_j &\sim \text{Gamma}(1, 0.1) \\ \psi_j &\sim \text{Gamma}(1, 0.1) \\ \phi_{\text{pre}} &\sim \text{Uniform}(0, 1) \\ \phi_{\text{post}} &\sim \text{Uniform}(0, 1) \end{aligned}$$

where j indicates the isolate type (acute, chronic, QVOA, rebound). All α_k , $\beta_{j,k}$ were given flat priors and $\beta_{\text{ifn}} \sim \text{Normal}(0, 10)$ and $\beta_{\text{batch}} \sim \text{Normal}(0, 10)$.

Posterior probabilities were estimated with 50 Markov chain Monte Carlo chains of 5,000 iterations each using Stan (91).

Supplemental Figure S2

Supplemental Figure S3

Supplemental Figure S4

Supplemental Figure S6

Table S1. Generation of HIV-1 isolates from plasma and peripheral blood mononuclear cells of 10 individuals sampled from acute infection throughout their clinical course

Participant ¹	Number of TF viruses ²	Date ³	DFOSx ⁴	Viral load (copies/ml)	CD4 count (cells/μl)	Number of SGA derived viral sequences (plasma) ⁵	Number of SGA derived viral sequences (PBMC) ⁶	Number of limiting dilution isolates (plasma) ⁷	Number of bulk isolates (plasma) ⁸	Number of outgrowth viruses (PBMC) ⁹
MM14		21-Jun-01	11	6,235,600						
		12-Jul-01	32	1,950,600	420					
	2	20-Jul-01	40	37,611,600	430	9			3 (2)	
		27-Jul-01	47	2,162,300	460					
		2-Aug-01	53	613,400	530					
	SI	9-Aug-01	60	269,000	490					
		26-Oct-01	138	15,800	480	9			2	
		6-Dec-01	179	27,200	380					
		7-Mar-02	270	52,700	390	3			2	
		11-Nov-02	519	45,300	390	14			2	
		9-Jan-03	578	16,000	420					
		2-Jun-03	722	44,400	240	5			2 (1)	
		6-Oct-03	848	30,100	330					
		20-Apr-04	1,045			3			2 (1)	
		4-Oct-04	1,212	6,100	320					
		24-Jan-05	1,324	12,600	210	3			2	
		4-Apr-05	1,394	19,700	340	4			2	
		1-Aug-05	1,513	52,500	210					
		19-Sep-05	1,562		200					
		16-Jan-06	1,681	14,000	280					
		13-Feb-06	1,709	100	340					
		27-Mar-06	1,751	50	380					
		26-Jun-06	1,842	50	270					
		27-Nov-06	1,996	200	440					
		19-Feb-07	2,080	50	630					
		18-Jun-07	2,199	50	620					
		19-Nov-07	2,353	50	660					
		30-Sep-08	2,669	50	610					
		9-Mar-09	2,829	50	520					
		18-Aug-09	2,991	50	630					
		9-Nov-09	3,074	50	770					
		8-Mar-10	3,193	50	630					1
		15-Mar-12	3,931	50	790					
		22-Oct-13	4,517	240	640					
MM15	1	6-Sep-01	5	39,000						
		21-Sep-01	20	10,600	1,070					
		28-Sep-01	27	13,200	1,200	15			3 (1)	
		8-Oct-01	37	28,600	1,030	17			4 (1)	
		15-Oct-01	44	24,500	970					
		29-Oct-01	58	127,200	980					
		19-Nov-01	79	59,900	1,450	11			1 (1)	
		17-Dec-01	107	381,500	820	15			1 (1)	
		11-Mar-02	191	43,200	660	6			1 (1)	
		10-Jun-02	282	110,700	620					
		9-Sep-02	373	45,200	420	7			1 (1)	
		9-Dec-02	464	69,900	370					
		3-Mar-03	548	41,700	260	6			1 (1)	
		17-Apr-03	593	19,400	280					
		30-Apr-03	606	39,700						
		9-Jun-03	646	22,800	240					
		22-Aug-03	720	27,500	320	9			1	
		10-Oct-03	769	27,000	220					
		10-Nov-03	800	70	450					
		10-Dec-03	830	4,300	310					
		9-Jan-04	860	50	460					
		22-Mar-04	933	50	540					
		23-Jun-04	1,026	50	430					
		15-Dec-04	1,201	50	560					
		11-May-05	1,348	50	580					
		5-Jul-05	1,403	50	700					1
		5-Jan-06	1,587	50	750					
		22-Aug-06	1,816	50	820					
		16-Jan-07	1,963	200	570					
		9-Aug-07	2,168	50	940					
		22-Jan-08	2,334	50	700					
		12-Jun-08	2,476	50	750					
		9-Jan-09	2,687	50	900					
		29-Apr-09	2,797	250	950					
		13-May-09	2,811	50						
		1-Feb-10	3,075	50	1,000					
		1-Sep-11	3,652	50	830					
	1	5-Mar-02	9	11,105,300	330	41		12		
		11-Mar-02	15	8,871,700	410					
		18-Mar-02	22	5,140,100	410					
		2-Apr-02	37		400					
		29-Apr-02	64	200,500	590	9		4		
		17-Jun-02	113	147,700	510					
		16-Sep-02	204	117,600	330	43		8		
		6-Jan-03	316	100,100	300			11		
	SI	7-Jul-03	498	76,300	410					
		30-Sep-03	583	111,200	220					
		17-Nov-03	631	74,700	350					
		16-Feb-04	722	52,400	550			9		
		18-May-04	814	41,600	250					

Table S1

MM23		7-Jul-04	864		320				
		30-Nov-04	1,010	157,800	230				
		24-Jan-05	1,065	45,700	240			5	
		1-Aug-05	1,254	105,800	230				
		8-May-06	1,534	168,300	190			8	
		29-Jun-06	1,586						
		17-Jul-06	1,604	200	200				
		2-Oct-06	1,681	60	260				
		26-Feb-07	1,828	50	230				
		9-Jul-07	1,961	50	290				
		17-Dec-07	2,122	50	280				
		15-Apr-08	2,242	50	250				
		1-Sep-08	2,381	50	280				
		4-Dec-08	2,475	50	310				
		19-Mar-09	2,580	50	400				
		24-Aug-09	2,738	50	380		33		2
		25-Feb-10	2,923	50	350				
		17-Mar-11	3,308	50	380				
		19-Apr-12	3,707	50	380				
		2-Oct-12	3,873	50	600				
MM33	2	7-Jul-03	12	1,451,400	940	42		8	
		14-Jul-03	19	215,700	940	44			
		21-Jul-03	26	163,800	1,070	22			
		28-Jul-03	33	100,500	840	28			
	SI	4-Aug-03	40	129,800	810	29			
		2-Sep-03	69	147,400	1,000	19			
		29-Sep-03	96	62,200	860	14		4	
		12-Jan-04	201	80,000	770	8		8	2
		6-Apr-04	286	83,200	740	13			
		20-Jul-04	391	31,200	670	21			
		29-Nov-04	523	43,500	710				
		7-Mar-05	621	65,100	830	20			
		13-Jun-05	719	83,200	640	7		7	1
		26-Sep-05	824	42,600	670				
		27-Mar-06	1,006	72,100	660	5		7	2
		19-Sep-06	1,182	41,800	740				
		19-Feb-07	1,335	105,200	510				
		5-Jun-07	1,441	131,000	600				
		5-Nov-07	1,594	30,000	440				
		11-Mar-08	1,721	110,000	480	9		9	2
		12-Jun-08	1,814	23,000	390				
		24-Jul-08	1,856	180,000	350				
		19-Sep-08	1,913	110,000	340	22			
		15-Jan-09	2,031	28,000	240	19		15	1
		16-Feb-09	2,063	330	330				
		23-Mar-09	2,098		640				
		23-Apr-09	2,129	50	470				
		17-Jul-09	2,214	50	460				
		6-Oct-09	2,295	50	560				
		26-Jan-10	2,407	50					
		23-Feb-10	2,435	50	640				
		16-Aug-10	2,609	50	680				
		15-Feb-11	2,792	50	810				
		13-Feb-12	3,155	50	810				
		23-Aug-12	3,347	50	780				
		15-Jan-13	3,492	50	720				
		7-Oct-13	3,757	50	770				
		13-Jan-14	3,855	50	1,130				
MM34	2	21-Jul-03	17	29,900	570	40		11	
		29-Jul-03	25	19,900	780				
		5-Aug-03	32	21,400	660				
		14-Aug-03	41	16,400	620				
		18-Aug-03	45	6,800	730				
		16-Sep-03	74	2,400	620	10		1	
		14-Oct-03	102	5,900	670				
		12-Jan-04	192	9,600	630	40		5	
		21-Jun-04	353	5,900	560	19			
		20-Sep-04	444	8,200	500				
		3-Mar-05	608	9,500	480				
		2-Aug-05	760	5,500	470	13		4	
		16-Feb-06	958		590				
		6-Apr-06	1,007	11,400	600			6	
		6-Feb-07	1,313	40,700	450	12		7	
		3-May-07	1,399	14,000	490			3	
		19-Feb-08	1,691	13,000	420			6	
		26-Mar-09	2,092		440				
		7-May-09	2,134		380				
		10-Aug-09	2,229	14,000	340			14	
		14-Sep-09	2,264						
		12-Oct-09	2,292		480				
		9-Nov-09	2,320	50	480				
		22-Feb-10	2,425	50	540				
		25-Oct-10	2,670	50	530				
		10-Jan-11	2,747	50	620				
		23-Jun-11	2,911						1
		3-Nov-11	3,044	50	890				
		7-Jun-12	3,261	50	780		38		2
		21-Feb-13	3,520	50	730				
	1	21-Apr-04	3	2,203,800					
		23-Apr-04	5	350,600	610				
		26-Apr-04	8		400				

Table S1

MM39		29-Apr-04	11	1,508,000	680	36*		15*	
		11-May-04	23	6,700	490				
		25-May-04	37	7,400	520	21*			
		22-Jun-04	65	900	530				
		19-Jul-04	92	3,000	610	14*			
		2-Sep-04	137	8,400	580				
		14-Oct-04	179	7,000	510	17*		4*	
		13-Jan-05	270	13,400	580	19*			
		7-Apr-05	354	99,300	610	20*		15*	1
		21-Jul-05	459	35,600	510	21*			
		13-Oct-05	543	15,300	580	21*			
		17-Jan-06	639	15,600	490	19*		8*	1
		18-Jul-06	821	75,400	380	17*		7*	
		31-Oct-06	926	24,700	490				
		23-Jan-07	1,010	40,300	480				
		7-Aug-07	1,206	280,000	190	16*		13*	3
		31-Aug-07	1,230	280,000	190				
		1-Nov-07	1,292	63,000	90				
		13-Nov-07	1,304						
		11-Dec-07	1,332	240	340				
		29-Jan-08	1,381	50	290				
		25-Apr-08	1,468	50	370				
		11-Jul-08	1,545	50	380				
		9-Jan-09	1,727	50	350				
		24-Apr-09	1,832	50	430				
		21-Aug-09	1,951	50	430				
MM40	3 or more	21-Jun-04	8	350,100	290				
		24-Jun-04	11	79,300	410	34		17	2
		1-Jul-04	18	13,700	380				
		8-Jul-04	25	1,000	470				
		15-Jul-04	32	2,100	490				
		22-Jul-04	39	6,500	430				
		5-Aug-04	53	5,500	380				
		19-Aug-04	67	6,400	470				
		16-Sep-04	95	10,800	450	18		8	
		14-Dec-04	184	39,300	510				
		17-Mar-05	277	16,400	380				
		7-Jul-05	389	26,800	330				
		13-Oct-05	487	50,100	390				
		20-Jan-06	586	30,600	490				
		30-Jun-06	747	89,000	310	13		5	2
		15-Oct-06	854	25,400	340				
		9-Feb-07	971	18,000	280				
		23-Aug-07	1,166	140,000	250	13		10	
		10-Jan-08	1,306	54,000	390				
		30-Jun-08	1,478		330				
		21-Aug-08	1,530	310,000	250	12		18	1
		16-Oct-08	1,586		170				
		20-Oct-08	1,590	1,200,000					
		10-Nov-08	1,611						
		20-Jan-09	1,682	60	320				
		2-Mar-09	1,723	50	350				
		2-Jul-09	1,845	50	370				
		14-Jan-10	2,041	50	320				1
		7-Apr-10	2,124	50	460				
		16-Nov-10	2,347	50	440	33			
MM55	1	25-Sep-07	24	23,000	640				
		2-Oct-07	31	1,200	730	13			1
		9-Oct-07	38	6,100	670				
		22-Oct-07	51	4,200	570	12			2 (1)
		30-Oct-07	59	2,100	740				
		6-Nov-07	66	880	630				
		4-Dec-07	94	450	680				
		10-Jan-08	131	50	560				
		16-Apr-08	228	1,500	550				
		14-Aug-08	348	2,500	550	6			1
		12-Mar-09	558	3,500	540				
		23-Jun-09	661	4,300	560	6			1
		10-Dec-09	831	10,000		15			2
		24-Feb-10	907		650				
		23-Aug-10	1,087	40,000	530				
MM62	1	24-Mar-11	1,300	11,000	490	1			2
		2-Oct-12	1,858	17,000	460	18			2
		16-Apr-13	2,054	17,000	630				2 (1)
		17-Dec-08	16	2,200	700				
		23-Dec-08	22			11			3 (1)
		27-Jan-09	57	680	1,130	2			2
		13-Feb-09	74						2 (1)
		25-Feb-09	86	270	1,000				
		31-Mar-09	120	190	1,240				3 (1)
		4-Jun-09	185	2,200	880	1			2
		1-Oct-09	304	520	860				1
		11-Feb-10	437	410	820				
		20-Sep-10	658	860	900	1			1 (1)
		5-Jan-12	1,130	1,100	1,090				2
		24-Jul-12	1,331	20,000	1,200				2
		7-Mar-13	1,557	11,000	1,200				
		2-Dec-14	2,192	5,200	980				
	1	30-May-90	-5	216,415	358	45*			
		31-May-90	-4			2*			2 (2)

Table S1

WEAU		4-Jun-90	0	355,184					2 (2)	
		7-Jun-90	3	355,360		44*				
		11-Jun-90	7	146,816	748					
		14-Jun-90	10			58*				
		18-Jun-90	14	100,877	568					
		24-Jun-90	20		972					
		28-Jun-90	24	34,737		30*			2 (1)	
		26-Jul-90	52	11,385					2 (2)	
		28-Sep-90	116	17,322		1*				
		13-Dec-90	192			29*				
		14-Feb-91	255		197					
		10-Jun-91	371	55,269	89	2*			2	
		6-Nov-91	520	94,474	14				2	
		24-Jan-92 †	599		43					
		3-May-92 †	699	61,667						
		25-Jun-92 †	752	55,900	30	1*			2	
		14-Jul-92 †	771	52,745					2	
		6-Oct-92 †	855		14					
		9-Feb-93 †	981						2 (2)	
		22-Feb-93 †	994		8	1*				
		16-Mar-93 †	1,016		6					
		13-Apr-93 †	1,044		7					
		19-May-93 †	1,080			1*				
		15-Jun-93 †	1,107		4					
		19-Jun-93 †	1,111			1*				
		24-Jul-93 †	1,146			1*				
		26-Jul-93 †	1,148		5					
		1-Jan-94 †	1,307		2					
		5-Jul-94 †	1,492		1					

¹All subjects were men-who-have-sex-with-men (MSM) from the United Kingdom (MM) or the United States (WEAU), who were diagnosed with symptomatic primary subtype B infection and longitudinally followed before and after (shading) antiretroviral therapy.

²The number of transmitted founder (TF) viruses was inferred as previously described (54) from single genome amplification (SGA) derived viral sequences from the first available plasma sample (fig. S1); subjects MM14, MM23 and MM33 were superinfected (SI) with additional subtype B strains at the timepoints indicated.

³Visit date; grey shading indicates time on suppressive antiretroviral therapy; subject WEAU received AZT monotherapy (indicated by †), which did not reduce viral loads.

⁴Days following onset of symptoms (DFOSx).

⁵Number of SGA derived 3' half genome or Env sequences amplified directly from plasma (Genbank accession number are listed in table S5); Env sequences for subjects MM39 and WEAU that have previously been reported (43, 54, 57, 86) are indicated by asterisks.

⁶Number of SGA derived 3' half genome or Env sequences amplified directly from peripheral blood mononuclear cells (PBMCs) (Genbank accession number are listed in table S5).

⁷Number of limiting dilution derived plasma isolates; all isolates were confirmed to be single virion derived by sequence analysis (Genbank accession number are listed in table S5).

⁸Number of conventional (bulk) plasma isolates; most isolates were sequenced and those that represent single virion derived strains are shown in parentheses (Genbank accession number are listed in table S5).

⁹Number of limiting dilution derived outgrowth viruses from peripheral blood mononuclear cells (PBMCs); all isolates were confirmed to be single virion derived by sequence analysis (Genbank accession number are listed in table S5).

Table S1

Table S2. IFN-I resistance of plasma and QVOA isolates from longitudinally sampled study participants

Isolate	Sequence ID ¹	DFOSx ²	Replicative capacity (ng p24/ml) ³	IFNα2 IC50 (pg/ml) ⁴	IFNβ IC50 (pg/ml) ⁴
MM14.02.2C3.bulk	MM14.PLAS.ISO.00040.003	40	1,148	0.639	8.160
MM14.02.2B4.bulk	MM14.PLAS.ISO.00040.002	40	899	0.682	8.666
MM14.02.2A1.bulk	MM14.PLAS.ISO.00040.001	40	924	0.800	7.161
MM14.06.2B1.bulk	MM14.PLAS.ISO.00138.001	138	525	0.010	0.021
MM14.06.2B2.bulk	MM14.PLAS.ISO.00138.002	138	394	0.003	0.032
MM14.08.2B3.bulk	MM14.PLAS.ISO.00270.001	270	447	0.007	0.050
MM14.08.2B4.bulk	MM14.PLAS.ISO.00270.002	270	511	0.004	0.023
MM14.10.2C1.bulk	MM14.PLAS.ISO.00519.001	519	449	0.004	0.007
MM14.10.2C2.bulk	MM14.PLAS.ISO.00519.002	519	251	0.006	0.001
MM14.12.1A1.bulk	MM14.PLAS.ISO.00722.001	722	414	0.015	0.060
MM14.12.1A2.bulk	MM14.PLAS.ISO.00722.002	722	476	0.019 ⁵	0.248 ⁵
MM14.14.1A1.bulk	MM14.PLAS.ISO.01045.001	1,045	273	0.007	0.006
MM14.14.1A2.bulk	MM14.PLAS.ISO.01045.002	1,045	215	0.007	0.003
MM14.16.1B1.bulk	MM14.PLAS.ISO.01324.001	1,324	688	0.028	0.133
MM14.16.1B2.bulk	MM14.PLAS.ISO.01324.002	1,324	725	0.032 ⁵	0.128 ⁵
MM14.17.1B3.bulk	MM14.PLAS.ISO.01394.001	1,394	304	0.011	0.007
MM14.17.1B4.bulk	MM14.PLAS.ISO.01394.002	1,394	253	0.011 ⁵	0.012 ⁵
MM14.23.1A3.QVOA	MM14.PBMC.QVOA.03193.001	3,193	347	0.029	0.067
MM15.02.2B5.bulk	MM15.PLAS.ISO.00027.002	27	876	0.577 ⁵	18.246 ⁵
MM15.02.2A2.bulk	MM15.PLAS.ISO.00027.001	27	904	0.523	20.371
MM15.02.2A4.bulk	MM15.PLAS.ISO.00027.003	27	489	0.582	25.291
MM15.03.2B6.bulk	MM15.PLAS.ISO.00037.002	37	729	0.412	18.431
MM15.03.2A3.bulk	MM15.PLAS.ISO.00037.001	37	571	0.439	14.984
MM15.03.1B2.bulk	MM15.PLAS.ISO.00037.003	37	387	0.407	19.592
MM15.03.2B1.bulk	MM15.PLAS.ISO.00037.004	37	389	0.273	21.927
MM15.06.2A1.bulk	MM15.PLAS.ISO.00079.001	79	603	0.326	14.380
MM15.07.2A3.bulk	MM15.PLAS.ISO.00107.001	107	1,317	0.489	15.166
MM15.08.2B1.bulk	MM15.PLAS.ISO.00191.001	191	668	0.194	7.782
MM15.11.2B4.bulk	MM15.PLAS.ISO.00373.001	373	645	0.153	3.676
MM15.13.2C1.bulk	MM15.PLAS.ISO.00548.001	548	879	0.247 ⁵	9.677 ⁵
MM15.14.2C3.bulk	MM15.PLAS.ISO.00720.001	720	589	0.224	9.385
MM15.16.1B2.QVOA	MM15.PBMC.QVOA.01403.001	1,403	467	0.332	11.236
MM23.01.2A3	MM23.PLAS.ISO.00009.011	9	142	1.114	
MM23.01.2C2	MM23.PLAS.ISO.00009.012	9	186	0.925	
MM23.01.11A3	MM23.PLAS.ISO.00009.001	9	283	0.635	
MM23.01.11A6	MM23.PLAS.ISO.00009.002	9	249	0.784 ⁵	
MM23.01.11B5	MM23.PLAS.ISO.00009.003	9	232	0.730	
MM23.01.11C4	MM23.PLAS.ISO.00009.004	9	168	0.765 ⁵	
MM23.01.13A4	MM23.PLAS.ISO.00009.005	9	321	0.708 ⁵	
MM23.01.13A5	MM23.PLAS.ISO.00009.006	9	331	0.614	17.458
MM23.01.13B3	MM23.PLAS.ISO.00009.007	9	524	0.735	15.166
MM23.01.13C2	MM23.PLAS.ISO.00009.008	9	960	1.189	15.293
MM23.01.13D2	MM23.PLAS.ISO.00009.009	9	926	0.891	14.955
MM23.01.14D5	MM23.PLAS.ISO.00009.010	9	1,392	0.673	
MM23.05.2C1	MM23.PLAS.ISO.00064.004	64	245	0.542	14.380
MM23.05.14B3	MM23.PLAS.ISO.00064.001	64	591	0.356	10.750
MM23.05.14C3	MM23.PLAS.ISO.00064.002	64	218	0.389	11.426
MM23.05.14D2	MM23.PLAS.ISO.00064.003	64	317	0.355	8.262

Table S2

MM23.07.1C3	MM23.PLAS.ISO.00204.001	204	499	0.042	
MM23.07.2A2	MM23.PLAS.ISO.00204.002	204	119	0.048	
MM23.07.2A4	MM23.PLAS.ISO.00204.003	204	151	0.083	0.181
MM23.07.2A6	MM23.PLAS.ISO.00204.004	204	292	0.191	1.766
MM23.07.2B2	MM23.PLAS.ISO.00204.005	204	177	0.029	2.090
MM23.07.2B3	MM23.PLAS.ISO.00204.006	204	100	0.257	
MM23.07.2B5	MM23.PLAS.ISO.00204.007	204	526	0.007	0.186
MM23.07.2C6	MM23.PLAS.ISO.00204.008	204	397	0.187	
MM23.08.13C6	MM23.PLAS.ISO.00316.001	316	168	0.006	0.013
MM23.08.21B6	MM23.PLAS.ISO.00316.004	316	362	0.004	
MM23.08.21C2	MM23.PLAS.ISO.00316.005	316	144	0.003	0.006
MM23.08.22A3	MM23.PLAS.ISO.00316.006	316	434	0.003	0.006
MM23.08.22B4	MM23.PLAS.ISO.00316.007	316	477	0.004	
MM23.08.22B5	MM23.PLAS.ISO.00316.008	316	431	0.002	0.002
MM23.08.22C6	MM23.PLAS.ISO.00316.009	316	427	0.003	
MM23.11.1A1	MM23.PLAS.ISO.00722.001	722	291	0.007	
MM23.11.1A5	MM23.PLAS.ISO.00722.002	722	358	0.002	0.006
MM23.11.1C3	MM23.PLAS.ISO.00722.003	722	361	0.004	
MM23.11.1D3	MM23.PLAS.ISO.00722.004	722	157	0.002	0.007
MM23.11.1D4	MM23.PLAS.ISO.00722.005	722	165	0.002	0.004
MM23.11.1D6	MM23.PLAS.ISO.00722.006	722	128	0.002	0.008
MM23.11.2B2	MM23.PLAS.ISO.00722.007	722	403	0.008 ⁵	
MM23.11.2B3	MM23.PLAS.ISO.00722.008	722	268	0.006 ⁵	
MM23.11.2C2	MM23.PLAS.ISO.00722.009	722	290	0.009	
MM23.12.21B1	MM23.PLAS.ISO.01065.001	1,065	300	0.023	0.011
MM23.12.22A3	MM23.PLAS.ISO.01065.002	1,065	284	0.033	0.023
MM23.12.22C1	MM23.PLAS.ISO.01065.003	1,065	231	0.026	0.073
MM23.12.22C6	MM23.PLAS.ISO.01065.004	1,065	323	0.032	0.041
MM23.13.1B4	MM23.PLAS.ISO.01534.001	1,534	335	0.068 ⁵	
MM23.13.2D1	MM23.PLAS.ISO.01534.008	1,534	157	0.053 ⁵	0.246
MM23.13.21A3	MM23.PLAS.ISO.01534.002	1,534	290	0.045 ⁵	
MM23.13.21B5	MM23.PLAS.ISO.01534.003	1,534	374	0.040 ⁵	0.130
MM23.13.21B6	MM23.PLAS.ISO.01534.004	1,534	272	0.052	0.256
MM23.13.21D4	MM23.PLAS.ISO.01534.005	1,534	284	0.038	
MM23.13.22B3	MM23.PLAS.ISO.01534.006	1,534	302	0.050	
MM23.13.22C5	MM23.PLAS.ISO.01534.007	1,534	427	0.027	0.064
MM23.18.1A1.QVOA	MM23.PBMC.QVOA.02738.001	2,738	354	0.059	0.099
MM23.18.2A1.QVOA	MM23.PBMC.QVOA.02738.002	2,738	284	0.044	0.046

MM33.01.1C1	MM33.PLAS.ISO.00012.007	12	418	0.734 ⁵	
MM33.01.13C1	MM33.PLAS.ISO.00012.001	12	1,013	0.820	13.488
MM33.01.14C4	MM33.PLAS.ISO.00012.002	12	558	0.394 ⁵	7.507
MM33.01.16A5	MM33.PLAS.ISO.00012.003	12	582	0.744 ⁵	9.406
MM33.01.16C3	MM33.PLAS.ISO.00012.004	12	1,035	0.739	
MM33.01.18A5	MM33.PLAS.ISO.00012.005	12	552	0.581 ⁵	
MM33.01.19C4	MM33.PLAS.ISO.00012.006	12	91	0.419 ⁵	6.764
MM33.01.20D1	MM33.PLAS.ISO.00012.008	12	1,020	0.295	
MM33.07.1A2	MM33.PLAS.ISO.00096.001	96	471	0.150 ⁵	4.223
MM33.07.1B6	MM33.PLAS.ISO.00096.002	96	137	0.093 ⁵	3.217
MM33.07.1D4	MM33.PLAS.ISO.00096.003	96	367	0.133 ⁵	0.612
MM33.07.2D2	MM33.PLAS.ISO.00096.004	96	757	0.147 ⁵	2.419
MM33.08.1A2	MM33.PLAS.ISO.00201.001	201	390	0.019 ⁵	0.047
MM33.08.1A3	MM33.PLAS.ISO.00201.002	201	372	0.050 ⁵	0.047
MM33.08.1A4	MM33.PLAS.ISO.00201.003	201	320	0.045 ⁵	
MM33.08.1D2	MM33.PLAS.ISO.00201.004	201	312	0.012 ⁵	0.012

Table S2

MM33.08.1D4	MM33.PLAS.ISO.00201.005	201	533	0.057 ⁵	0.061
MM33.08.1D5	MM33.PLAS.ISO.00201.006	201	791	0.043 ⁵	
MM33.08.2A3	MM33.PLAS.ISO.00201.007	201	436	0.018 ⁵	
MM33.08.2B6	MM33.PLAS.ISO.00201.008	201	587	0.043 ⁵	0.052
MM33.08.1A4.bulk	MM33.PLAS.ISO.00201.009	201	313	0.030	0.031
MM33.08.1A3.bulk	MM33.PLAS.ISO.00201.010	201	344	0.025	0.016
MM33.13.1D3	MM33.PLAS.ISO.00719.004	719	681	0.008	0.006
MM33.13.1D6	MM33.PLAS.ISO.00719.005	719	244	0.004 ⁵	
MM33.13.2A4	MM33.PLAS.ISO.00719.006	719	507	0.004	0.003
MM33.13.2D6	MM33.PLAS.ISO.00719.007	719	174	0.005 ⁵	0.006
MM33.13.11B1	MM33.PLAS.ISO.00719.001	719	608	0.003	0.002
MM33.13.11B5	MM33.PLAS.ISO.00719.002	719	684	0.009	
MM33.13.12A4	MM33.PLAS.ISO.00719.003	719	598	0.003	
MM33.13.1.bulk	MM33.PLAS.ISO.00719.008	719	121	0.003	0.006
MM33.14.11A3	MM33.PLAS.ISO.01006.001	1,006	682	0.009 ⁵	0.004
MM33.14.11B1	MM33.PLAS.ISO.01006.002	1,006	682	0.005	
MM33.14.11B4	MM33.PLAS.ISO.01006.003	1,006	645	0.004	
MM33.14.11C6	MM33.PLAS.ISO.01006.004	1,006	690	0.004	
MM33.14.12A2	MM33.PLAS.ISO.01006.005	1,006	580	0.004	0.008
MM33.14.12A4	MM33.PLAS.ISO.01006.006	1,006	559	0.004 ⁵	0.009
MM33.14.12C6	MM33.PLAS.ISO.01006.007	1,006	639	0.005 ⁵	0.008
MM33.14.1A1.bulk	MM33.PLAS.ISO.01006.008	1,006	106	0.004	0.014
MM33.14.1A2.bulk	MM33.PLAS.ISO.01006.009	1,006	536	0.003	0.012
MM33.17.1D2	MM33.PLAS.ISO.01721.009	1,721	493	0.019	0.005
MM33.17.1D6	MM33.PLAS.ISO.01721.001	1,721	260	0.014	0.017
MM33.17.2A4	MM33.PLAS.ISO.01721.002	1,721	639	0.017 ⁵	0.015
MM33.17.2B3	MM33.PLAS.ISO.01721.003	1,721	140	0.019 ⁵	
MM33.17.2B4	MM33.PLAS.ISO.01721.004	1,721	59	0.028 ⁵	0.007
MM33.17.2B5	MM33.PLAS.ISO.01721.005	1,721	114	0.017 ⁵	
MM33.17.2C3	MM33.PLAS.ISO.01721.006	1,721	50	0.009	
MM33.17.2D4	MM33.PLAS.ISO.01721.007	1,721	356	0.029 ⁵	0.003
MM33.17.2D5	MM33.PLAS.ISO.01721.008	1,721	484	0.008	0.006
MM33.17.1A1.bulk	MM33.PLAS.ISO.01721.010	1,721	381	0.031	0.022
MM33.17.1A2.bulk	MM33.PLAS.ISO.01721.011	1,721	615	0.040	0.019
MM33.19.1A2	MM33.PLAS.ISO.02031.001	2,031	565	0.015	
MM33.19.1A4	MM33.PLAS.ISO.02031.002	2,031	331	0.018	
MM33.19.1B1	MM33.PLAS.ISO.02031.003	2,031	616	0.017	
MM33.19.1C2	MM33.PLAS.ISO.02031.004	2,031	274	0.011	0.089
MM33.19.2A4	MM33.PLAS.ISO.02031.005	2,031	244	0.027	0.047
MM33.19.2B1	MM33.PLAS.ISO.02031.006	2,031	224	0.016	0.028
MM33.19.2B5	MM33.PLAS.ISO.02031.007	2,031	689	0.010	0.133
MM33.19.2C1	MM33.PLAS.ISO.02031.008	2,031	621	0.018	
MM33.19.2D2	MM33.PLAS.ISO.02031.009	2,031	591	0.032	
MM33.19.3A1	MM33.PLAS.ISO.02031.010	2,031	220	0.036	
MM33.19.3B4	MM33.PLAS.ISO.02031.011	2,031	242	0.035	
MM33.19.3D2	MM33.PLAS.ISO.02031.012	2,031	551	0.024	
MM33.19.4A5	MM33.PLAS.ISO.02031.013	2,031	149	0.022	
MM33.19.4B5	MM33.PLAS.ISO.02031.014	2,031	655	0.033	
MM33.19.4D1	MM33.PLAS.ISO.02031.015	2,031	628	0.046	
MM33.19.1B1.bulk	MM33.PLAS.ISO.02031.016	2,031	267	0.029	0.057

MM34.01.1A5	MM34.PLAS.ISO.00017.002	17	176	0.518	9.675
MM34.01.1B3	MM34.PLAS.ISO.00017.003	17	154	0.425	17.497
MM34.01.1B6	MM34.PLAS.ISO.00017.004	17	279	0.485	
MM34.01.1C2	MM34.PLAS.ISO.00017.001	17	135	1.485	17.631

Table S2

MM34.01.1D1	MM34.PLAS.ISO.00017.006	17	128	1.094	
MM34.01.2A4	MM34.PLAS.ISO.00017.007	17	237	0.725	
MM34.01.2B3	MM34.PLAS.ISO.00017.008	17	343	0.386	
MM34.01.2C2	MM34.PLAS.ISO.00017.009	17	200	0.944	18.025
MM34.01.2D4	MM34.PLAS.ISO.00017.010	17	218	0.691	
MM34.01.2D5	MM34.PLAS.ISO.00017.011	17	503	0.821	
MM34.06.21C6	MM34.PLAS.ISO.00074.001	74	266	0.478	10.531
MM34.08.11B5	MM34.PLAS.ISO.00192.001	192	392	0.032 ⁵	0.168 ⁵
MM34.08.11C2	MM34.PLAS.ISO.00192.002	192	439	0.037 ⁵	3.350 ⁵
MM34.08.11D3	MM34.PLAS.ISO.00192.004	192	409	0.04	3.475 ⁵
MM34.08.21A3	MM34.PLAS.ISO.00192.005	192	624	0.025	2.088 ⁵
MM34.12.21A1	MM34.PLAS.ISO.00760.001	760	340	0.026	0.035
MM34.12.21C5	MM34.PLAS.ISO.00760.002	760	236	0.012	0.021
MM34.12.21D1	MM34.PLAS.ISO.00760.003	760	59	0.030	0.049
MM34.12.21D3	MM34.PLAS.ISO.00760.004	760	100	0.028	0.030
MM34.13.11A1	MM34.PLAS.ISO.01007.001	1,007	66	0.005	0.004
MM34.13.11A2	MM34.PLAS.ISO.01007.002	1,007	268	0.006	
MM34.13.11B1	MM34.PLAS.ISO.01007.003	1,007	154	0.004	0.001
MM34.13.11C5	MM34.PLAS.ISO.01007.004	1,007	640	0.017	0.002
MM34.13.11D2	MM34.PLAS.ISO.01007.005	1,007	143	0.002	0.001
MM34.13.11D5	MM34.PLAS.ISO.01007.006	1,007	214	0.007	
MM34.14.1A4	MM34.PLAS.ISO.01313.001	1,313	482	0.072	
MM34.14.1B2	MM34.PLAS.ISO.01313.002	1,313	389	0.018	
MM34.14.1B3	MM34.PLAS.ISO.01313.003	1,313	354	0.062	0.060
MM34.14.1C6	MM34.PLAS.ISO.01313.004	1,313	646	0.036	
MM34.14.1D4	MM34.PLAS.ISO.01313.005	1,313	478	0.022	0.124
MM34.14.2A1	MM34.PLAS.ISO.01313.006	1,313	596	0.041 ⁵	0.326 ⁵
MM34.14.2B1	MM34.PLAS.ISO.01313.007	1,313	153		0.050
MM34.15.11A1	MM34.PLAS.ISO.01399.001	1,399	188	0.007	0.004
MM34.15.11C1	MM34.PLAS.ISO.01399.002	1,399	242	0.008	0.001
MM34.15.11D3	MM34.PLAS.ISO.01399.003	1,399	384	0.004 ⁵	0.001 ⁵
MM34.16.11A5	MM34.PLAS.ISO.01691.002	1,691	414	0.017	0.052
MM34.16.11C1	MM34.PLAS.ISO.01691.003	1,691	278	0.048	0.035
MM34.16.11C3	MM34.PLAS.ISO.01691.004	1,691	591	0.032	
MM34.16.11D1	MM34.PLAS.ISO.01691.005	1,691	413	0.026	0.045
MM34.16.11D2	MM34.PLAS.ISO.01691.006	1,691	255	0.056	0.019
MM34.18.1A4	MM34.PLAS.ISO.02229.003	2,229	619	0.072	
MM34.18.1A6	MM34.PLAS.ISO.02229.004	2,229	588	0.088	0.139
MM34.18.1C5	MM34.PLAS.ISO.02229.006	2,229	232	0.098	
MM34.18.2A4	MM34.PLAS.ISO.02229.009	2,229	274	0.058	0.466
MM34.18.2A6	MM34.PLAS.ISO.02229.010	2,229	102	0.106	0.490
MM34.18.2C2	MM34.PLAS.ISO.02229.011	2,229	258	0.052	
MM34.18.2D1	MM34.PLAS.ISO.02229.013	2,229	118	0.073	
MM34.18.2D2	MM34.PLAS.ISO.02229.014	2,229	276	0.062	0.429
MM34.23.1B2.QVOA	MM34.PBMC.QVOA.02911.001	2,911	392	0.059	0.150
MM34.25.3A5.QVOA	MM34.PBMC.QVOA.03261.002	3,261	303	0.033	0.204
MM34.25.2B5.QVOA	MM34.PBMC.QVOA.03261.001	3,261	254	0.026	0.162

MM39.02.1B4	MM39.PLAS.ISO.00011.001	11	424	0.584 ⁵	14.857
MM39.02.2A2	MM39.PLAS.ISO.00011.002	11	180	0.756 ⁵	
MM39.02.2B5	MM39.PLAS.ISO.00011.003	11	276	0.700 ⁵	
MM39.02.13B5	MM39.PLAS.ISO.00011.004	11	437	0.799 ⁵	
MM39.02.13C3	MM39.PLAS.ISO.00011.005	11	326	0.796 ⁵	
MM39.02.13D2	MM39.PLAS.ISO.00011.006	11	275	0.631 ⁵	9.659
MM39.02.13D3	MM39.PLAS.ISO.00011.007	11	249	0.620	

Table S2

MM39.02.13D6	MM39.PLAS.ISO.00011.008	11	453	0.731 ⁵	
MM39.02.14C1	MM39.PLAS.ISO.00011.010	11	637	0.897 ⁵	
MM39.02.14C2	MM39.PLAS.ISO.00011.011	11	566	0.787 ⁵	
MM39.02.14C3	MM39.PLAS.ISO.00011.012	11	828	0.767 ⁵	17.371
MM39.02.14C5	MM39.PLAS.ISO.00011.013	11	758	0.652 ⁵	15.713
MM39.02.14D4	MM39.PLAS.ISO.00011.014	11	132	0.929 ⁵	
MM39.02.14D5	MM39.PLAS.ISO.00011.015	11	228	0.850 ⁵	
MM39.07.11A3	MM39.PLAS.ISO.00179.001	179	288	0.104 ⁵	5.980
MM39.07.11A4	MM39.PLAS.ISO.00179.002	179	178	0.042	4.497
MM39.07.11C1	MM39.PLAS.ISO.00179.003	179	117	0.185 ⁵	3.633
MM39.07.11C2	MM39.PLAS.ISO.00179.004	179	195	0.140 ⁵	6.435
MM39.10.11B3	MM39.PLAS.ISO.00354.001	354	94	0.007 ⁵	
MM39.10.11B4	MM39.PLAS.ISO.00354.002	354	298	0.007 ⁵	
MM39.10.11D1	MM39.PLAS.ISO.00354.003	354	415	0.006 ⁵	
MM39.10.11D4	MM39.PLAS.ISO.00354.004	354	198	0.004 ⁵	0.148
MM39.10.11D6	MM39.PLAS.ISO.00354.005	354	129	0.007	
MM39.10.12A2	MM39.PLAS.ISO.00354.006	354	127	0.007	
MM39.10.12A6	MM39.PLAS.ISO.00354.007	354	143	0.003	
MM39.10.12B5	MM39.PLAS.ISO.00354.008	354	91	0.007	
MM39.10.12C3	MM39.PLAS.ISO.00354.009	354	121	0.004	
MM39.10.12C4	MM39.PLAS.ISO.00354.010	354	130	0.005 ⁵	0.137 ⁵
MM39.10.12D3	MM39.PLAS.ISO.00354.011	354	271	0.008	0.114
MM39.10.12D4	MM39.PLAS.ISO.00354.012	354	80	0.005	
MM39.10.14A3	MM39.PLAS.ISO.00354.015	354	295	0.003	
MM39.10.14B4	MM39.PLAS.ISO.00354.013	354	86	0.007	0.079
MM39.10.14C5	MM39.PLAS.ISO.00354.014	354	206	0.005	
MM39.10.1C1.bulk	MM39.PLAS.ISO.00354.016	354	121	0.004 ⁵	0.214 ⁵
MM39.13.1B1	MM39.PLAS.ISO.00639.001	639	594	0.008	0.030
MM39.13.11A2	MM39.PLAS.ISO.00639.002	639	180	0.006	
MM39.13.11A4	MM39.PLAS.ISO.00639.003	639	349	0.007	
MM39.13.11B1	MM39.PLAS.ISO.00639.004	639	188	0.005	
MM39.13.11B2	MM39.PLAS.ISO.00639.008	639	124	0.007	0.007
MM39.13.11C3	MM39.PLAS.ISO.00639.005	639	379	0.006	0.031
MM39.13.11C5	MM39.PLAS.ISO.00639.006	639	167	0.010	0.023
MM39.13.11D1	MM39.PLAS.ISO.00639.007	639	247	0.005	
MM39.13.1C3.bulk	MM39.PLAS.ISO.00639.009	639	66	0.003	0.022
MM39.14.1A2	MM39.PLAS.ISO.00821.001	821	107	0.042	0.005
MM39.14.1A5	MM39.PLAS.ISO.00821.002	821	339	0.040	0.004
MM39.14.1B3	MM39.PLAS.ISO.00821.003	821	547	0.039	
MM39.14.2A3	MM39.PLAS.ISO.00821.004	821	233	0.026	
MM39.14.2B1	MM39.PLAS.ISO.00821.005	821	455	0.035 ⁵	0.006 ⁵
MM39.14.2B5	MM39.PLAS.ISO.00821.007	821	318	0.023	0.020
MM39.14.2D4	MM39.PLAS.ISO.00821.006	821	93	0.022	
MM39.16.1A4	MM39.PLAS.ISO.01206.002	1,206	189	0.009	
MM39.16.1B2	MM39.PLAS.ISO.01206.003	1,206	239	0.024 ⁵	0.200
MM39.16.1B4	MM39.PLAS.ISO.01206.004	1,206	167	0.017 ⁵	0.121
MM39.16.1C4	MM39.PLAS.ISO.01206.005	1,206	107	0.016 ⁵	0.123
MM39.16.2A5	MM39.PLAS.ISO.01206.006	1,206	172	0.022 ⁵	0.192
MM39.16.2C3	MM39.PLAS.ISO.01206.001	1,206	539	0.020 ⁵	
MM39.16.2D2	MM39.PLAS.ISO.01206.007	1,206	635	0.018 ⁵	
MM39.16.13A2	MM39.PLAS.ISO.01206.013	1,206	426	0.068	
MM39.16.13A5	MM39.PLAS.ISO.01206.008	1,206	113	0.037	0.291
MM39.16.13B1	MM39.PLAS.ISO.01206.009	1,206	117	0.059	0.216
MM39.16.13B3	MM39.PLAS.ISO.01206.010	1,206	270	0.020	
MM39.16.14B3	MM39.PLAS.ISO.01206.011	1,206	183	0.023	

Table S2

MM39.16.14C1	MM39.PLAS.ISO.01206.012	1,206	617	0.010	0.123
MM39.16.1A1.bulk	MM39.PLAS.ISO.01206.014	1,206	80	0.010	0.205
MM39.16.1A2.bulk	MM39.PLAS.ISO.01206.015	1,206	493	0.041	0.669
MM39.16.1A3.bulk	MM39.PLAS.ISO.01206.016	1,206	628	0.046	0.349

MM40.01.1A1	MM40.PLAS.ISO.00011.001	11	518	0.712 ⁵	5.287
MM40.01.1A2	MM40.PLAS.ISO.00011.002	11	736	0.741 ⁵	
MM40.01.1A4	MM40.PLAS.ISO.00011.003	11	557	0.736 ⁵	
MM40.01.1A5	MM40.PLAS.ISO.00011.004	11	709	0.722	
MM40.01.1A6	MM40.PLAS.ISO.00011.005	11	654	0.782	
MM40.01.1B1	MM40.PLAS.ISO.00011.006	11	315	0.723 ⁵	5.738
MM40.01.1B2	MM40.PLAS.ISO.00011.007	11	727	0.999	
MM40.01.1B3	MM40.PLAS.ISO.00011.008	11	532	0.653	
MM40.01.1B4	MM40.PLAS.ISO.00011.009	11	132	0.233	
MM40.01.1B5	MM40.PLAS.ISO.00011.010	11	685	0.627	
MM40.01.1C6	MM40.PLAS.ISO.00011.011	11	538	0.528	
MM40.01.1D1	MM40.PLAS.ISO.00011.012	11	484	0.652	
MM40.01.2A4	MM40.PLAS.ISO.00011.013	11	629	0.821	
MM40.01.2B5	MM40.PLAS.ISO.00011.014	11	312	0.679	
MM40.01.2C2	MM40.PLAS.ISO.00011.015	11	366	0.681	7.361
MM40.01.2D4	MM40.PLAS.ISO.00011.016	11	657	0.722	7.624
MM40.01.2D5	MM40.PLAS.ISO.00011.017	11	417	0.782	
MM40.01.2A1.bulk	MM40.PLAS.ISO.00011.018	11	1,254	0.732	11.993
MM40.01.2A2.bulk	MM40.PLAS.ISO.00011.019	11	583	0.394	13.197
MM40.07.11A3	MM40.PLAS.ISO.00095.004	95	421	0.429	1.899
MM40.07.11A4	MM40.PLAS.ISO.00095.001	95	319	0.590	
MM40.07.11B1	MM40.PLAS.ISO.00095.002	95	314	0.750	
MM40.07.11B3	MM40.PLAS.ISO.00095.005	95	387	0.701	
MM40.07.11B4	MM40.PLAS.ISO.00095.003	95	287	0.149	
MM40.07.11B5	MM40.PLAS.ISO.00095.006	95	266	0.208	1.598
MM40.07.11C1	MM40.PLAS.ISO.00095.008	95	200	0.120	2.256
MM40.07.12B1	MM40.PLAS.ISO.00095.007	95	233	0.154	2.568
MM40.12.13A6	MM40.PLAS.ISO.00747.001	747	166	0.006	0.008
MM40.12.13C1	MM40.PLAS.ISO.00747.002	747	176	0.002	0.012
MM40.12.13D1	MM40.PLAS.ISO.00747.003	747	178	0.004	
MM40.12.14C5	MM40.PLAS.ISO.00747.004	747	192	0.006 ⁵	0.006
MM40.12.14D2	MM40.PLAS.ISO.00747.005	747	219	0.006 ⁵	0.007
MM40.12.1A1.bulk	MM40.PLAS.ISO.00747.006	747	267	0.010	0.011
MM40.12.1A2.bulk	MM40.PLAS.ISO.00747.007	747	529	0.003	0.011
MM40.13.11A1	MM40.PLAS.ISO.01166.002	1,166	289	0.009 ⁵	
MM40.13.11A5	MM40.PLAS.ISO.01166.003	1,166	237	0.017 ⁵	
MM40.13.11B3	MM40.PLAS.ISO.01166.004	1,166	208	0.008 ⁵	
MM40.13.11D4	MM40.PLAS.ISO.01166.005	1,166	238	0.011 ⁵	0.017
MM40.13.12A1	MM40.PLAS.ISO.01166.006	1,166	182	0.007 ⁵	0.025
MM40.13.12B2	MM40.PLAS.ISO.01166.007	1,166	189	0.006 ⁵	0.009
MM40.13.12B5	MM40.PLAS.ISO.01166.008	1,166	195	0.009 ⁵	
MM40.13.12C2	MM40.PLAS.ISO.01166.009	1,166	263	0.010 ⁵	0.010
MM40.13.12C3	MM40.PLAS.ISO.01166.010	1,166	251	0.006 ⁵	
MM40.13.13D5	MM40.PLAS.ISO.01166.001	1,166	162	0.028 ⁵	0.008
MM40.15.1A3	MM40.PLAS.ISO.01530.001	1,530	192	0.048 ⁵	
MM40.15.1A5	MM40.PLAS.ISO.01530.002	1,530	241	0.032 ⁵	
MM40.15.1B1	MM40.PLAS.ISO.01530.003	1,530	230	0.025 ⁵	0.034
MM40.15.1B6	MM40.PLAS.ISO.01530.004	1,530	251	0.042	
MM40.15.1C1	MM40.PLAS.ISO.01530.005	1,530	423	0.067 ⁵	
MM40.15.2A2	MM40.PLAS.ISO.01530.006	1,530	126	0.043 ⁵	

Table S2

MM40.15.2B1	MM40.PLAS.ISO.01530.007	1,530	257	0.051 ⁵	
MM40.15.2B5	MM40.PLAS.ISO.01530.008	1,530	247	0.025 ⁵	
MM40.15.2B6	MM40.PLAS.ISO.01530.009	1,530	606	0.033 ⁵	
MM40.15.2C1	MM40.PLAS.ISO.01530.010	1,530	235	0.009 ⁵	0.031
MM40.15.2C3	MM40.PLAS.ISO.01530.011	1,530	465	0.069 ⁵	0.084
MM40.15.2D1	MM40.PLAS.ISO.01530.012	1,530	290	0.042 ⁵	
MM40.15.2D6	MM40.PLAS.ISO.01530.013	1,530	267	0.048 ⁵	0.035
MM40.15.13B6	MM40.PLAS.ISO.01530.014	1,530	217	0.041	
MM40.15.13C1	MM40.PLAS.ISO.01530.018	1,530	210	0.043	
MM40.15.14B3	MM40.PLAS.ISO.01530.015	1,530	212	0.061	0.159
MM40.15.14C3	MM40.PLAS.ISO.01530.016	1,530	273	0.034	
MM40.15.14D5	MM40.PLAS.ISO.01530.017	1,530	175	0.029	
MM40.15.1.bulk	MM40.PLAS.ISO.01530.020	1,530	144	0.090	0.271
MM40.18.1C7.QVOA	MM40.PBMC.QVOA.02041.001	2,041	373	0.030	0.066

MM55.01.1A3.bulk	MM55.PLAS.ISO.00031.001	31	210	0.019 ⁵	0.108 ⁵
MM55.03.2B4.bulk	MM55.PLAS.ISO.00051.002	51	265	0.021 ⁵	0.073 ⁵
MM55.03.2A1.bulk	MM55.PLAS.ISO.00051.001	51	310	0.081 ⁵	0.422 ⁵
MM55.09.2A1.bulk	MM55.PLAS.ISO.00348.001	348	184	0.008	0.074
MM55.11.2A3.bulk	MM55.PLAS.ISO.00661.001	661	133	0.002	0.007
MM55.12.2B1.bulk	MM55.PLAS.ISO.00831.001	831	174	0.005 ⁵	0.029 ⁵
MM55.12.2B2.bulk	MM55.PLAS.ISO.00831.002	831	181	0.007	0.011
MM55.14.1B4.bulk	MM55.PLAS.ISO.01300.003	1,300	475	0.003	0.010
MM55.14.2B5.bulk	MM55.PLAS.ISO.01300.001	1,300	477	0.003	0.010
MM55.15.1A3.bulk	MM55.PLAS.ISO.01858.001	1,858	222	0.007	0.009
MM55.15.1A4.bulk	MM55.PLAS.ISO.01858.002	1,858	209	0.005	0.047
MM55.16.1C2.bulk	MM55.PLAS.ISO.02054.001	2,054	402	0.006	0.006
MM55.16.1E1.bulk	MM55.PLAS.ISO.02054.002	2,054	513	0.007	0.004

MM62.01.1A3.bulk	MM62.PLAS.ISO.00022.003	22	404	0.200 ⁵	1.723 ⁵
MM62.01.1C4.bulk	MM62.PLAS.ISO.00022.001	22	227	0.160	1.614
MM62.01.2C6.bulk	MM62.PLAS.ISO.00022.002	22	238	0.260	1.808
MM62.02.1B1.bulk	MM62.PLAS.ISO.00057.002	57	295	0.090	0.751
MM62.02.2D1.bulk	MM62.PLAS.ISO.00057.001	57	223	0.081	0.871
MM62.03.1B3.bulk	MM62.PLAS.ISO.00074.001	74	255	0.008	0.014
MM62.03.2D2.bulk	MM62.PLAS.ISO.00074.002	74	245	0.010	0.022
MM62.04.1C1.bulk	MM62.PLAS.ISO.00120.001	120	298	0.005 ⁵	0.004 ⁵
MM62.04.1D3.bulk	MM62.PLAS.ISO.00120.002	120	243	0.007	0.008
MM62.04.1E5.bulk	MM62.PLAS.ISO.00120.003	120	279	0.007	0.008
MM62.05.2C1.bulk	MM62.PLAS.ISO.00185.001	185	358	0.016 ⁵	0.021 ⁵
MM62.05.2D5.bulk	MM62.PLAS.ISO.00185.002	185	374	0.030	0.079
MM62.06.1C3.bulk	MM62.PLAS.ISO.00304.001	304	267	0.006	0.007
MM62.08.2A1.bulk	MM62.PLAS.ISO.00658.001	658	362	0.009	0.011
MM62.10.1D6.bulk	MM62.PLAS.ISO.01130.001	1,130	258	0.012	0.022
MM62.10.1G6.bulk	MM62.PLAS.ISO.01130.002	1,130	246	0.014	0.018
MM62.11.2B5.bulk	MM62.PLAS.ISO.01331.001	1,331	298	0.010	0.016
MM62.11.2A2.bulk	MM62.PLAS.ISO.01331.002	1,331	307	0.015	0.022

WEAU.02.1A1.bulk	WEAU.PLAS.ISO.-0004.001	-4	257	0.843	19.873
WEAU.02.1A2.bulk	WEAU.PLAS.ISO.-0004.002	-4	464	0.854	20.646
WEAU.03.1A4.bulk	WEAU.PLAS.ISO.00000.001	0	260	1.006	18.580
WEAU.03.1A5.bulk	WEAU.PLAS.ISO.00000.002	0	146	0.972	17.459
WEAU.08.1B1.bulk	WEAU.PLAS.ISO.00024.001	24	283	0.302	9.336
WEAU.08.1B2.bulk	WEAU.PLAS.ISO.00024.002	24	295	0.298	8.530
WEAU.11.1B5.bulk	WEAU.PLAS.ISO.00052.001	52	228	0.264	6.061

Table S2

WEAU.11.1B6.bulk	WEAU.PLAS.ISO.00052.002	52	287	0.215	4.924
WEAU.14.1C1.bulk	WEAU.PLAS.ISO.00371.001	371	306	0.151 ⁵	7.139 ⁵
WEAU.14.1C3.bulk	WEAU.PLAS.ISO.00371.002	371	158	0.302	4.073
WEAU.15.1C4.bulk	WEAU.PLAS.ISO.00520.001	520	140	0.266	8.100
WEAU.15.1C5.bulk	WEAU.PLAS.ISO.00520.002	520	121	0.333	8.758
WEAU.17.1D1.bulk	WEAU.PLAS.ISO.00752.001	752	146	0.298	11.100
WEAU.17.1D2.bulk	WEAU.PLAS.ISO.00752.002	752	189	0.353	7.279
WEAU.18.1D4.bulk	WEAU.PLAS.ISO.00771.001	771	245	0.241	6.080
WEAU.18.1D5.bulk	WEAU.PLAS.ISO.00771.002	771	178	0.431	8.211
WEAU.19.1A1.bulk	WEAU.PLAS.ISO.00981.001	981	299	0.466	11.906
WEAU.19.1A3.bulk	WEAU.PLAS.ISO.00981.002	981	380	0.533	11.227

¹For GenBank accession numbers see Table S5.

²Days following onset of symptoms

³Concentration of p24 in culture supernatant at day 7 in the absence of IFN treatment.

⁴Concentration of IFN α 2 and IFN β that reduced virus replication by 50%.

⁵Average of multiple biological replicates.

Table S2

Table S3. Generation of viral isolates from ART suppressed individuals with and without treatment interruption

Virus	Subjects ¹	Gender ²	Years on ART before ATI ³	Sample time point	Viral load (copies/μl)	CD4 count (cells/μl)	Sample ⁴	Number of Limiting dilution virus isolates ⁵	Study Number	References
QVOA	B199	M	4	second leukapheresis	<20	200	QVOA Supernatant	1	MNU-0628	Lorenzi et al., 2016
QVOA	B106	M	7	first and second leukapheresis	<20	390	QVOA Supernatant	2		
QVOA	9242	M	2	during ATI (12 weeks) before rebound	<20	967	QVOA Supernatant	2	NCT02825797	Mendoza et al., 2018
QVOA	9243	M	5	during ATI (12 weeks) before rebound	<20	545	QVOA Supernatant	1		
QVOA	9244	M	5	2 weeks pre ATI	<20	796	QVOA Supernatant	4		
QVOA	9244	M	5	during ATI (12 weeks) before rebound	<20	796	QVOA Supernatant	2		
QVOA	9241	M	5	during ATI (12 weeks) before rebound	<20	709	QVOA Supernatant	1		
QVOA	9241	M	5	2 weeks pre ATI	<20		QVOA Supernatant	4		
Rebound	9242	M	2	16 weeks post ATI	65,520	450	Plasma	5		
Rebound	9243	M	5	21 weeks post ATI	10,110	350	Plasma	1		
Rebound	9244	M	5	22 weeks post ATI	120,330	730	Plasma	5		
Rebound	9241	M	5	22 weeks post ATI	13,250	500	Plasma	1		
QVOA	A06	M	>3.6	2.5 weeks pre ATI	<50	>470	QVOA Supernatant and cryopreserved PBMC	6	NCT02463227	Bar et al., 2016; Salantes et al., 2018
QVOA	A06	M	>3.6	10.5 months post ATI	<50		QVOA Supernatant	3		
QVOA	A08	M	>3.6	4 weeks pre ATI	<50	>470	QVOA Supernatant	4		
QVOA	A08	M	>3.6	11 months post ATI	<50		QVOA Supernatant and cryopreserved PBMC	16		
QVOA	A09	M	>3.6	1 week pre ATI	<50	>470	QVOA Supernatant	4		
QVOA	A09	M	>3.6	12 months post ATI	<50		QVOA Supernatant	2		
Rebound	A09	M	>3.6	3 weeks post ATI	2,330	>350	Plasma	8		
Rebound	A08	M	>3.6	5 weeks post ATI	20,000	>350	Plasma	17		
Rebound	S22	M	8	during 2nd ATI	750,000	449	Plasma	5	NCT00051818	Papasavvas et al., 2004
Rebound	S23	M	5	during 2nd ATI	556,372	351	Plasma	2		
Rebound	S30	M	5	during 3rd ATI	517,473	467	Plasma	4		
Rebound	004	M	>1	4 weeks post ATI (week 12 of study)	33,812	794	Plasma	4	NCT02227277	Azzoni et al, 2020
Rebound	030	M	>1	4 weeks post ATI (week 12 of study)	18,056	377	Plasma	4		
Rebound	044	F	>1	4 weeks post ATI (week 12 of study)	20,171	496	Plasma	4		
Rebound	601	M	20	5 weeks post ATI (week 29 of study)	112,160	707	Plasma	6	NCT02588586	Cohen et al., 2018

¹All subjects were recruited in the US and had subtype B infections, except for subject A09 who also harbored a subtype A strain (only subtype B viruses were isolated)

²M, male; F, female.

³ATI, analytical treatment interruption

⁴QVOA, quantitative viral outgrowth assay

⁵Viral isolates were confirmed by sequence analysis to be single virion-derived (Genbank accession number are shown in table S5)

Table S4. IFN-I resistance of viral outgrowth and rebound isolates

Type ¹	Isolate ID ²	Study number	Replicative capacity (ng p24/ml) ³	IFNα2 IC ₅₀ (pg/ml) ⁴	IFNβ IC ₅₀ (pg/ml) ⁴
QVOA	B199.2.C.BF.1	MNU-0628	80	0.04	0.12
QVOA	B106.1.C.3.8 ⁵		100	0.18	3.12
QVOA	B106.2.C.D6.S8 ⁶		195	0.16	1.96
QVOA - week 12 ⁵	9242.QVOA.12F23	NCT02825797	386	0.02	0.04
QVOA - week 12 ⁵	9242.QVOA.12M6		641	0.01	0.01
QVOA - week 12 ⁵	9243.QVOA.12Y10		679	0.02	0.04
QVOA - week 12 ⁵	9244.QVOA.12I10		492	0.02	0.04
QVOA - week 12 ⁵	9244.QVOA.12J17		483	0.02	0.09
QVOA - week -2 ⁵	9244.QVOA.G12		694	0.01	0.10
QVOA - week -2 ⁵	9244.QVOA.H1		496	0.02	0.06
QVOA - week -2 ⁵	9244.QVOA.K2		404	0.02	0.15
QVOA - week -2 ⁵	9244.QVOA.P11		423	0.02	0.11
QVOA - week 12 ⁵	9241.QVOA.12AU7		360	0.03	0.25
QVOA - week -2 ⁵	9241.QVOA.D2		445	0.02	0.09
QVOA - week -2 ⁵	9241.QVOA.A10		315	0.04	0.13
QVOA - week -2 ⁵	9241.QVOA.C19		282	0.04	0.09
QVOA - week -2 ⁵	9241.QVOA.C8		278	0.04	0.10
Rebound	9242.REB.6B8		299	1.13	45.04
Rebound	9242.REB.6A7		309	1.05	21.99
Rebound	9242.REB.6B2		286	1.93	30.49
Rebound	9242.REB.13B1		547	1.26	61.88
Rebound	9242.REB.13B8		418	1.70	58.24
Rebound	9243.REB.13F7		554	1.56	49.26
Rebound	9244.REB.7A8		499	1.53	54.25
Rebound	9244.REB.7A1		459	1.59	31.67
Rebound	9244.REB.7C1		567	1.72	34.43
Rebound	9244.REB.9D3		578	1.35	48.06
Rebound	9244.REB.9E6		535	1.70	77.03
Rebound	9241.REB.7D4		626	1.62	82.64
QVOA - Pre ATI	A06.QVOA.M5		139	0.15	1.70
QVOA - Pre ATI	A06.QVOA.M10		144	0.11	1.57
QVOA - Pre ATI	A06.QVOA.M30		158	0.09	1.81
QVOA - Pre ATI	A06.QVOA.M28		97	0.09	1.17
QVOA - Pre ATI	A06.QVOA.M19		150	0.08	1.40
QVOA - Pre ATI	A06.QVOA.M29		124	0.07	2.99
QVOA - Post ATI	A06.QVOA.2B		143	0.07	0.85
QVOA - Post ATI	A06.QVOA.M20		126	0.09	1.67
QVOA - Post ATI	A06.QVOA.M3		117	0.09	1.10
QVOA - Pre ATI	A08.QVOA.1E2		99	0.04	0.32
QVOA - Pre ATI	A08.QVOA.M1		1548	0.02	0.01
QVOA - Pre ATI	A08.QVOA.M4		965	0.01	0.04
QVOA - Pre ATI	A08.QVOA.M5		665	0.01	0.10
QVOA - Post ATI	A08.QVOA.M17		977	0.01	0.60
QVOA - Post ATI	A08.QVOA.M20		620	0.01	0.08
QVOA - Post ATI	A08.QVOA.1B5		122	0.03	0.90
QVOA - Post ATI	A08.QVOA.1C8		152	0.03	0.08
QVOA - Post ATI	A08.QVOA.1F8		163	0.03	0.07
QVOA - Post ATI	A08.QVOA.3D8		65	1.47	5.17
QVOA - Post ATI	A08.QVOA.4A1		103	0.02	0.15
QVOA - Post ATI	A08.QVOA.4E4		120	0.02	0.09
QVOA - Post ATI	A08.QVOA.5C3		83	0.03	0.39
QVOA - Post ATI	A08.QVOA.5E2		142	0.02	0.03
QVOA - Post ATI	A08.QVOA.5E4		119	0.04	0.49
QVOA - Post ATI	A08.QVOA.6D3		120	0.03	0.04
QVOA - Post ATI	A08.QVOA.6E2		86	0.02	0.08
QVOA - Post ATI	A08.QVOA.6F6		66	1.23	8.24

Table S4

QVOA - Post ATI	A08.QVOA.7F8	NCT02463227	150	0.04	0.14
QVOA - Post ATI	A08.QVOA.8E8		50	0.03	0.03
Rebound	A08.REB.1A3		451	1.06	83.13
Rebound	A08.REB.1D1		496	1.45	51.37
Rebound	A08.REB.5C2		125	1.22	80.62
Rebound	A08.REB.5D2		250	1.44	45.44
Rebound	A08.REB.6B3		125	0.85	55.84
Rebound	A08.REB.6D6		728	1.22	46.83
Rebound	A08.REB.7A3		504	1.51	75.85
Rebound	A08.REB.7C1		707	1.43	68.06
Rebound	A08.REB.7C2		176	2.07	44.85
Rebound	A08.REB.7D3		309	1.65	38.78
Rebound	A08.REB.8A5		768	1.59	41.98
Rebound	A08.REB.8B3		763	1.61	41.17
Rebound	A08.REB.8D1		425	1.33	31.24
Rebound	A08.REB.6B5		510	2.28	64.49
Rebound	A08.REB.8B5		510	1.94	69.78
Rebound	A08.REB.2F4		420	3.01	92.25
Rebound	A08.REB.1A5		506	1.69	42.34
QVOA - Pre ATI	A09.QVOA.M25	NCT00051818	194	0.26	1.29
QVOA - Pre ATI	A09.QVOA.M22		206	0.05	0.19
QVOA - Pre ATI	A09.QVOA.M2		254	0.05	0.46
QVOA - Pre ATI	A09.QVOA.M6		171	0.06	0.70
QVOA - Post ATI	A09.QVOA.M9		171	0.21	0.06
QVOA - Post ATI	A09.QVOA.M16		285	0.05	0.69
Rebound	A09.REB.1B5		275	3.16	58.67
Rebound	A09.REB.1D5		101	2.19	51.20
Rebound	A09.REB.2B2		171	2.79	26.36
Rebound	A09.REB.1A1		376	2.40	46.03
Rebound	A09.REB.1A3		227	1.78	58.57
Rebound	A09.REB.1A4		239	2.48	70.36
Rebound	A09.REB.1A5		249	2.55	61.27
Rebound	A09.REB.1A2		221	2.54	83.45
Rebound	S22.REB.24C4	NCT02227277	399	1.64	90.59
Rebound	S22.REB.1E2		389	1.03	61.14
Rebound	S22.REB.1F5		374	1.62	93.32
Rebound	S22.REB.3A6		487	1.45	97.27
Rebound	S22.REB.3B6		378	1.00	75.65
Rebound	S23.REB.3D1		358	1.70	66.56
Rebound	S23.REB.24A5		475	1.25	76.30
Rebound	S30.REB.8D1		407	1.21	84.20
Rebound	S30.REB.2D1		303	2.14	87.20
Rebound	S30.REB.2D2		350	1.54	70.82
Rebound	S30.REB.7D1	NCT02588586	336	1.72	72.69
Rebound	004.REB.4D4		413	2.58	93.58
Rebound	004.REB.4E6		263	2.54	63.21
Rebound	004.REB.4D1		259	2.65	97.87
Rebound	004.REB.4E3		252	5.55	111.80
Rebound	030.REB.3E1		371	2.99	56.49
Rebound	030.REB.2E1		396	2.84	47.24
Rebound	030.REB.4E1		427	3.48	70.43
Rebound	030.REB.8E1		308	2.84	69.21
Rebound	044.REB.6F1		283	3.42	79.99
Rebound	044.REB.5F1	NCT02588586	348	2.75	69.41
Rebound	044.REB.7F1		329	2.80	72.71
Rebound	044.REB.8F1		355	2.48	91.45
Rebound	601.REB.4B7		497	2.15	64.85
Rebound	601.REB.4C3	NCT02588586	483	2.03	33.29
Rebound	601.REB.4B4		468	2.17	65.81
Rebound	601.REB.4A8		546	1.81	42.24

Table S4

Rebound	601.REB.4A7	562	2.25	60.84
Rebound	601.REB.4C1	536	2.02	54.66

¹Isolates were obtained by expanding previously generated quantitative viral outgrowth assay (QVOA) supernatants , or generated de novo from cryopreserved PBMCs or plasma samples (61-67).

²For GenBank accession numbers see Table S5.

³Concentration of p24 in culture supernatant at day 7 in the absence of IFN treatment.

⁴Dose of IFN that reduced viral replication in CD4+ T cells by 50%.

⁵Samples from the NCT02825797 study were collected before (-2 week) and during (12 week) treatment interruption, but prior to any detectable rebound virus.

⁶B106.1.C.3.8 was isolated from the first and 106.2.C.D6.S8 from the second leukapheresis sample.

Table S5. GenBank accession numbers of viral sequences

Type	Sequence ID	Region Sequenced	Genbank Accession Number	Original Isolate Designation
Pre-ART	MM14.PLAS.ISO.00040.002	env	pending	this study
Pre-ART	MM14.PLAS.ISO.00040.003	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00040.003	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00040.004	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00040.005	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00040.006	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00040.007	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00040.008	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00040.009	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00040.010	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00040.011	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00138.001	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00138.002	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00138.003	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00138.004	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00138.005	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00138.007	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00138.008	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00138.009	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00138.010	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00270.001	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00270.002	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00270.003	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.001	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.002	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.003	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.004	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.005	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.006	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.007	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.008	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.009	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.010	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.011	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.012	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.013	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00519.014	3' half	pending	this study
Pre-ART	MM14.PLAS.ISO.00722.001	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00722.001	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00722.003	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00722.004	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.00722.005	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.00722.008	env	pending	this study
Pre-ART	MM14.PLAS.ISO.01045.001	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.01045.001	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.01045.002	3' half	pending	this study
Plasma SGS	MM14.PLAS.SGS.01045.003	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.01324.001	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.01324.002	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.01324.003	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.01394.002	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.01394.003	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.01394.004	env	pending	this study
Plasma SGS	MM14.PLAS.SGS.01394.005	env	pending	this study
QVOA	MM14.PBMC.QVOA.03193.001	3' half	pending	this study
Pre-ART	MM15.PLAS.ISO.00027.003	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.001	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.002	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.003	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.004	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.005	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.006	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.007	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.008	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.009	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.010	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.011	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.012	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.013	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.014	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00027.017	3' half	pending	this study
Pre-ART	MM15.PLAS.ISO.00037.002	env	pending	this study
Pre-ART	MM15.PLAS.ISO.00037.003	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.001	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.002	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.003	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.004	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.005	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.006	3' half	pending	this study

Table S5

Plasma SGS	MM15.PLAS.SGS.00037.007	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.008	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.009	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.010	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.011	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.012	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.013	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.014	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.015	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.016	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00037.017	3' half	pending	this study
Pre-ART	MM15.PLAS.ISO.00079.001	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.001	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.002	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.003	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.004	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.005	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.006	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.007	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.008	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.009	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.010	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00079.011	env	pending	this study
Pre-ART	MM15.PLAS.ISO.00107.001	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.001	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.002	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.003	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.004	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.005	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.006	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.007	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.008	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.009	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.010	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.011	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.012	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.013	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.014	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00107.015	3' half	pending	this study
Pre-ART	MM15.PLAS.ISO.00191.001	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00191.001	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00191.002	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00191.003	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00191.004	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00191.005	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00191.006	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00373.001	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00373.002	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00373.003	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00373.004	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00373.005	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00373.006	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00373.007	env	pending	this study
Pre-ART	MM15.PLAS.ISO.00548.001	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00548.001	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00548.002	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00548.003	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00548.004	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00548.005	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00548.006	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00720.001	env	pending	this study
Plasma SGS	MM15.PLAS.SGS.00720.002	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00720.003	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00720.004	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00720.005	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00720.006	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00720.007	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00720.008	3' half	pending	this study
Plasma SGS	MM15.PLAS.SGS.00720.009	3' half	pending	this study
QVOA	MM15.PBMC.QVOA.01403.001	env	pending	this study

Pre-ART	MM23.PLAS.ISO.00009.001	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.002	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.003	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.004	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.005	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.006	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.007	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.008	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.009	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.010	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.011	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00009.012	full-length	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.001	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.002	3' half	pending	this study

Table S5

Plasma SGS	MM23.PLAS.SGS.00009.003	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.004	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.005	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.006	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.007	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.008	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.009	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.010	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.011	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.012	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.013	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.014	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.016	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.017	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.018	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.019	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.020	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.021	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.022	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.023	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.024	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.025	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.026	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.027	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.028	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.029	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.030	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.031	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.032	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.033	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.034	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.035	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.036	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.037	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.038	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.039	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.040	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.041	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00009.042	env	pending	this study
Pre-ART	MM23.PLAS.ISO.00064.001	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00064.002	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00064.003	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00064.004	full-length	pending	this study
Plasma SGS	MM23.PLAS.SGS.00064.001	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00064.002	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00064.003	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00064.004	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00064.005	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00064.006	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00064.007	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00064.008	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00064.009	env	pending	this study
Pre-ART	MM23.PLAS.ISO.00204.001	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00204.002	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00204.003	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00204.004	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00204.005	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00204.006	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00204.007	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00204.008	full-length	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.001	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.002	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.003	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.004	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.005	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.006	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.007	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.008	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.009	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.010	3' half	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.011	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.012	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.013	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.014	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.015	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.016	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.017	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.018	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.019	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.020	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.021	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.022	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.023	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.024	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.025	env	pending	this study

Table S5

Plasma SGS	MM23.PLAS.SGS.00204.026	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.027	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.028	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.029	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.030	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.031	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.032	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.033	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.034	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.035	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.036	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.037	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.038	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.039	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.040	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.041	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.042	env	pending	this study
Plasma SGS	MM23.PLAS.SGS.00204.043	env	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.001	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.002	3' half	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.003	3' half	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.004	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.005	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.006	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.007	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.008	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.009	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.010	3' half	pending	this study
Pre-ART	MM23.PLAS.ISO.00316.011	3' half	pending	this study
Pre-ART	MM23.PLAS.ISO.00722.001	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00722.002	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00722.003	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00722.004	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00722.005	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00722.006	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00722.007	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00722.008	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.00722.009	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01065.001	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01065.002	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01065.003	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01065.004	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01065.005	3' half	pending	this study
Pre-ART	MM23.PLAS.ISO.01534.001	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01534.002	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01534.003	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01534.004	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01534.005	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01534.006	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01534.007	full-length	pending	this study
Pre-ART	MM23.PLAS.ISO.01534.008	full-length	pending	this study
QVOA	MM23.PBMC.QVOA.02738.001	full-length	pending	this study
QVOA	MM23.PBMC.QVOA.02738.002	full-length	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.001	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.002	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.003	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.004	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.005	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.006	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.007	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.008	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.009	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.010	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.011	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.012	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.013	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.014	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.015	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.016	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.017	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.018	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.019	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.020	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.021	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.022	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.023	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.024	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.025	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.026	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.027	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.028	env	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.029	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.030	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.031	3' half	pending	this study
PBMC SGS	MM23.PBMC.SGS.02738.032	3' half	pending	this study

Table S5

PBMC SGS	MM23.PBMC.SGS.02738.033	3' half	pending	this study
Pre-ART	MM33.PLAS.ISO.00012.001	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00012.002	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00012.003	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00012.004	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00012.005	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00012.006	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00012.007	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00012.008	full-length	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.010	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.011	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.012	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.013	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.014	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.015	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.016	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.017	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.018	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.019	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.020	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.021	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.022	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.023	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.024	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.025	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.026	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.027	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.028	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.029	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.030	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.031	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.032	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.033	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.034	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.035	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.036	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.037	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.038	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.039	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.040	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.041	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00012.042	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.010	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.011	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.012	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.013	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.014	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.015	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.016	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.017	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.018	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.019	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.020	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.021	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.022	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.023	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.024	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.025	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.026	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.027	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.028	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.029	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.030	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.031	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.032	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00019.033	env	pending	this study

Table S5

[illegible]

Table S5

Plasma SGS	MM33.PLAS.SGS.00040.025	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00040.026	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00040.027	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00040.028	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00040.029	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.010	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.011	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.012	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.013	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.014	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.015	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.016	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.017	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.018	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00069.019	env	pending	this study
Pre-ART	MM33.PLAS.ISO.00096.001	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00096.002	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00096.003	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00096.004	full-length	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.010	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.011	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.012	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.013	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00096.014	env	pending	this study
Pre-ART	MM33.PLAS.ISO.00201.001	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00201.002	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00201.003	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00201.004	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00201.005	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00201.006	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00201.007	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00201.008	full-length	pending	this study
Plasma SGS	MM33.PLAS.SGS.00201.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00201.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00201.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00201.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00201.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00201.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00201.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00201.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.010	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.011	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.012	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00286.013	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.010	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.011	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.012	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.013	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.014	env	pending	this study

Table S5

Plasma SGS	MM33.PLAS.SGS.00391.015	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.016	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.017	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.018	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.019	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.020	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00391.021	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.010	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.011	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.012	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.013	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.014	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.015	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.016	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.017	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.018	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.019	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00621.020	env	pending	this study
Pre-ART	MM33.PLAS.ISO.00719.001	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00719.002	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00719.003	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00719.004	3' half	pending	this study
Pre-ART	MM33.PLAS.ISO.00719.005	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.00719.006	3' half	pending	this study
Pre-ART	MM33.PLAS.ISO.00719.007	full-length	pending	this study
Plasma SGS	MM33.PLAS.SGS.00719.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00719.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00719.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00719.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00719.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00719.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.00719.007	env	pending	this study
Pre-ART	MM33.PLAS.ISO.01006.001	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01006.002	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01006.003	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01006.004	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01006.005	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01006.007	full-length	pending	this study
Plasma SGS	MM33.PLAS.SGS.01006.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01006.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01006.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01006.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01006.005	env	pending	this study
Pre-ART	MM33.PLAS.ISO.01721.009	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01721.001	3' half	pending	this study
Pre-ART	MM33.PLAS.ISO.01721.002	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01721.003	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01721.004	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01721.005	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01721.006	env	pending	this study
Pre-ART	MM33.PLAS.ISO.01721.007	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.01721.008	3' half	pending	this study
Plasma SGS	MM33.PLAS.SGS.01721.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01721.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01721.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01721.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01721.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01721.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01721.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01721.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01721.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.010	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.011	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.012	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.013	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.014	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.015	env	pending	this study

Table S5

Plasma SGS	MM33.PLAS.SGS.01913.016	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.017	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.018	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.019	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.020	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.021	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.01913.022	env	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.001	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.002	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.003	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.004	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.005	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.006	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.007	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.008	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.009	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.010	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.011	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.012	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.013	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.014	full-length	pending	this study
Pre-ART	MM33.PLAS.ISO.02031.015	full-length	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.001	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.002	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.003	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.004	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.005	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.006	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.007	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.008	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.009	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.010	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.011	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.012	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.013	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.014	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.015	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.016	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.017	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.018	env	pending	this study
Plasma SGS	MM33.PLAS.SGS.02031.019	env	pending	this study

Pre-ART	MM34.PLAS.ISO.00017.001	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.002	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.003	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.004	env	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.005	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.006	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.007	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.008	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.009	env	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.010	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.00017.011	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.001	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.002	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.003	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.004	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.005	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.006	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.007	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.008	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.009	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.010	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.011	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.012	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.013	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.014	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.015	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.016	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.017	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.018	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.019	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.020	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.021	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.023	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.024	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.025	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.026	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.027	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.028	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.029	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.030	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.031	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.032	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.033	env	pending	this study

Table S5

Plasma SGS	MM34.PLAS.SGS.00017.034	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.035	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.036	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.037	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.038	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.039	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.040	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00017.041	env	pending	this study
Pre-ART	MM34.PLAS.ISO.00074.001	full-length	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.001	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.002	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.003	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.004	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.005	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.006	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.007	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.008	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.009	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00074.010	env	pending	this study
Pre-ART	MM34.PLAS.ISO.00192.001	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.00192.002	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.00192.003	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.00192.004	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.00192.005	full-length	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.001	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.002	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.003	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.004	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.005	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.006	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.007	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.008	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.009	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.010	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.011	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.012	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.013	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.014	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.015	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.016	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.017	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.018	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.019	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.020	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.021	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.022	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.023	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.024	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.025	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.026	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.027	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.028	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.029	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.030	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.031	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.032	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.033	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.034	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.035	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.036	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.037	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.038	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.039	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00192.040	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.001	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.002	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.003	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.004	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.005	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.006	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.007	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.008	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.009	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.010	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.011	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.012	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.013	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.014	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.015	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.016	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.017	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.018	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00353.019	env	pending	this study
Pre-ART	MM34.PLAS.ISO.00760.001	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.00760.002	full-length	pending	this study

Table S5

Pre-ART	MM34.PLAS.ISO.00760.003	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.00760.004	full-length	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.001	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.002	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.003	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.004	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.005	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.006	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.007	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.008	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.009	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.010	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.011	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.012	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.00760.013	env	pending	this study
Pre-ART	MM34.PLAS.ISO.01007.002	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01007.003	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01007.004	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01007.005	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01007.006	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01313.001	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01313.002	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01313.003	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01313.004	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01313.005	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01313.006	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01313.007	full-length	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.001	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.002	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.003	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.004	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.005	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.006	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.007	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.008	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.009	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.010	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.011	env	pending	this study
Plasma SGS	MM34.PLAS.SGS.01313.012	env	pending	this study
Pre-ART	MM34.PLAS.ISO.01399.001	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01399.002	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01399.003	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01691.001	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.01691.002	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01691.003	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01691.004	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01691.005	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.01691.006	full-length	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.001	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.002	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.003	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.004	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.005	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.006	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.007	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.008	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.009	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.010	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.011	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.012	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.013	3' half	pending	this study
Pre-ART	MM34.PLAS.ISO.02229.014	3' half	pending	this study
QVOA	MM34.PBMC.QVOA.02911.001	full-length	pending	this study
QVOA	MM34.PBMC.QVOA.03261.001	full-length	pending	this study
QVOA	MM34.PBMC.QVOA.03261.002	full-length	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.001	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.002	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.003	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.004	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.005	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.006	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.007	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.008	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.009	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.010	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.011	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.012	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.013	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.014	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.015	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.016	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.017	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.018	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.019	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.020	3' half	pending	this study

Table S5

PBMC SGS	MM34.PBMC.SGS.03261.021	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.022	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.023	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.024	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.025	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.026	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.027	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.028	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.029	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.030	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.031	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.032	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.033	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.034	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.035	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.036	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.037	3' half	pending	this study
PBMC SGS	MM34.PBMC.SGS.03261.038	3' half	pending	this study

Pre-ART	MM39.PLAS.ISO.00011.001	full-length	pending	this study
Pre-ART	MM39.PLAS.ISO.00011.002	3' half	MG902541	MM39_d0021_ipe015_isol_2A2
Pre-ART	MM39.PLAS.ISO.00011.003	full-length	pending	this study
Pre-ART	MM39.PLAS.ISO.00011.004	3' half	MG902534	MM39_d0021_ipe015_isol_13B5
Pre-ART	MM39.PLAS.ISO.00011.005	3' half	MG902535	MM39_d0021_ipe015_isol_13C3
Pre-ART	MM39.PLAS.ISO.00011.006	3' half	MG902536	MM39_d0021_ipe015_isol_13D2
Pre-ART	MM39.PLAS.ISO.00011.007	full-length	pending	this study
Pre-ART	MM39.PLAS.ISO.00011.008	full-length	pending	this study
Pre-ART	MM39.PLAS.ISO.00011.009	3' half	MG902537	MM39_d0021_ipe015_isol_14A3
Pre-ART	MM39.PLAS.ISO.00011.010	full-length	pending	this study
Pre-ART	MM39.PLAS.ISO.00011.011	3' half	MG902538	MM39_d0021_ipe015_isol_14C2
Pre-ART	MM39.PLAS.ISO.00011.012	full-length	pending	this study
Pre-ART	MM39.PLAS.ISO.00011.013	3' half	MG902539	MM39_d0021_ipe015_isol_14C5
Pre-ART	MM39.PLAS.ISO.00011.014	full-length	pending	this study
Pre-ART	MM39.PLAS.ISO.00011.015	3' half	MG902540	MM39_d0021_ipe015_isol_14D5
Plasma SGS	MM39.PLAS.SGS.00011.001	3' half	MG902515	MM39_d0021_ipe015_SGA_2
Plasma SGS	MM39.PLAS.SGS.00011.003	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.004	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.005	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.006	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.007	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.008	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.009	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.010	3' half	MG902516	MM39_d0021_ipe015_SGA_20
Plasma SGS	MM39.PLAS.SGS.00011.011	3' half	MG902529	MM39_d0021_ipe015_SGA_35
Plasma SGS	MM39.PLAS.SGS.00011.012	3' half	MG902510	MM39_d0021_ipe015_SGA_1
Plasma SGS	MM39.PLAS.SGS.00011.013	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.014	3' half	MG902513	MM39_d0021_ipe015_SGA_13
Plasma SGS	MM39.PLAS.SGS.00011.015	3' half	MG902518	MM39_d0021_ipe015_SGA_22
Plasma SGS	MM39.PLAS.SGS.00011.016	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.017	3' half	MG902528	MM39_d0021_ipe015_SGA_34
Plasma SGS	MM39.PLAS.SGS.00011.018	3' half	MG902530	MM39_d0021_ipe015_SGA_37
Plasma SGS	MM39.PLAS.SGS.00011.019	3' half	MG902531	MM39_d0021_ipe015_SGA_4
Plasma SGS	MM39.PLAS.SGS.00011.020	3' half	MG902526	MM39_d0021_ipe015_SGA_32
Plasma SGS	MM39.PLAS.SGS.00011.021	3' half	MG902523	MM39_d0021_ipe015_SGA_28
Plasma SGS	MM39.PLAS.SGS.00011.022	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.023	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.024	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.025	3' half	MG902524	MM39_d0021_ipe015_SGA_30
Plasma SGS	MM39.PLAS.SGS.00011.026	3' half	MG902527	MM39_d0021_ipe015_SGA_33
Plasma SGS	MM39.PLAS.SGS.00011.027	3' half	MG902520	MM39_d0021_ipe015_SGA_24
Plasma SGS	MM39.PLAS.SGS.00011.028	3' half	MG902532	MM39_d0021_ipe015_SGA_5
Plasma SGS	MM39.PLAS.SGS.00011.029	3' half	MG902514	MM39_d0021_ipe015_SGA_16
Plasma SGS	MM39.PLAS.SGS.00011.030	3' half	MG902512	MM39_d0021_ipe015_SGA_11
Plasma SGS	MM39.PLAS.SGS.00011.031	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.032	3' half	MG902511	MM39_d0021_ipe015_SGA_10
Plasma SGS	MM39.PLAS.SGS.00011.033	3' half	MG902521	MM39_d0021_ipe015_SGA_25
Plasma SGS	MM39.PLAS.SGS.00011.034	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00011.035	3' half	MG902519	MM39_d0021_ipe015_SGA_23
Plasma SGS	MM39.PLAS.SGS.00011.036	3' half	MG902525	MM39_d0021_ipe015_SGA_31
Plasma SGS	MM39.PLAS.SGS.00011.037	3' half	MG902522	MM39_d0021_ipe015_SGA_27
Plasma SGS	MM39.PLAS.SGS.00037.001	3' half	MG902546	MM39_d0047_ipe015_SGA_206
Plasma SGS	MM39.PLAS.SGS.00037.002	3' half	MG902556	MM39_d0047_ipe015_SGA_228
Plasma SGS	MM39.PLAS.SGS.00037.003	3' half	MG902554	MM39_d0047_ipe015_SGA_226
Plasma SGS	MM39.PLAS.SGS.00037.004	3' half	MG902558	MM39_d0047_ipe015_SGA_231
Plasma SGS	MM39.PLAS.SGS.00037.005	3' half	MG902547	MM39_d0047_ipe015_SGA_209
Plasma SGS	MM39.PLAS.SGS.00037.006	3' half	MG902542	MM39_d0047_ipe015_SGA_201
Plasma SGS	MM39.PLAS.SGS.00037.007	3' half	MG902557	MM39_d0047_ipe015_SGA_229
Plasma SGS	MM39.PLAS.SGS.00037.008	3' half	MG902548	MM39_d0047_ipe015_SGA_213
Plasma SGS	MM39.PLAS.SGS.00037.009	3' half	MG902551	MM39_d0047_ipe015_SGA_217
Plasma SGS	MM39.PLAS.SGS.00037.010	3' half	MG902549	MM39_d0047_ipe015_SGA_214
Plasma SGS	MM39.PLAS.SGS.00037.011	3' half	MG902545	MM39_d0047_ipe015_SGA_205
Plasma SGS	MM39.PLAS.SGS.00037.012	3' half	MG902559	MM39_d0047_ipe015_SGA_232
Plasma SGS	MM39.PLAS.SGS.00037.013	3' half	MG902544	MM39_d0047_ipe015_SGA_203
Plasma SGS	MM39.PLAS.SGS.00037.014	3' half	MG902553	MM39_d0047_ipe015_SGA_224
Plasma SGS	MM39.PLAS.SGS.00037.015	3' half	MG902555	MM39_d0047_ipe015_SGA_227

Table S5

Plasma SGS	MM39.PLAS.SGS.00037.016	3' half	MG902552	MM39_d0047_ipe015_SGA_218
Plasma SGS	MM39.PLAS.SGS.00037.017	3' half	MG902543	MM39_d0047_ipe015_SGA_202
Plasma SGS	MM39.PLAS.SGS.00037.018	3' half	MG902550	MM39_d0047_ipe015_SGA_215
Plasma SGS	MM39.PLAS.SGS.00037.019	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00037.020	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00037.021	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00092.002	3' half	MG902566	MM39_d0102_ipe015_SGA_215
Plasma SGS	MM39.PLAS.SGS.00092.003	3' half	MG902564	MM39_d0102_ipe015_SGA_210
Plasma SGS	MM39.PLAS.SGS.00092.004	3' half	MG902574	MM39_d0102_ipe015_SGA_230
Plasma SGS	MM39.PLAS.SGS.00092.005	3' half	MG902562	MM39_d0102_ipe015_SGA_207
Plasma SGS	MM39.PLAS.SGS.00092.006	3' half	MG902568	MM39_d0102_ipe015_SGA_218
Plasma SGS	MM39.PLAS.SGS.00092.007	3' half	MG902569	MM39_d0102_ipe015_SGA_219
Plasma SGS	MM39.PLAS.SGS.00092.008	3' half	MG902573	MM39_d0102_ipe015_SGA_229
Plasma SGS	MM39.PLAS.SGS.00092.009	3' half	MG902572	MM39_d0102_ipe015_SGA_227
Plasma SGS	MM39.PLAS.SGS.00092.010	3' half	MG902563	MM39_d0102_ipe015_SGA_209
Plasma SGS	MM39.PLAS.SGS.00092.011	3' half	MG902567	MM39_d0102_ipe015_SGA_216
Plasma SGS	MM39.PLAS.SGS.00092.012	3' half	MG902570	MM39_d0102_ipe015_SGA_224
Plasma SGS	MM39.PLAS.SGS.00092.013	3' half	MG902571	MM39_d0102_ipe015_SGA_226
Plasma SGS	MM39.PLAS.SGS.00092.014	3' half	MG902561	MM39_d0102_ipe015_SGA_204
Plasma SGS	MM39.PLAS.SGS.00092.015	3' half	MG902565	MM39_d0102_ipe015_SGA_211
Pre-ART	MM39.PLAS.ISO.00179.001	3' half	MG902592	MM39_d0189_ipe015_isol_11A3
Pre-ART	MM39.PLAS.ISO.00179.002	3' half	MG902593	MM39_d0189_ipe015_isol_11A4
Pre-ART	MM39.PLAS.ISO.00179.003	3' half	MG902594	MM39_d0189_ipe015_isol_11C1
Plasma SGS	MM39.PLAS.SGS.00179.001	3' half	MG902584	MM39_d0189_ipe015_SGA_213
Plasma SGS	MM39.PLAS.SGS.00179.002	3' half	MG902580	MM39_d0189_ipe015_SGA_207
Plasma SGS	MM39.PLAS.SGS.00179.003	3' half	MG902586	MM39_d0189_ipe015_SGA_215
Plasma SGS	MM39.PLAS.SGS.00179.004	3' half	MG902579	MM39_d0189_ipe015_SGA_205
Plasma SGS	MM39.PLAS.SGS.00179.005	3' half	MG902581	MM39_d0189_ipe015_SGA_208
Plasma SGS	MM39.PLAS.SGS.00179.006	3' half	MG902575	MM39_d0189_ipe015_SGA_201
Plasma SGS	MM39.PLAS.SGS.00179.007	3' half	MG902576	MM39_d0189_ipe015_SGA_202
Plasma SGS	MM39.PLAS.SGS.00179.008	3' half	MG902578	MM39_d0189_ipe015_SGA_204
Plasma SGS	MM39.PLAS.SGS.00179.009	3' half	MG902588	MM39_d0189_ipe015_SGA_217
Plasma SGS	MM39.PLAS.SGS.00179.010	3' half	MG902587	MM39_d0189_ipe015_SGA_216
Plasma SGS	MM39.PLAS.SGS.00179.011	3' half	MG902591	MM39_d0189_ipe015_SGA_221
Plasma SGS	MM39.PLAS.SGS.00179.012	3' half	MG902583	MM39_d0189_ipe015_SGA_212
Plasma SGS	MM39.PLAS.SGS.00179.013	3' half	MG902577	MM39_d0189_ipe015_SGA_203
Plasma SGS	MM39.PLAS.SGS.00179.014	3' half	MG902585	MM39_d0189_ipe015_SGA_214
Plasma SGS	MM39.PLAS.SGS.00179.015	3' half	MG902589	MM39_d0189_ipe015_SGA_218
Plasma SGS	MM39.PLAS.SGS.00179.016	3' half	MG902582	MM39_d0189_ipe015_SGA_209
Plasma SGS	MM39.PLAS.SGS.00179.017	3' half	MG902590	MM39_d0189_ipe015_SGA_220
Plasma SGS	MM39.PLAS.SGS.00270.001	3' half	MG902607	MM39_d0280_ipe015_SGA_225
Plasma SGS	MM39.PLAS.SGS.00270.002	3' half	MG902600	MM39_d0280_ipe015_SGA_211
Plasma SGS	MM39.PLAS.SGS.00270.003	3' half	MG902602	MM39_d0280_ipe015_SGA_214
Plasma SGS	MM39.PLAS.SGS.00270.004	3' half	MG902614	MM39_d0280_ipe015_SGA_234
Plasma SGS	MM39.PLAS.SGS.00270.005	3' half	MG902596	MM39_d0280_ipe015_SGA_203
Plasma SGS	MM39.PLAS.SGS.00270.006	3' half	MG902601	MM39_d0280_ipe015_SGA_212
Plasma SGS	MM39.PLAS.SGS.00270.007	3' half	MG902608	MM39_d0280_ipe015_SGA_226
Plasma SGS	MM39.PLAS.SGS.00270.008	3' half	MG902610	MM39_d0280_ipe015_SGA_229
Plasma SGS	MM39.PLAS.SGS.00270.009	3' half	MG902612	MM39_d0280_ipe015_SGA_232
Plasma SGS	MM39.PLAS.SGS.00270.010	3' half	MG902606	MM39_d0280_ipe015_SGA_222
Plasma SGS	MM39.PLAS.SGS.00270.011	3' half	MG902597	MM39_d0280_ipe015_SGA_204
Plasma SGS	MM39.PLAS.SGS.00270.012	3' half	MG902603	MM39_d0280_ipe015_SGA_217
Plasma SGS	MM39.PLAS.SGS.00270.013	3' half	MG902605	MM39_d0280_ipe015_SGA_221
Plasma SGS	MM39.PLAS.SGS.00270.014	3' half	MG902613	MM39_d0280_ipe015_SGA_233
Plasma SGS	MM39.PLAS.SGS.00270.015	3' half	MG902599	MM39_d0280_ipe015_SGA_208
Plasma SGS	MM39.PLAS.SGS.00270.016	3' half	MG902598	MM39_d0280_ipe015_SGA_206
Plasma SGS	MM39.PLAS.SGS.00270.017	3' half	MG902604	MM39_d0280_ipe015_SGA_218
Plasma SGS	MM39.PLAS.SGS.00270.018	3' half	MG902611	MM39_d0280_ipe015_SGA_231
Plasma SGS	MM39.PLAS.SGS.00270.019	3' half	MG902609	MM39_d0280_ipe015_SGA_228
Pre-ART	MM39.PLAS.ISO.00354.001	3' half	MG902634	MM39_d0364_ipe015_isol_11B3
Pre-ART	MM39.PLAS.ISO.00354.002	3' half	MG902635	MM39_d0364_ipe015_isol_11B4
Pre-ART	MM39.PLAS.ISO.00354.003	3' half	MG902636	MM39_d0364_ipe015_isol_11D1
Pre-ART	MM39.PLAS.ISO.00354.004	3' half	MG902637	MM39_d0364_ipe015_isol_11D4
Pre-ART	MM39.PLAS.ISO.00354.005	3' half	MG902638	MM39_d0364_ipe015_isol_11D6
Pre-ART	MM39.PLAS.ISO.00354.006	3' half	MG902639	MM39_d0364_ipe015_isol_12A2
Pre-ART	MM39.PLAS.ISO.00354.007	3' half	MG902640	MM39_d0364_ipe015_isol_12A6
Pre-ART	MM39.PLAS.ISO.00354.008	3' half	MG902641	MM39_d0364_ipe015_isol_12B5
Pre-ART	MM39.PLAS.ISO.00354.009	3' half	MG902642	MM39_d0364_ipe015_isol_12C3
Pre-ART	MM39.PLAS.ISO.00354.010	3' half	MG902643	MM39_d0364_ipe015_isol_12C4
Pre-ART	MM39.PLAS.ISO.00354.011	3' half	MG902644	MM39_d0364_ipe015_isol_12D3
Pre-ART	MM39.PLAS.ISO.00354.012	3' half	MG902645	MM39_d0364_ipe015_isol_12D4
Pre-ART	MM39.PLAS.ISO.00354.013	3' half	MG902647	MM39_d0364_ipe015_isol_14B4
Pre-ART	MM39.PLAS.ISO.00354.014	3' half	MG902648	MM39_d0364_ipe015_isol_14C5
Plasma SGS	MM39.PLAS.SGS.00354.001	3' half	MG902616	MM39_d0364_ipe015_SGA_1021
Plasma SGS	MM39.PLAS.SGS.00354.002	3' half	MG902623	MM39_d0364_ipe015_SGA_1029
Plasma SGS	MM39.PLAS.SGS.00354.003	3' half	MG902630	MM39_d0364_ipe015_SGA_304
Plasma SGS	MM39.PLAS.SGS.00354.004	3' half	MG902615	MM39_d0364_ipe015_SGA_1020
Plasma SGS	MM39.PLAS.SGS.00354.005	3' half	MG902619	MM39_d0364_ipe015_SGA_1024
Plasma SGS	MM39.PLAS.SGS.00354.006	3' half	MG902627	MM39_d0364_ipe015_SGA_1037
Plasma SGS	MM39.PLAS.SGS.00354.007	3' half	MG902632	MM39_d0364_ipe015_SGA_313
Plasma SGS	MM39.PLAS.SGS.00354.008	3' half	MG902631	MM39_d0364_ipe015_SGA_312
Plasma SGS	MM39.PLAS.SGS.00354.009	3' half	MG902629	MM39_d0364_ipe015_SGA_1040
Plasma SGS	MM39.PLAS.SGS.00354.010	3' half	MG902622	MM39_d0364_ipe015_SGA_1027
Plasma SGS	MM39.PLAS.SGS.00354.011	env	pending	this study
Plasma SGS	MM39.PLAS.SGS.00354.012	3' half	MG902617	MM39_d0364_ipe015_SGA_1022

Table S5

Plasma SGS	MM39.PLAS.SGS.00354.013	3' half	MG902626	MM39_d0364_ipe015_SGA_1034
Plasma SGS	MM39.PLAS.SGS.00354.014	3' half	MG902620	MM39_d0364_ipe015_SGA_1025
Plasma SGS	MM39.PLAS.SGS.00354.015	3' half	MG902625	MM39_d0364_ipe015_SGA_1033
Plasma SGS	MM39.PLAS.SGS.00354.016	3' half	MG902633	MM39_d0364_ipe015_SGA_317
Plasma SGS	MM39.PLAS.SGS.00354.017	3' half	MG902624	MM39_d0364_ipe015_SGA_1030
Plasma SGS	MM39.PLAS.SGS.00354.018	3' half	MG902618	MM39_d0364_ipe015_SGA_1023
Plasma SGS	MM39.PLAS.SGS.00354.019	3' half	MG902628	MM39_d0364_ipe015_SGA_1039
Plasma SGS	MM39.PLAS.SGS.00354.020	3' half	MG902621	MM39_d0364_ipe015_SGA_1026
Plasma SGS	MM39.PLAS.SGS.00459.001	3' half	MG902653	MM39_d0469_ipe015_SGA_308
Plasma SGS	MM39.PLAS.SGS.00459.002	3' half	MG902665	MM39_d0469_ipe015_SGA_332
Plasma SGS	MM39.PLAS.SGS.00459.003	3' half	MG902668	MM39_d0469_ipe015_SGA_337
Plasma SGS	MM39.PLAS.SGS.00459.004	3' half	MG902658	MM39_d0469_ipe015_SGA_318
Plasma SGS	MM39.PLAS.SGS.00459.005	3' half	MG902649	MM39_d0469_ipe015_SGA_301
Plasma SGS	MM39.PLAS.SGS.00459.006	3' half	MG902669	MM39_d0469_ipe015_SGA_339
Plasma SGS	MM39.PLAS.SGS.00459.007	3' half	MG902661	MM39_d0469_ipe015_SGA_322
Plasma SGS	MM39.PLAS.SGS.00459.008	3' half	MG902656	MM39_d0469_ipe015_SGA_315
Plasma SGS	MM39.PLAS.SGS.00459.009	3' half	MG902655	MM39_d0469_ipe015_SGA_313
Plasma SGS	MM39.PLAS.SGS.00459.010	3' half	MG902666	MM39_d0469_ipe015_SGA_335
Plasma SGS	MM39.PLAS.SGS.00459.011	3' half	MG902651	MM39_d0469_ipe015_SGA_304
Plasma SGS	MM39.PLAS.SGS.00459.012	3' half	MG902663	MM39_d0469_ipe015_SGA_327
Plasma SGS	MM39.PLAS.SGS.00459.013	3' half	MG902654	MM39_d0469_ipe015_SGA_311
Plasma SGS	MM39.PLAS.SGS.00459.014	3' half	MG902659	MM39_d0469_ipe015_SGA_319
Plasma SGS	MM39.PLAS.SGS.00459.015	3' half	MG902667	MM39_d0469_ipe015_SGA_336
Plasma SGS	MM39.PLAS.SGS.00459.016	3' half	MG902650	MM39_d0469_ipe015_SGA_303
Plasma SGS	MM39.PLAS.SGS.00459.017	3' half	MG902657	MM39_d0469_ipe015_SGA_316
Plasma SGS	MM39.PLAS.SGS.00459.018	3' half	MG902652	MM39_d0469_ipe015_SGA_307
Plasma SGS	MM39.PLAS.SGS.00459.019	3' half	MG902660	MM39_d0469_ipe015_SGA_320
Plasma SGS	MM39.PLAS.SGS.00459.020	3' half	MG902664	MM39_d0469_ipe015_SGA_330
Plasma SGS	MM39.PLAS.SGS.00459.021	3' half	MG902662	MM39_d0469_ipe015_SGA_324
Plasma SGS	MM39.PLAS.SGS.00543.001	3' half	MG902690	MM39_d0553_ipe015_SGA_536
Plasma SGS	MM39.PLAS.SGS.00543.002	3' half	MG902672	MM39_d0553_ipe015_SGA_308
Plasma SGS	MM39.PLAS.SGS.00543.003	3' half	MG902681	MM39_d0553_ipe015_SGA_518
Plasma SGS	MM39.PLAS.SGS.00543.004	3' half	MG902675	MM39_d0553_ipe015_SGA_512
Plasma SGS	MM39.PLAS.SGS.00543.005	3' half	MG902671	MM39_d0553_ipe015_SGA_303
Plasma SGS	MM39.PLAS.SGS.00543.006	3' half	MG902683	MM39_d0553_ipe015_SGA_524
Plasma SGS	MM39.PLAS.SGS.00543.007	3' half	MG902687	MM39_d0553_ipe015_SGA_531
Plasma SGS	MM39.PLAS.SGS.00543.008	3' half	MG902688	MM39_d0553_ipe015_SGA_533
Plasma SGS	MM39.PLAS.SGS.00543.009	3' half	MG902676	MM39_d0553_ipe015_SGA_513
Plasma SGS	MM39.PLAS.SGS.00543.010	3' half	MG902677	MM39_d0553_ipe015_SGA_514
Plasma SGS	MM39.PLAS.SGS.00543.011	3' half	MG902670	MM39_d0553_ipe015_SGA_301
Plasma SGS	MM39.PLAS.SGS.00543.012	3' half	MG902686	MM39_d0553_ipe015_SGA_529
Plasma SGS	MM39.PLAS.SGS.00543.013	3' half	MG902673	MM39_d0553_ipe015_SGA_510
Plasma SGS	MM39.PLAS.SGS.00543.014	3' half	MG902684	MM39_d0553_ipe015_SGA_526
Plasma SGS	MM39.PLAS.SGS.00543.015	3' half	MG902674	MM39_d0553_ipe015_SGA_511
Plasma SGS	MM39.PLAS.SGS.00543.016	3' half	MG902678	MM39_d0553_ipe015_SGA_515
Plasma SGS	MM39.PLAS.SGS.00543.017	3' half	MG902689	MM39_d0553_ipe015_SGA_535
Plasma SGS	MM39.PLAS.SGS.00543.018	3' half	MG902680	MM39_d0553_ipe015_SGA_517
Plasma SGS	MM39.PLAS.SGS.00543.019	3' half	MG902682	MM39_d0553_ipe015_SGA_520
Plasma SGS	MM39.PLAS.SGS.00543.020	3' half	MG902679	MM39_d0553_ipe015_SGA_516
Plasma SGS	MM39.PLAS.SGS.00543.021	3' half	MG902685	MM39_d0553_ipe015_SGA_527
Pre-ART	MM39.PLAS.ISO.00639.001	3' half	MG902718	MM39_d0649_ipe015_isol_1B1
Pre-ART	MM39.PLAS.ISO.00639.002	3' half	MG902710	MM39_d0649_ipe015_isol_11A2
Pre-ART	MM39.PLAS.ISO.00639.003	3' half	MG902711	MM39_d0649_ipe015_isol_11A4
Pre-ART	MM39.PLAS.ISO.00639.004	3' half	MG902712	MM39_d0649_ipe015_isol_11B1
Pre-ART	MM39.PLAS.ISO.00639.005	3' half	MG902714	MM39_d0649_ipe015_isol_11C3
Pre-ART	MM39.PLAS.ISO.00639.006	3' half	MG902715	MM39_d0649_ipe015_isol_11C5
Pre-ART	MM39.PLAS.ISO.00639.007	3' half	MG902716	MM39_d0649_ipe015_isol_11D1
Pre-ART	MM39.PLAS.ISO.00639.008	3' half	MG902713	MM39_d0649_ipe015_isol_11B2
Plasma SGS	MM39.PLAS.SGS.00639.001	3' half	MG902692	MM39_d0649_ipe015_SGA_10
Plasma SGS	MM39.PLAS.SGS.00639.002	3' half	MG902693	MM39_d0649_ipe015_SGA_11
Plasma SGS	MM39.PLAS.SGS.00639.003	3' half	MG902698	MM39_d0649_ipe015_SGA_16
Plasma SGS	MM39.PLAS.SGS.00639.004	3' half	MG902696	MM39_d0649_ipe015_SGA_14
Plasma SGS	MM39.PLAS.SGS.00639.005	3' half	MG902691	MM39_d0649_ipe015_SGA_1
Plasma SGS	MM39.PLAS.SGS.00639.006	3' half	MG902694	MM39_d0649_ipe015_SGA_12
Plasma SGS	MM39.PLAS.SGS.00639.007	3' half	MG902705	MM39_d0649_ipe015_SGA_5
Plasma SGS	MM39.PLAS.SGS.00639.008	3' half	MG902708	MM39_d0649_ipe015_SGA_8
Plasma SGS	MM39.PLAS.SGS.00639.009	3' half	MG902707	MM39_d0649_ipe015_SGA_7
Plasma SGS	MM39.PLAS.SGS.00639.010	3' half	MG902706	MM39_d0649_ipe015_SGA_6
Plasma SGS	MM39.PLAS.SGS.00639.011	3' half	MG902702	MM39_d0649_ipe015_SGA_2
Plasma SGS	MM39.PLAS.SGS.00639.012	3' half	MG902700	MM39_d0649_ipe015_SGA_18
Plasma SGS	MM39.PLAS.SGS.00639.013	3' half	MG902697	MM39_d0649_ipe015_SGA_15
Plasma SGS	MM39.PLAS.SGS.00639.014	3' half	MG902704	MM39_d0649_ipe015_SGA_4
Plasma SGS	MM39.PLAS.SGS.00639.015	3' half	MG902699	MM39_d0649_ipe015_SGA_17
Plasma SGS	MM39.PLAS.SGS.00639.016	3' half	MG902695	MM39_d0649_ipe015_SGA_13
Plasma SGS	MM39.PLAS.SGS.00639.017	3' half	MG902701	MM39_d0649_ipe015_SGA_19
Plasma SGS	MM39.PLAS.SGS.00639.018	3' half	MG902709	MM39_d0649_ipe015_SGA_9
Plasma SGS	MM39.PLAS.SGS.00639.019	3' half	MG902703	MM39_d0649_ipe015_SGA_3
Pre-ART	MM39.PLAS.ISO.00821.001	3' half	MG902736	MM39_d0831_ipe015_isol_1A2
Pre-ART	MM39.PLAS.ISO.00821.002	3' half	MG902737	MM39_d0831_ipe015_isol_1A5
Pre-ART	MM39.PLAS.ISO.00821.003	3' half	MG902738	MM39_d0831_ipe015_isol_1B3
Pre-ART	MM39.PLAS.ISO.00821.004	3' half	MG902739	MM39_d0831_ipe015_isol_2A3
Pre-ART	MM39.PLAS.ISO.00821.005	3' half	MG902740	MM39_d0831_ipe015_isol_2B1
Pre-ART	MM39.PLAS.ISO.00821.006	3' half	MG902742	MM39_d0831_ipe015_isol_2D4
Pre-ART	MM39.PLAS.ISO.00821.007	3' half	MG902741	MM39_d0831_ipe015_isol_2B5
Plasma SGS	MM39.PLAS.SGS.00821.001	3' half	MG902719	MM39_d0831_ipe015_SGA_1

Table S5

Plasma SGS	MM39.PLAS.SGS.00821.002	3' half	MG902728	MM39_d0831_ipe015_SGA_2
Plasma SGS	MM39.PLAS.SGS.00821.003	3' half	MG902720	MM39_d0831_ipe015_SGA_10
Plasma SGS	MM39.PLAS.SGS.00821.004	3' half	MG902733	MM39_d0831_ipe015_SGA_7
Plasma SGS	MM39.PLAS.SGS.00821.005	3' half	MG902721	MM39_d0831_ipe015_SGA_11
Plasma SGS	MM39.PLAS.SGS.00821.006	3' half	MG902726	MM39_d0831_ipe015_SGA_16
Plasma SGS	MM39.PLAS.SGS.00821.007	3' half	MG902731	MM39_d0831_ipe015_SGA_5
Plasma SGS	MM39.PLAS.SGS.00821.008	3' half	MG902727	MM39_d0831_ipe015_SGA_17
Plasma SGS	MM39.PLAS.SGS.00821.009	3' half	MG902729	MM39_d0831_ipe015_SGA_3
Plasma SGS	MM39.PLAS.SGS.00821.010	3' half	MG902735	MM39_d0831_ipe015_SGA_9
Plasma SGS	MM39.PLAS.SGS.00821.011	3' half	MG902722	MM39_d0831_ipe015_SGA_12
Plasma SGS	MM39.PLAS.SGS.00821.012	3' half	MG902725	MM39_d0831_ipe015_SGA_15
Plasma SGS	MM39.PLAS.SGS.00821.013	3' half	MG902730	MM39_d0831_ipe015_SGA_4
Plasma SGS	MM39.PLAS.SGS.00821.014	3' half	MG902724	MM39_d0831_ipe015_SGA_14
Plasma SGS	MM39.PLAS.SGS.00821.015	3' half	MG902723	MM39_d0831_ipe015_SGA_13
Plasma SGS	MM39.PLAS.SGS.00821.016	3' half	MG902734	MM39_d0831_ipe015_SGA_8
Plasma SGS	MM39.PLAS.SGS.00821.017	3' half	MG902732	MM39_d0831_ipe015_SGA_6
Pre-ART	MM39.PLAS.ISO.01206.001	3' half	MG902772	MM39_d1216_ipe015_isol_P2C3
Pre-ART	MM39.PLAS.ISO.01206.002	3' half	MG902766	MM39_d1216_ipe015_isol_1A4
Pre-ART	MM39.PLAS.ISO.01206.003	3' half	MG902767	MM39_d1216_ipe015_isol_1B2
Pre-ART	MM39.PLAS.ISO.01206.004	3' half	MG902768	MM39_d1216_ipe015_isol_1B4
Pre-ART	MM39.PLAS.ISO.01206.005	3' half	MG902769	MM39_d1216_ipe015_isol_1C4
Pre-ART	MM39.PLAS.ISO.01206.006	3' half	MG902770	MM39_d1216_ipe015_isol_2A5
Pre-ART	MM39.PLAS.ISO.01206.007	3' half	MG902771	MM39_d1216_ipe015_isol_2D2
Pre-ART	MM39.PLAS.ISO.01206.008	3' half	MG902760	MM39_d1216_ipe015_isol_13A5
Pre-ART	MM39.PLAS.ISO.01206.009	3' half	MG902761	MM39_d1216_ipe015_isol_13B1
Pre-ART	MM39.PLAS.ISO.01206.010	3' half	MG902762	MM39_d1216_ipe015_isol_13B3
Pre-ART	MM39.PLAS.ISO.01206.011	3' half	MG902764	MM39_d1216_ipe015_isol_14B3
Pre-ART	MM39.PLAS.ISO.01206.012	3' half	MG902765	MM39_d1216_ipe015_isol_14C1
Plasma SGS	MM39.PLAS.SGS.01206.001	3' half	MG902755	MM39_d1216_ipe015_SGA_519
Plasma SGS	MM39.PLAS.SGS.01206.002	3' half	MG902747	MM39_d1216_ipe015_SGA_50103
Plasma SGS	MM39.PLAS.SGS.01206.003	3' half	MG902745	MM39_d1216_ipe015_SGA_50101
Plasma SGS	MM39.PLAS.SGS.01206.004	3' half	MG902746	MM39_d1216_ipe015_SGA_50102
Plasma SGS	MM39.PLAS.SGS.01206.005	3' half	MG902758	MM39_d1216_ipe015_SGA_582
Plasma SGS	MM39.PLAS.SGS.01206.006	3' half	MG902749	MM39_d1216_ipe015_SGA_50105
Plasma SGS	MM39.PLAS.SGS.01206.007	3' half	MG902752	MM39_d1216_ipe015_SGA_50109
Plasma SGS	MM39.PLAS.SGS.01206.008	3' half	MG902748	MM39_d1216_ipe015_SGA_50104
Plasma SGS	MM39.PLAS.SGS.01206.009	3' half	MG902743	MM39_d1216_ipe015_SGA_50098
Plasma SGS	MM39.PLAS.SGS.01206.010	3' half	MG902756	MM39_d1216_ipe015_SGA_525
Plasma SGS	MM39.PLAS.SGS.01206.011	3' half	MG902753	MM39_d1216_ipe015_SGA_50110
Plasma SGS	MM39.PLAS.SGS.01206.012	3' half	MG902750	MM39_d1216_ipe015_SGA_50106
Plasma SGS	MM39.PLAS.SGS.01206.013	3' half	MG902757	MM39_d1216_ipe015_SGA_528
Plasma SGS	MM39.PLAS.SGS.01206.014	3' half	MG902754	MM39_d1216_ipe015_SGA_512
Plasma SGS	MM39.PLAS.SGS.01206.015	3' half	MG902751	MM39_d1216_ipe015_SGA_50108
Plasma SGS	MM39.PLAS.SGS.01206.016	3' half	MG902744	MM39_d1216_ipe015_SGA_50099

Pre-ART	MM40.PLAS.ISO.00011.001	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.002	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.003	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.004	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.005	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.006	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.007	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.008	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.009	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.010	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.011	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.012	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.013	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.014	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.015	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.016	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00011.017	full-length	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.001.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.002.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.003.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.004.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.005.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.006.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.007.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.008.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.009.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.010.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.011.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.012.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.013.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.014.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.015.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.016.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.017.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.018.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.019.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.020.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.021.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.022.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.023.01	env	pending	this study

Table S5

Plasma SGS	MM40.PLAS.SGS.00011.024.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.025.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.026.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.027.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.028.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.029.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.030.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.031.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.032.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.033.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00011.034.01	env	pending	this study
Pre-ART	MM40.PLAS.ISO.00095.001	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00095.002	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00095.003	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00095.004	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00095.005	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00095.006	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00095.007	full-length	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.001.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.002.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.003.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.004.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.005.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.006.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.007.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.008.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.009.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.010.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.011.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.012.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.013.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.014.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.015.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.016.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.017.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00095.018.01	env	pending	this study
Pre-ART	MM40.PLAS.ISO.00747.001	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00747.002	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00747.003	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00747.004	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.00747.005	full-length	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.001.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.002.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.003.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.004.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.005.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.006.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.007.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.008.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.009.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.010.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.011.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.012.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.00747.013.01	env	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.001	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.002	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.003	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.004	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.005	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.006	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.007	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.008	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.009	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01166.010	full-length	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.001.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.002.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.003.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.004.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.005.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.006.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.007.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.008.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.009.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.010.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.011.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.012.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01166.013.01	env	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.001	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.002	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.003	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.004	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.005	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.006	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.007	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.008	full-length	pending	this study

Table S5

Pre-ART	MM40.PLAS.ISO.01530.009	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.010	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.011	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.012	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.013	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.014	full-length	pending	this study
Pre-ART	MM40.PLAS.ISO.01530.017	full-length	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.001.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.002.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.003.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.004.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.005.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.006.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.007.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.008.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.009.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.010.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.011.01	env	pending	this study
Plasma SGS	MM40.PLAS.SGS.01530.012.01	env	pending	this study
QVOA	MM40.PBMC.QVOA.02041.001	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.001.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.002.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.003.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.004.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.005.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.006.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.007.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.008.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.009.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.010.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.011.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.012.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.013.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.014.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.015.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.016.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.017.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.018.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.019.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.020.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.021.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.022.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.023.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.024.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.025.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.026.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.027.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.028.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.029.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.030.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.031.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.032.01	3' half	pending	this study
PBMC SGS	MM40.PBMC.SGS.02347.033.01	3' half	pending	this study

Plasma SGS	MM55.PLAS.SGS.00031.001.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.002.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.003.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.004.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.005.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.006.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.007.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.008.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.009.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.010.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.011.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.012.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00031.013.01	env	pending	this study
Pre-ART	MM55.PLAS.ISO.00051.001	3' half	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.001.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.002.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.003.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.004.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.005.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.006.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.007.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.008.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.010.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.011.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.012.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00051.013.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00348.002.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00348.003.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00348.004.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00348.005.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00348.006.01	env	pending	this study

Table S5

Plasma SGS	MM55.PLAS.SGS.00348.007.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00661.001.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00661.002.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00661.003.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00661.004.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00661.005.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00661.006.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.001.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.002.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.003.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.004.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.005.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.006.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.007.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.008.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.009.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.010.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.011.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.012.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.013.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.014.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.00831.015.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01300.001.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.001.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.002.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.003.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.004.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.005.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.006.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.007.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.008.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.009.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.010.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.011.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.012.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.013.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.014.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.015.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.016.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.017.01	env	pending	this study
Plasma SGS	MM55.PLAS.SGS.01858.018.01	env	pending	this study
Pre-ART	MM55.PLAS.ISO.02054.002	3' half	pending	this study

Pre-ART	MM62.PLAS.ISO.00022.001	env	pending	this study
Pre-ART	MM62.PLAS.ISO.00022.002	env	pending	this study
Pre-ART	MM62.PLAS.ISO.00022.003	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.001.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.002.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.003.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.004.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.005.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.006.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.007.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.008.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.009.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.010.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00022.011.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00057.001.01	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00057.002.01	env	pending	this study
Pre-ART	MM62.PLAS.ISO.00074.001	env	pending	this study
Pre-ART	MM62.PLAS.ISO.00120.001	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00185.001.01	env	pending	this study
Pre-ART	MM62.PLAS.ISO.00658.001	env	pending	this study
Plasma SGS	MM62.PLAS.SGS.00658.001.01	env	pending	this study

Plasma SGS	WEAU.PLAS.SGS.-0005.001.01	env	EU577356	B.US.1990.WEAUd15 A8.EU577356
Plasma SGS	WEAU.PLAS.SGS.-0005.002.01	env	EU577372	B.US.1990.WEAUd15 B3.EU577372
Plasma SGS	WEAU.PLAS.SGS.-0005.003.01	env	EU577346	B.US.1990.WEAUd15 A12.EU577346
Plasma SGS	WEAU.PLAS.SGS.-0005.004.01	env	EU577363	B.US.1990.WEAUd15 B16.EU577363
Plasma SGS	WEAU.PLAS.SGS.-0005.005.01	env	EU577369	B.US.1990.WEAUd15 B21.EU577369
Plasma SGS	WEAU.PLAS.SGS.-0005.006.01	env	EU577344	B.US.1990.WEAUd15 A10.EU577344
Plasma SGS	WEAU.PLAS.SGS.-0005.007.01	env	EU289202	B.US.1990.WEAUd15 410 5017.EU289202
Plasma SGS	WEAU.PLAS.SGS.-0005.008.01	env	EU577345	B.US.1990.WEAUd15 A11.EU577345
Plasma SGS	WEAU.PLAS.SGS.-0005.009.01	env	EU577358	B.US.1990.WEAUd15 B10.EU577358
Plasma SGS	WEAU.PLAS.SGS.-0005.010.01	env	EU577366	B.US.1990.WEAUd15 B19.EU577366
Plasma SGS	WEAU.PLAS.SGS.-0005.011.01	env	EU577383	B.US.1990.WEAUd15 C5.EU577383
Plasma SGS	WEAU.PLAS.SGS.-0005.012.01	env	EU577371	B.US.1990.WEAUd15 B2.EU577371
Plasma SGS	WEAU.PLAS.SGS.-0005.013.01	env	EU577367	B.US.1990.WEAUd15 A9.EU577367
Plasma SGS	WEAU.PLAS.SGS.-0005.014.01	env	EU577382	B.US.1990.WEAUd15 C3.EU577382
Plasma SGS	WEAU.PLAS.SGS.-0005.015.01	env	EU577349	B.US.1990.WEAUd15 A15.EU577349
Plasma SGS	WEAU.PLAS.SGS.-0005.016.01	env	EU577357	B.US.1990.WEAUd15 A9.EU577357
Plasma SGS	WEAU.PLAS.SGS.-0005.017.01	env	EU577354	B.US.1990.WEAUd15 A6.EU577354
Plasma SGS	WEAU.PLAS.SGS.-0005.018.01	env	EU577348	B.US.1990.WEAUd15 A14.EU577348
Plasma SGS	WEAU.PLAS.SGS.-0005.019.01	env	EU577364	B.US.1990.WEAUd15 B17.EU577364
Plasma SGS	WEAU.PLAS.SGS.-0005.020.01	env	EU577370	B.US.1990.WEAUd15 B22.EU577370

Table S5

Plasma SGS	WEAU.PLAS.SGS.-0005.021.01	env	EU577381	B.US.1990.WEAUd15 C2.EU577381
Plasma SGS	WEAU.PLAS.SGS.-0005.022.01	env	EU577359	B.US.1990.WEAUd15 B12.EU577359
Plasma SGS	WEAU.PLAS.SGS.-0005.023.01	env	EU577360	B.US.1990.WEAUd15 B13.EU577360
Plasma SGS	WEAU.PLAS.SGS.-0005.024.01	env	EU577350	B.US.1990.WEAUd15 A16.EU577350
Plasma SGS	WEAU.PLAS.SGS.-0005.025.01	env	EU577378	B.US.1990.WEAUd15 C11.EU577378
Plasma SGS	WEAU.PLAS.SGS.-0005.026.01	env	EU577380	B.US.1990.WEAUd15 C1.EU577380
Plasma SGS	WEAU.PLAS.SGS.-0005.027.01	env	EU577355	B.US.1990.WEAUd15 C7.EU577355
Plasma SGS	WEAU.PLAS.SGS.-0005.028.01	env	EU577362	B.US.1990.WEAUd15 B15.EU577362
Plasma SGS	WEAU.PLAS.SGS.-0005.029.01	env	EU577353	B.US.1990.WEAUd15 A4.EU577353
Plasma SGS	WEAU.PLAS.SGS.-0005.030.01	env	EU577387	B.US.1990.WEAUd15 C9.EU577387
Plasma SGS	WEAU.PLAS.SGS.-0005.031.01	env	EU577385	B.US.1990.WEAUd15 C7.EU577385
Plasma SGS	WEAU.PLAS.SGS.-0005.032.01	env	EU577375	B.US.1990.WEAUd15 B7.EU577375
Plasma SGS	WEAU.PLAS.SGS.-0005.033.01	env	EU577386	B.US.1990.WEAUd15 C8.EU577386
Plasma SGS	WEAU.PLAS.SGS.-0005.034.01	env	EU577347	B.US.1990.WEAUd15 A13.EU577347
Plasma SGS	WEAU.PLAS.SGS.-0005.035.01	env	EU577377	B.US.1990.WEAUd15 C10.EU577377
Plasma SGS	WEAU.PLAS.SGS.-0005.036.01	env	EU577379	B.US.1990.WEAUd15 C12.EU577379
Plasma SGS	WEAU.PLAS.SGS.-0005.037.01	env	EU577368	B.US.1990.WEAUd15 B20.EU577368
Plasma SGS	WEAU.PLAS.SGS.-0005.038.01	env	EU577361	B.US.1990.WEAUd15 B14.EU577361
Plasma SGS	WEAU.PLAS.SGS.-0005.039.01	env	EU577384	B.US.1990.WEAUd15 C6.EU577384
Plasma SGS	WEAU.PLAS.SGS.-0005.040.01	env	EU577374	B.US.1990.WEAUd15 B5.EU577374
Plasma SGS	WEAU.PLAS.SGS.-0005.041.01	env	EU577373	B.US.1990.WEAUd15 B4.EU577373
Plasma SGS	WEAU.PLAS.SGS.-0005.042.01	env	EU577352	B.US.1990.WEAUd15 A3.EU577352
Plasma SGS	WEAU.PLAS.SGS.-0005.043.01	env	EU577376	B.US.1990.WEAUd15 B9.EU577376
Plasma SGS	WEAU.PLAS.SGS.-0005.044.01	env	EF593278	B.US.1990.WEAUd15 SGA 12 2.EF593278
Plasma SGS	WEAU.PLAS.SGS.-0005.045.01	env	EU577365	B.US.1990.WEAUd15 B18.EU577365
Pre-ART	WEAU.PLAS.ISO.-0004.001	env	pending	this study
Pre-ART	WEAU.PLAS.ISO.-0004.002	env	pending	this study
Plasma SGS	WEAU.PLAS.SGS.-0004.001.01	env	AY223743	B.US.1990.WEAU16 02.AY223743
Plasma SGS	WEAU.PLAS.SGS.-0004.002.01	env	AY223744	B.US.1990.WEAU16 08.AY223744
Pre-ART	WEAU.PLAS.ISO.00000.001	env	pending	this study
Pre-ART	WEAU.PLAS.ISO.00000.002	env	pending	this study
Plasma SGS	WEAU.PLAS.SGS.00003.001.01	env	EU579192	B.US.1990.WEAUd23 4C6.EU579192
Plasma SGS	WEAU.PLAS.SGS.00003.002.01	env	EU579200	B.US.1990.WEAUd23 6D3.EU579200
Plasma SGS	WEAU.PLAS.SGS.00003.003.01	env	EU579203	B.US.1990.WEAUd23 6E6.EU579203
Plasma SGS	WEAU.PLAS.SGS.00003.004.01	env	EU579164	B.US.1990.WEAUd23 10A8.EU579164
Plasma SGS	WEAU.PLAS.SGS.00003.005.01	env	EU579186	B.US.1990.WEAUd23 11E8.EU579186
Plasma SGS	WEAU.PLAS.SGS.00003.006.01	env	EU579197	B.US.1990.WEAUd23 6A6.EU579197
Plasma SGS	WEAU.PLAS.SGS.00003.007.01	env	EU579195	B.US.1990.WEAUd23 5F6.EU579195
Plasma SGS	WEAU.PLAS.SGS.00003.008.01	env	EU579178	B.US.1990.WEAUd23 10H6.EU579178
Plasma SGS	WEAU.PLAS.SGS.00003.009.01	env	EU579204	B.US.1990.WEAUd23 6G1.EU579204
Plasma SGS	WEAU.PLAS.SGS.00003.010.01	env	EU579172	B.US.1990.WEAUd23 10F2.EU579172
Plasma SGS	WEAU.PLAS.SGS.00003.011.01	env	EU579184	B.US.1990.WEAUd23 11E10.EU579184
Plasma SGS	WEAU.PLAS.SGS.00003.012.01	env	EU579196	B.US.1990.WEAUd23 5G11.EU579196
Plasma SGS	WEAU.PLAS.SGS.00003.013.01	env	EU579179	B.US.1990.WEAUd23 10H8.EU579179
Plasma SGS	WEAU.PLAS.SGS.00003.014.01	env	EU579177	B.US.1990.WEAUd23 10H4.EU579177
Plasma SGS	WEAU.PLAS.SGS.00003.015.01	env	EU579174	B.US.1990.WEAUd23 10G1.EU579174
Plasma SGS	WEAU.PLAS.SGS.00003.016.01	env	EU579181	B.US.1990.WEAUd23 11A6.EU579181
Plasma SGS	WEAU.PLAS.SGS.00003.017.01	env	EU579191	B.US.1990.WEAUd23 3H6.EU579191
Plasma SGS	WEAU.PLAS.SGS.00003.018.01	env	EU579194	B.US.1990.WEAUd23 5C12.EU579194
Plasma SGS	WEAU.PLAS.SGS.00003.019.01	env	EU579168	B.US.1990.WEAUd23 10C12.EU579168
Plasma SGS	WEAU.PLAS.SGS.00003.020.01	env	EU579173	B.US.1990.WEAUd23 10F6.EU579173
Plasma SGS	WEAU.PLAS.SGS.00003.021.01	env	EU579205	B.US.1990.WEAUd23 6H11.EU579205
Plasma SGS	WEAU.PLAS.SGS.00003.022.01	env	EU579170	B.US.1990.WEAUd23 10F12.EU579170
Plasma SGS	WEAU.PLAS.SGS.00003.023.01	env	EU579180	B.US.1990.WEAUd23 11A2.EU579180
Plasma SGS	WEAU.PLAS.SGS.00003.024.01	env	EU579201	B.US.1990.WEAUd23 6D4.EU579201
Plasma SGS	WEAU.PLAS.SGS.00003.025.01	env	EU579166	B.US.1990.WEAUd23 10B11.EU579166
Plasma SGS	WEAU.PLAS.SGS.00003.026.01	env	EU579169	B.US.1990.WEAUd23 10C1.EU579169
Plasma SGS	WEAU.PLAS.SGS.00003.027.01	env	EU579171	B.US.1990.WEAUd23 10F1.EU579171
Plasma SGS	WEAU.PLAS.SGS.00003.028.01	env	EU579183	B.US.1990.WEAUd23 11C9.EU579183
Plasma SGS	WEAU.PLAS.SGS.00003.029.01	env	EU579198	B.US.1990.WEAUd23 6B5.EU579198
Plasma SGS	WEAU.PLAS.SGS.00003.030.01	env	EU579176	B.US.1990.WEAUd23 10H3.EU579176
Plasma SGS	WEAU.PLAS.SGS.00003.031.01	env	EU579165	B.US.1990.WEAUd23 10A9.EU579165
Plasma SGS	WEAU.PLAS.SGS.00003.032.01	env	EU579189	B.US.1990.WEAUd23 1G2.EU579189
Plasma SGS	WEAU.PLAS.SGS.00003.033.01	env	EU579163	B.US.1990.WEAUd23 10A11.EU579163
Plasma SGS	WEAU.PLAS.SGS.00003.034.01	env	EU579202	B.US.1990.WEAUd23 6E4.EU579202
Plasma SGS	WEAU.PLAS.SGS.00003.035.01	env	EU579167	B.US.1990.WEAUd23 10B2.EU579167
Plasma SGS	WEAU.PLAS.SGS.00003.036.01	env	EU579188	B.US.1990.WEAUd23 11H8.EU579188
Plasma SGS	WEAU.PLAS.SGS.00003.037.01	env	EU579162	B.US.1990.WEAUd23 10A10.EU579162
Plasma SGS	WEAU.PLAS.SGS.00003.038.01	env	EU579199	B.US.1990.WEAUd23 6C5.EU579199
Plasma SGS	WEAU.PLAS.SGS.00003.039.01	env	EU579190	B.US.1990.WEAUd23 3E7.EU579190
Plasma SGS	WEAU.PLAS.SGS.00003.040.01	env	EU579175	B.US.1990.WEAUd23 10G3.EU579175
Plasma SGS	WEAU.PLAS.SGS.00003.041.01	env	EU579182	B.US.1990.WEAUd23 11B2.EU579182
Plasma SGS	WEAU.PLAS.SGS.00003.042.01	env	EU579187	B.US.1990.WEAUd23 11F2.EU579187
Plasma SGS	WEAU.PLAS.SGS.00003.043.01	env	EU579185	B.US.1990.WEAUd23 11E12.EU579185
Plasma SGS	WEAU.PLAS.SGS.00003.044.01	env	EU579193	B.US.1990.WEAUd23 5A12.EU579193
Plasma SGS	WEAU.PLAS.SGS.00010.001.01	env	EU579255	B.US.1990.WEAUd30 A30.EU579255
Plasma SGS	WEAU.PLAS.SGS.00010.002.01	env	EU579212	B.US.1990.WEAUd30 6A9.EU579212
Plasma SGS	WEAU.PLAS.SGS.00010.003.01	env	EU579221	B.US.1990.WEAUd30 6D6.EU579221
Plasma SGS	WEAU.PLAS.SGS.00010.004.01	env	EU579216	B.US.1990.WEAUd30 6C4.EU579216
Plasma SGS	WEAU.PLAS.SGS.00010.005.01	env	EU579219	B.US.1990.WEAUd30 6C8.EU579219
Plasma SGS	WEAU.PLAS.SGS.00010.006.01	env	EU579225	B.US.1990.WEAUd30 6E3.EU579225
Plasma SGS	WEAU.PLAS.SGS.00010.007.01	env	EU579262	B.US.1990.WEAUd30 A8.EU579262
Plasma SGS	WEAU.PLAS.SGS.00010.008.01	env	EU579257	B.US.1990.WEAUd30 A33.EU579257
Plasma SGS	WEAU.PLAS.SGS.00010.009.01	env	EU579244	B.US.1990.WEAUd30 A16.EU579244
Plasma SGS	WEAU.PLAS.SGS.00010.010.01	env	EU579241	B.US.1990.WEAUd30 A13.EU579241

Table S5

Plasma SGS	WEAU.PLAS.SGS.00010.011.01	env	EU579240	B.US.1990.WEAUd30_A12.EU579240
Plasma SGS	WEAU.PLAS.SGS.00010.012.01	env	EU579211	B.US.1990.WEAUd30_6A4.EU579211
Plasma SGS	WEAU.PLAS.SGS.00010.013.01	env	EU579215	B.US.1990.WEAUd30_6B5.EU579215
Plasma SGS	WEAU.PLAS.SGS.00010.014.01	env	EU579226	B.US.1990.WEAUd30_6E7.EU579226
Plasma SGS	WEAU.PLAS.SGS.00010.015.01	env	EU579239	B.US.1990.WEAUd30_A11.EU579239
Plasma SGS	WEAU.PLAS.SGS.00010.016.01	env	EU579238	B.US.1990.WEAUd30_A10.EU579238
Plasma SGS	WEAU.PLAS.SGS.00010.017.01	env	EU579223	B.US.1990.WEAUd30_6E11.EU579223
Plasma SGS	WEAU.PLAS.SGS.00010.018.01	env	EU579210	B.US.1990.WEAUd30_6A3.EU579210
Plasma SGS	WEAU.PLAS.SGS.00010.019.01	env	EU579253	B.US.1990.WEAUd30_A28.EU579253
Plasma SGS	WEAU.PLAS.SGS.00010.020.01	env	EU579247	B.US.1990.WEAUd30_A19.EU579247
Plasma SGS	WEAU.PLAS.SGS.00010.021.01	env	EU579214	B.US.1990.WEAUd30_6B2.EU579214
Plasma SGS	WEAU.PLAS.SGS.00010.022.01	env	EU579245	B.US.1990.WEAUd30_A17.EU579245
Plasma SGS	WEAU.PLAS.SGS.00010.023.01	env	EU579248	B.US.1990.WEAUd30_A20.EU579248
Plasma SGS	WEAU.PLAS.SGS.00010.024.01	env	EU579237	B.US.1990.WEAUd30_6H7.EU579237
Plasma SGS	WEAU.PLAS.SGS.00010.025.01	env	EU579209	B.US.1990.WEAUd30_6A1.EU579209
Plasma SGS	WEAU.PLAS.SGS.00010.026.01	env	EU579233	B.US.1990.WEAUd30_6H10.EU579233
Plasma SGS	WEAU.PLAS.SGS.00010.027.01	env	EU579252	B.US.1990.WEAUd30_A27.EU579252
Plasma SGS	WEAU.PLAS.SGS.00010.028.01	env	EU579249	B.US.1990.WEAUd30_A22.EU579249
Plasma SGS	WEAU.PLAS.SGS.00010.029.01	env	EU579242	B.US.1990.WEAUd30_A14.EU579242
Plasma SGS	WEAU.PLAS.SGS.00010.030.01	env	EU579243	B.US.1990.WEAUd30_A15.EU579243
Plasma SGS	WEAU.PLAS.SGS.00010.031.01	env	EU579236	B.US.1990.WEAUd30_6H5.EU579236
Plasma SGS	WEAU.PLAS.SGS.00010.032.01	env	EU579207	B.US.1990.WEAUd30_6A10.EU579207
Plasma SGS	WEAU.PLAS.SGS.00010.033.01	env	EU579213	B.US.1990.WEAUd30_6B12.EU579213
Plasma SGS	WEAU.PLAS.SGS.00010.034.01	env	EU579234	B.US.1990.WEAUd30_6H1.EU579234
Plasma SGS	WEAU.PLAS.SGS.00010.035.01	env	EU579263	B.US.1990.WEAUd30_A9.EU579263
Plasma SGS	WEAU.PLAS.SGS.00010.036.01	env	EU579224	B.US.1990.WEAUd30_6E2.EU579224
Plasma SGS	WEAU.PLAS.SGS.00010.037.01	env	EU579208	B.US.1990.WEAUd30_6A11.EU579208
Plasma SGS	WEAU.PLAS.SGS.00010.038.01	env	EU579254	B.US.1990.WEAUd30_A29.EU579254
Plasma SGS	WEAU.PLAS.SGS.00010.039.01	env	EU579246	B.US.1990.WEAUd30_A18.EU579246
Plasma SGS	WEAU.PLAS.SGS.00010.040.01	env	EU579217	B.US.1990.WEAUd30_6C5.EU579217
Plasma SGS	WEAU.PLAS.SGS.00010.041.01	env	EU579206	B.US.1990.WEAUd30_4G5.EU579206
Plasma SGS	WEAU.PLAS.SGS.00010.042.01	env	EU579258	B.US.1990.WEAUd30_A4.EU579258
Plasma SGS	WEAU.PLAS.SGS.00010.043.01	env	EU579228	B.US.1990.WEAUd30_6F10.EU579228
Plasma SGS	WEAU.PLAS.SGS.00010.044.01	env	EU579261	B.US.1990.WEAUd30_A7.EU579261
Plasma SGS	WEAU.PLAS.SGS.00010.045.01	env	EU579230	B.US.1990.WEAUd30_6F4.EU579230
Plasma SGS	WEAU.PLAS.SGS.00010.046.01	env	EU579235	B.US.1990.WEAUd30_6H3.EU579235
Plasma SGS	WEAU.PLAS.SGS.00010.047.01	env	EU579256	B.US.1990.WEAUd30_A32.EU579256
Plasma SGS	WEAU.PLAS.SGS.00010.048.01	env	EU579220	B.US.1990.WEAUd30_6D10.EU579220
Plasma SGS	WEAU.PLAS.SGS.00010.049.01	env	EU579232	B.US.1990.WEAUd30_6G5.EU579232
Plasma SGS	WEAU.PLAS.SGS.00010.050.01	env	EU579260	B.US.1990.WEAUd30_A6.EU579260
Plasma SGS	WEAU.PLAS.SGS.00010.051.01	env	EU579250	B.US.1990.WEAUd30_A23.EU579250
Plasma SGS	WEAU.PLAS.SGS.00010.052.01	env	EU579231	B.US.1990.WEAUd30_6G2.EU579231
Plasma SGS	WEAU.PLAS.SGS.00010.053.01	env	EU579227	B.US.1990.WEAUd30_6E8.EU579227
Plasma SGS	WEAU.PLAS.SGS.00010.054.01	env	EU579251	B.US.1990.WEAUd30_A25.EU579251
Plasma SGS	WEAU.PLAS.SGS.00010.055.01	env	EU579259	B.US.1990.WEAUd30_A5.EU579259
Plasma SGS	WEAU.PLAS.SGS.00010.056.01	env	EU579218	B.US.1990.WEAUd30_6C7.EU579218
Plasma SGS	WEAU.PLAS.SGS.00010.057.01	env	EU579222	B.US.1990.WEAUd30_6D8.EU579222
Plasma SGS	WEAU.PLAS.SGS.00010.058.01	env	EU579229	B.US.1990.WEAUd30_6F11.EU579229
Pre-ART	WEAU.PLAS.ISO.00024.001	env	pending	this study
Plasma SGS	WEAU.PLAS.SGS.00024.001.01	env	EU579285	B.US.1990.WEAUd44_7A11.EU579285
Plasma SGS	WEAU.PLAS.SGS.00024.002.01	env	EU579271	B.US.1990.WEAUd44_5E12.EU579271
Plasma SGS	WEAU.PLAS.SGS.00024.003.01	env	EU579280	B.US.1990.WEAUd44_6F4.EU579280
Plasma SGS	WEAU.PLAS.SGS.00024.004.01	env	EU579289	B.US.1990.WEAUd44_7B4.EU579289
Plasma SGS	WEAU.PLAS.SGS.00024.005.01	env	EU579278	B.US.1990.WEAUd44_6E5.EU579278
Plasma SGS	WEAU.PLAS.SGS.00024.006.01	env	EU579284	B.US.1990.WEAUd44_6H5.EU579284
Plasma SGS	WEAU.PLAS.SGS.00024.007.01	env	EU579288	B.US.1990.WEAUd44_7B2.EU579288
Plasma SGS	WEAU.PLAS.SGS.00024.008.01	env	EU579272	B.US.1990.WEAUd44_5G5.EU579272
Plasma SGS	WEAU.PLAS.SGS.00024.009.01	env	EU579290	B.US.1990.WEAUd44_7C11.EU579290
Plasma SGS	WEAU.PLAS.SGS.00024.010.01	env	EU579276	B.US.1990.WEAUd44_6E10.EU579276
Plasma SGS	WEAU.PLAS.SGS.00024.011.01	env	EU579265	B.US.1990.WEAUd44_2D9.EU579265
Plasma SGS	WEAU.PLAS.SGS.00024.012.01	env	EU579291	B.US.1990.WEAUd44_7C1.EU579291
Plasma SGS	WEAU.PLAS.SGS.00024.013.01	env	EU579274	B.US.1990.WEAUd44_6B2.EU579274
Plasma SGS	WEAU.PLAS.SGS.00024.014.01	env	EU579292	B.US.1990.WEAUd44_7G2.EU579292
Plasma SGS	WEAU.PLAS.SGS.00024.015.01	env	EU579273	B.US.1990.WEAUd44_6A5.EU579273
Plasma SGS	WEAU.PLAS.SGS.00024.016.01	env	EU579283	B.US.1990.WEAUd44_6G6.EU579283
Plasma SGS	WEAU.PLAS.SGS.00024.017.01	env	EU579287	B.US.1990.WEAUd44_7B1.EU579287
Plasma SGS	WEAU.PLAS.SGS.00024.018.01	env	EU579266	B.US.1990.WEAUd44_2G7.EU579266
Plasma SGS	WEAU.PLAS.SGS.00024.019.01	env	EU579268	B.US.1990.WEAUd44_4A12.EU579268
Plasma SGS	WEAU.PLAS.SGS.00024.020.01	env	EU579293	B.US.1990.WEAUd44_7H8.EU579293
Plasma SGS	WEAU.PLAS.SGS.00024.021.01	env	EU579282	B.US.1990.WEAUd44_6G12.EU579282
Plasma SGS	WEAU.PLAS.SGS.00024.022.01	env	EU579281	B.US.1990.WEAUd44_6F5.EU579281
Plasma SGS	WEAU.PLAS.SGS.00024.023.01	env	EU579267	B.US.1990.WEAUd44_3H7.EU579267
Plasma SGS	WEAU.PLAS.SGS.00024.024.01	env	EU579264	B.US.1990.WEAUd44_2B9.EU579264
Plasma SGS	WEAU.PLAS.SGS.00024.025.01	env	EU579279	B.US.1990.WEAUd44_6E9.EU579279
Plasma SGS	WEAU.PLAS.SGS.00024.026.01	env	EU579286	B.US.1990.WEAUd44_7A8.EU579286
Plasma SGS	WEAU.PLAS.SGS.00024.027.01	env	EU579275	B.US.1990.WEAUd44_6D11.EU579275
Plasma SGS	WEAU.PLAS.SGS.00024.028.01	env	EU579277	B.US.1990.WEAUd44_6E2.EU579277
Plasma SGS	WEAU.PLAS.SGS.00024.029.01	env	EU579269	B.US.1990.WEAUd44_4E1.EU579269
Plasma SGS	WEAU.PLAS.SGS.00024.030.01	env	EU579270	B.US.1990.WEAUd44_5A1.EU579270
Pre-ART	WEAU.PLAS.ISO.00052.001	env	pending	this study
Pre-ART	WEAU.PLAS.ISO.00052.002	env	pending	this study
Plasma SGS	WEAU.PLAS.SGS.00116.001.01	env	AY223745	B.US.1990.WEAU136_14.AY223745
Plasma SGS	WEAU.PLAS.SGS.00192.001.01	env	EU579135	B.US.1990.WEAUd212_2F11.EU579135
Plasma SGS	WEAU.PLAS.SGS.00192.002.01	env	EU579136	B.US.1990.WEAUd212_3D12.EU579136
Plasma SGS	WEAU.PLAS.SGS.00192.003.01	env	EU579154	B.US.1990.WEAUd212_7C4.EU579154

Table S5

Plasma SGS	WEAU.PLAS.SGS.00192.004.01	env	AY223746	B.US.1991.WEAU212_52.AY223746
Plasma SGS	WEAU.PLAS.SGS.00192.005.01	env	EU579143	B.US.1990.WEAUd212_6G1.EU579143
Plasma SGS	WEAU.PLAS.SGS.00192.006.01	env	EU579161	B.US.1990.WEAUd212_7F8.EU579161
Plasma SGS	WEAU.PLAS.SGS.00192.007.01	env	EU579160	B.US.1990.WEAUd212_7F5.EU579160
Plasma SGS	WEAU.PLAS.SGS.00192.008.01	env	EU579146	B.US.1990.WEAUd212_6H9.EU579146
Plasma SGS	WEAU.PLAS.SGS.00192.009.01	env	EU579148	B.US.1990.WEAUd212_7B11.EU579148
Plasma SGS	WEAU.PLAS.SGS.00192.010.01	env	EU579152	B.US.1990.WEAUd212_7B5.EU579152
Plasma SGS	WEAU.PLAS.SGS.00192.011.01	env	EU579157	B.US.1990.WEAUd212_7E9.EU579157
Plasma SGS	WEAU.PLAS.SGS.00192.012.01	env	EU579158	B.US.1990.WEAUd212_7F11.EU579158
Plasma SGS	WEAU.PLAS.SGS.00192.013.01	env	EU579156	B.US.1990.WEAUd212_7E7.EU579156
Plasma SGS	WEAU.PLAS.SGS.00192.014.01	env	EU579151	B.US.1990.WEAUd212_7B4.EU579151
Plasma SGS	WEAU.PLAS.SGS.00192.015.01	env	EU579149	B.US.1990.WEAUd212_7B12.EU579149
Plasma SGS	WEAU.PLAS.SGS.00192.016.01	env	EU579138	B.US.1990.WEAUd212_6A6.EU579138
Plasma SGS	WEAU.PLAS.SGS.00192.017.01	env	EU579147	B.US.1990.WEAUd212_7A2.EU579147
Plasma SGS	WEAU.PLAS.SGS.00192.018.01	env	EU579159	B.US.1990.WEAUd212_7F1.EU579159
Plasma SGS	WEAU.PLAS.SGS.00192.019.01	env	EU579144	B.US.1990.WEAUd212_6H4.EU579144
Plasma SGS	WEAU.PLAS.SGS.00192.020.01	env	EU579150	B.US.1990.WEAUd212_7B2.EU579150
Plasma SGS	WEAU.PLAS.SGS.00192.021.01	env	EU579141	B.US.1990.WEAUd212_6F11.EU579141
Plasma SGS	WEAU.PLAS.SGS.00192.022.01	env	EU579155	B.US.1990.WEAUd212_7E3.EU579155
Plasma SGS	WEAU.PLAS.SGS.00192.023.01	env	EU579137	B.US.1990.WEAUd212_6A4.EU579137
Plasma SGS	WEAU.PLAS.SGS.00192.024.01	env	EU579145	B.US.1990.WEAUd212_6H8.EU579145
Plasma SGS	WEAU.PLAS.SGS.00192.025.01	env	EU579153	B.US.1990.WEAUd212_7C10.EU579153
Plasma SGS	WEAU.PLAS.SGS.00192.026.01	env	AY223747	B.US.1991.WEAU212_55.AY223747
Plasma SGS	WEAU.PLAS.SGS.00192.027.01	env	EU579140	B.US.1990.WEAUd212_6D4.EU579140
Plasma SGS	WEAU.PLAS.SGS.00192.028.01	env	EU579139	B.US.1990.WEAUd212_6B8.EU579139
Plasma SGS	WEAU.PLAS.SGS.00192.029.01	env	EU579142	B.US.1990.WEAUd212_6E2.EU579142
Plasma SGS	WEAU.PLAS.SGS.00371.001.01	env	AY223748	B.US.1991.WEAU391_03.AY223748
Plasma SGS	WEAU.PLAS.SGS.00371.002.01	env	AY223749	B.US.1991.WEAU391_12.AY223749
Plasma SGS	WEAU.PLAS.SGS.00752.001.01	env	AY223750	B.US.1992.WEAU772_22.AY223750
Pre-ART	WEAU.PLAS.ISO.00981.001	env	pending	this study
Pre-ART	WEAU.PLAS.ISO.00981.002	env	pending	this study
Plasma SGS	WEAU.PLAS.SGS.00994.001.01	env	AY223752	B.US.1993.WEAU1014_24.AY223752
Plasma SGS	WEAU.PLAS.SGS.01080.001.01	env	AY223753	B.US.1993.WEAU1100_24.AY223753
Plasma SGS	WEAU.PLAS.SGS.01111.001.01	env	AY223754	B.US.1993.WEAU1131_9.AY223754
Plasma SGS	WEAU.PLAS.SGS.01146.001.01	env	AY223751	B.US.1993.WEAU1166_39.AY223751

QVOA	B199.2.C.BF.1	env	KY113419.1	B199.2.c.BF.1.e7.03.07.16.S18
QVOA	B106.1.C.3.8	env	KY114038.1	B106.1.c.3.8
QVOA	B106.2.C.D6.S8	env	KY113973.1	B106.2.c.D6.S8

QVOA - Pre ATI	9242.QVOA.12F23	env	MH576342.1	9242_W12_12F23
QVOA - Pre ATI	9242.QVOA.12M6	env	MH576367.1	9242_W12_12M6
QVOA - Pre ATI	9243.QVOA.12Y10	env	MH576285.1	9243_W12_12Y10
QVOA - Pre ATI	9244.QVOA.12I10	env	MH576183.1	9244_W12_12I10
QVOA - Pre ATI	9244.QVOA.12J17	env	MH576186.1	9244_W12_12J17
QVOA - Pre ATI	9244.QVOA.G12	env	MH576218.1	9244_pre_G12
QVOA - Pre ATI	9244.QVOA.H1	env	MH576220.1	9244_pre_H1
QVOA - Pre ATI	9244.QVOA.K2	env	MH576228.1	9244_pre_K2
QVOA - Pre ATI	9244.QVOA.P11	env	MH576237.1	9244_pre_P11
QVOA - Pre ATI	9241.QVOA.12AU7	env	MH575949.1	9241_W12_12AU7
QVOA - Pre ATI	9241.QVOA.D2	env	MH575980.1	9241_pre_D2
QVOA - Pre ATI	9241.QVOA.A10	env	pending	this study
QVOA - Pre ATI	9241.QVOA.C19	env	pending	this study
QVOA - Pre ATI	9241.QVOA.C8	env	pending	this study
Rebound	9242.REB.6B8	full-length	pending	this study
Rebound	9242.REB.6A7	full-length	pending	this study
Rebound	9242.REB.6B2	full-length	pending	this study
Rebound	9242.REB.13B1	full-length	pending	this study
Rebound	9242.REB.13B8	full-length	pending	this study
Rebound	9243.REB.13F7	full-length	pending	this study
Rebound	9244.REB.7A8	full-length	pending	this study
Rebound	9244.REB.7A1	full-length	pending	this study
Rebound	9244.REB.7C1	full-length	pending	this study
Rebound	9244.REB.9D3	full-length	pending	this study
Rebound	9244.REB.9E6	full-length	pending	this study
Rebound	9241.REB.7D4	full-length	pending	this study

QVOA - Pre ATI	A06.QVOA.M5	env	MH264083	A06.Q1.6M5B5
QVOA - Pre ATI	A06.QVOA.M10	env	MH264073	A06.Q1.6M10C6
QVOA - Pre ATI	A06.QVOA.M30	env	MH264082	A06.Q1.6M30D4
QVOA - Pre ATI	A06.QVOA.M28	env	MH264080	A06.Q1.6M28G2
QVOA - Pre ATI	A06.QVOA.M19	env	MH264077	A06.Q1.6M19G9
QVOA - Pre ATI	A06.QVOA.M29	env	MH264081	A06.Q1.6M29A3
QVOA - Post ATI	A06.QVOA.2B	env	MH264088	A06.Q2.232BE2
QVOA - Post ATI	A06.QVOA.M20	env	MH264089	A06.Q2.23M20B1
QVOA - Post ATI	A06.QVOA.M3	env	MH264091	A06.Q2.23M3G7
QVOA - Pre ATI	A08.QVOA.1E2	3' half	pending	this study
QVOA - Pre ATI	A08.QVOA.M1	env	pending	this study
QVOA - Pre ATI	A08.QVOA.M4	env	MH264211	A08.Q1.15M4G1
QVOA - Pre ATI	A08.QVOA.M5	env	MH264213	A08.Q1.16M5A2
QVOA - Post ATI	A08.QVOA.M17	env	MH264236	A08.Q2.47M17F1
QVOA - Post ATI	A08.QVOA.M20	env	MH264231	A08.Q2.37M20B2
QVOA - Post ATI	A08.QVOA.1B5	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.1C8	3' half	pending	this study

Table S5

QVOA - Post ATI	A08.QVOA.1F8	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.3D8	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.4A1	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.4E4	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.5C3	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.5E2	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.5E4	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.6D3	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.6E2	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.6F6	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.7F8	3' half	pending	this study
QVOA - Post ATI	A08.QVOA.8E8	3' half	pending	this study
Rebound	A08.REB.1A3	full-length	pending	this study
Rebound	A08.REB.1D1	full-length	pending	this study
Rebound	A08.REB.5C2	3' half	pending	this study
Rebound	A08.REB.5D2	full-length	pending	this study
Rebound	A08.REB.6B3	full-length	pending	this study
Rebound	A08.REB.6D6	full-length	pending	this study
Rebound	A08.REB.7A3	3' half	pending	this study
Rebound	A08.REB.7C1	full-length	pending	this study
Rebound	A08.REB.7C2	3' half	pending	this study
Rebound	A08.REB.7D3	full-length	pending	this study
Rebound	A08.REB.8A5	full-length	pending	this study
Rebound	A08.REB.8B3	3' half	pending	this study
Rebound	A08.REB.8D1	3' half	pending	this study
Rebound	A08.REB.8B5	3' half	pending	this study
Rebound	A08.REB.8B5	3' half	pending	this study
Rebound	A08.REB.2F4	full-length	pending	this study
Rebound	A08.REB.1A5	full-length	pending	this study
QVOA - Pre ATI	A09.QVOA.M25	env	MH264310	A09.Q1.4M25G4
QVOA - Pre ATI	A09.QVOA.M22	env	MH264312	A09.Q1.5M22G8
QVOA - Pre ATI	A09.QVOA.M2	env	MH264313	A09.Q1.5M29A3
QVOA - Pre ATI	A09.QVOA.M6	env	MH264315	A09.Q1.5M6D1
QVOA - Post ATI	A09.QVOA.M9	env	MH264318	A09.Q2.20M9D1
QVOA - Post ATI	A09.QVOA.M16	env	MH264316	A09.Q2.20M16H3
Rebound	A09.REB.1B5	3' half	pending	this study
Rebound	A09.REB.1D5	3' half	pending	this study
Rebound	A09.REB.2B2	3' half	pending	this study
Rebound	A09.REB.1A1	3' half	pending	this study
Rebound	A09.REB.1A3	3' half	pending	this study
Rebound	A09.REB.1A4	3' half	pending	this study
Rebound	A09.REB.1A5	3' half	pending	this study
Rebound	A09.REB.1A2	full-length	pending	this study
Rebound	S22.REB.24C4	full-length	pending	this study
Rebound	S22.REB.1E2	full-length	pending	this study
Rebound	S22.REB.1F5	full-length	pending	this study
Rebound	S22.REB.3A6	full-length	pending	this study
Rebound	S22.REB.3B6	full-length	pending	this study
Rebound	S23.REB.3D1	full-length	pending	this study
Rebound	S23.REB.24A5	full-length	pending	this study
Rebound	S30.REB.8D1	full-length	pending	this study
Rebound	S30.REB.2D1	full-length	pending	this study
Rebound	S30.REB.2D2	full-length	pending	this study
Rebound	S30.REB.7D1	full-length	pending	this study
Rebound	004.REB.4D4	full-length	pending	this study
Rebound	004.REB.4E6	full-length	pending	this study
Rebound	004.REB.4D1	full-length	pending	this study
Rebound	004.REB.4E3	full-length	pending	this study
Rebound	030.REB.3E1	full-length	pending	this study
Rebound	030.REB.2E1	full-length	pending	this study
Rebound	030.REB.4E1	full-length	pending	this study
Rebound	030.REB.8E1	full-length	pending	this study
Rebound	044.REB.6F1	full-length	pending	this study
Rebound	044.REB.5F1	full-length	pending	this study
Rebound	044.REB.7F1	full-length	pending	this study
Rebound	044.REB.8F1	full-length	pending	this study
Rebound	601.REB.4B7	full-length	pending	this study
Rebound	601.REB.4C3	full-length	pending	this study
Rebound	601.REB.4B4	full-length	pending	this study
Rebound	601.REB.4A8	full-length	pending	this study
Rebound	601.REB.4A7	full-length	pending	this study
Rebound	601.REB.4C1	full-length	pending	this study

Table S5